var title_f11_10_11424="Gram stain CSF 5";
var content_f11_10_11424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain CSF 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11424=[""].join("\n");
var outline_f11_10_11424=null;
var title_f11_10_11425="Fetal gallstones";
var content_f11_10_11425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal gallstones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of fetal abdomen at gestational age of 35 weeks shows a multiple echogenic masses consistent with gallstones within the gallbladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11425=[""].join("\n");
var outline_f11_10_11425=null;
var title_f11_10_11426="Raney clip";
var content_f11_10_11426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Raney clips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 530px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAISAUkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwL4ZeAtU+ImvT6Tok9lBcw2zXTNduyIUDopAKqxzlx29a9M/4Zb8bf9BLw7/4ETf/ABql/Yx/5Khqn/YGl/8AR8FfSiLqGpar4wubnxbquk6dpN4sKR2sNoY44hZ28zMTJA7E7pXPXpjAp9APmv8A4Zb8bf8AQS8O/wDgRN/8ao/4Zb8bf9BLw7/4ETf/ABqvd/hdrkPxJ0y8vNB8beMIRaTCGWG7tdNSQZXKthbdhtPOOf4TxXc/D/ULnVvAXhvUdQl869vNMtrieTaF3yPErMcAADJJ4AxRoI+T/wDhlrxv/wBBLw7/AOBE3/xqj/hlrxt/0E/Dn/gRN/8AGq+z6WnYZ8X/APDLXjf/AKCXh3/wIm/+NUf8MteN/wDoJeHf/Aib/wCNV9oiiiwHxf8A8Ms+N/8AoJ+HP/Aib/41R/wyz43/AOgn4c/8CJv/AI1X2hRRYD4v/wCGWfG//QT8Of8AgRN/8ao/4ZZ8b/8AQT8Of+BE3/xqvtGiiwHxd/wyx43/AOgn4c/8CJv/AI1R/wAMseN/+gn4c/8AAib/AONV9o0oNKwHxd/wyx43/wCgn4c/8CJv/jVH/DLHjf8A6Cfhz/wIm/8AjVfaOeaXNFgPi3/hljxx/wBBPw5/4ETf/GqP+GWPG/8A0E/Dn/gRN/8AGq+0s0UAfFv/AAyx44/6Cfhz/wACJv8A41R/wyv44/6Cfhz/AMCJv/jNfadFAHxZ/wAMr+OP+gn4c/8AAib/AONUf8Mr+OP+gn4c/wDAib/4zX2nRQB8Wf8ADK/jf/oJ+HP/AAIm/wDjNH/DK/jj/oJ+HP8AwIm/+M19p0UAfFv/AAyv44/6Cfhz/wACJv8A4zR/wyv44/6Cfhz/AMCJv/jNfaVLQB8Wf8Mr+OP+gn4c/wDAib/41R/wyv44/wCgn4c/8CJv/jNfadGaAPiz/hlfxx/0E/Dn/gRN/wDGaP8Ahlfxx/0E/Dn/AIETf/Ga+06WgD4r/wCGVvHH/QT8Of8AgRN/8Zo/4ZX8cf8AQT8Of+BE3/xmvtTNGaAPiv8A4ZW8cf8AQT8Of+BE3/xmj/hlfxx/0E/Dn/gRN/8AGa+0yaTNAHxZ/wAMr+OP+gn4c/8AAmb/AOM0f8Mr+N/+gn4c/wDAib/4zX2nmkoA+Lf+GV/G/wD0E/Dn/gRN/wDGaP8Ahljxv/0E/Dn/AIEzf/Gq+0s0mBQB8W/8Ms+N/wDoJ+HP/Aib/wCNUf8ADLHjj/oJeHf/AAIm/wDjVfadGaAPzu+Knws1v4aHTBr1zp0/9oeb5X2OR32+Xszu3Iv98YxnvXA19Tftx/f8F/S9/wDaFfLNJge9/sZf8lQ1T/sDS/8Ao+Cve/EWg6z4o0H4maH4dubS1u7/AFiGCSa5ZlVYTYWXmY2qSSVyMe55rwT9jL/kqGqf9geX/wBHwV9W6n4M8L6tfS3uq+G9FvbyXHmXFzYxSSPgADLMpJwAB9BVWugOW8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXQ/Cn/AJJf4P8A+wNZ/wDohKb/AMK78E/9Cf4c/wDBZB/8TXS2tvBZ2sNtaQxQW0KLHFFEoVI1AwFUDgADAAFCQieik70UwHUUlApALmlFNpRQMWiiigBaKSigBaWm0ooAWikpaBC0UmaXvSGLSUtAoAKKKM0AFFJRmgBaKTNFAC0UmaM0ALRSUUALRSZozQAUlLRQISiiimAlFBooGfLH7cX3vBf0vf8A2hXyzX1L+3D97wX9L3/2hXy1UsD3v9jL/kqGqf8AYGl/9HwV9mV8Z/sZf8lQ1T/sDy/+j4K+y6pALS0lLTAWikpryKhAZgCelAiSisLXfEtno0W+4SV/ZFzWdD4uubq2a4stFu5YhzuOB/M0rjUWzrqUV5XqnxistIdhqGjagAP+eag/1rCuf2k/C8PH9k6uX9DGo/8AZqSaew+Vo9xor58uf2ntCX/U6JqTf720f1qGL9qDSWbDaFfAf7y1QrH0TS14NbftKeHpP9bpmox/RVP9a6PR/jh4b1SRUig1BWP96A/0pXHY9WorlZPHmh29uk15cG1ibo0qlRWzpms2GqQLNp9zHPEwyGQ5Bo3FZo0qKYGzzS5oAdmim5ozQA7NKDTaKAHZopuaXNAC0cUmaKAHUU0kDkkCqE2sWMLlGuFZx1VfmP6UAaNJmuL1P4meFdNcpeaiI3HYo3+FZZ+NPgYNhtYUe5jb/CloFj0jNLXAQfGDwHM2B4htl/3sj+laMHxI8FzqTH4m0zj1nA/nQFjrelFc7D428LzjMXiDTW/7eF/xq3D4k0WZsRarZOfaZT/WmFjXpKgiu7eYZinicf7LA1MOeRQAtApKKAFpKDRQB8sftw/e8F/S9/8AaFfLVfUv7cP3vBf0vf8A2hXy1SYHvX7Gf/JUNU/7A8v/AKPgr7Mr4z/Yz/5Khqn/AGB5f/R8FfZeapALS0maM0wHVxPiPTJdc8SwQS3ktvaQDcRG5Qufr6V2ozXH+No2jxdWbF5xwyKeTSGkP17w5atp7It1KjAcPvzj868vvPE/jLTfN03R2t76MfKHEJ3Y/DitO81rVpbfnT71o+nCkg0/QvGUWiyBp9HnUg8/uzUq3Upvojgruw8X3LG5v/D08/ckIf8ACuVvobVLhzqXhmfzM844xX0vH8V9FMeZYLmNu4KVjax8RPDd6CJLUNnuyc048qIcW9z50LeFQc3Phu999rirNtdfDxCPtXhnVCPQMv8AjXpuq674VuST9kRT7KBXO3GoeGOStvmr5kuouVmUNZ+FjbFbwtqcYH90Dn/x6ut8MeNfhjpRX7Fo+qQv6tbl/wCprnf7c8OQHjTFkPvWppnjmOycNpXhy2ZgcgmEtRzJjs0d7e+MfB2rQR/bdL1B7fPyGaycKT+Vdhouo6NAkMFjCLQyrmOMpsJHsK8q1P4j+MdZtPsq6ZDaQnqyQNn8M0eC7jVL7xFYDVbqa52s2wuOF46Clz62Hbqe92s4KgE5qS3vrW4mkhS5i86P7ybhuH4VSshtjyeteS+IdIk8SX2sW+naJLeTXDtEb6R/LSEr/dPU/hRPTYWnU9qkuLaNsSXcCH0aQD+tKk8DthLqBj6Bwa+MvE3wjm0nU7Gxv/ENq19eyhEgEhJQd2YnsPWuZ8V+EbTw1q4sLfxCl7MF3O9uxxH7Eg9aQXv0PvSeeK3CmWaMBjtA3dTUvuK+X/2eD4f0rRr7xF4i1cu8chSL7VIfkA6kAnnNe63Pj/w9bWNtdS38QjuceUAcl89MDrSHY6yiuauPGmjQXdvbPdL504yo7fn0rVs79b6PzLf/AFWcBvX6U1qKzNCkZgB61gavrAtFfY6qqDLO3QVwer+Lbd9PvRb68U1E7TbMhG1c9iO9JtLcaTZ6fe28l7btF+8Td3Fc7beHdS0SSabRktp2lHK3DEc/WvC7r4ifEuBZ0g1mwlSI7Vc2qbnrlNR+IfxPumKyazcovfyERP5Ci9wWmx6V4l8HeOrvUrm6k8PWF35mceXOvH0zXnV74C8VW900l14NvJe+ItrD9DWI3iPx7O2Zde1zPtcMP5Vctde8dqBs8R60D0wZif5004pWsK2tyDUvD2qum2TwJq8WOrJbk/yrAudHa3fbc+G9agPXDWrf4V2kPiv4g26nZ4i1Eg/3lVv5ikl8ffEInB1+Y445t0/wovEZywj0v7MEGiapHMOrNbv/AIVveEdQ0fTLrdqGi3F1CexiYEfpVyDxt8Qpmwdb68c2yf4VoFvHd7FufW9y+gjVf6UmotWDXodKdd8HXtsVsbDVtMuQPkeJXXn65xUPhDW/GUOpYtdUvJrENgC5Xdx9TzXJww655+zUdSumXodmK7zw/Z2FpGs8F1ezXa4JWZvlP4VLVthKV3qe3adrBXT4pNQdRI2BkDgmttGDqGU5BrzJdfu9W0+GyEEcMSEFnHU47CvQdJ3iwhEmc7e9UncqSsXqKbmlzQQfLP7cH3vBf0vf/aFfLVfUn7cH3/Bf0vf/AGhXy3SYz3n9jT/kp+qf9geX/wBHwV9l18a/saf8lP1T/sDy/wDo+CvsrHFVHYBaKO9FMCO8EjWziE4cjiuJvI5omb7QkgPdsZzXdU10DcMAR70WGpWMLTta04W6QylY2UY5HFX1l0ucf6y2bPripZbC2k+/BEf+A1XOjWB62yfgKAdhWsdJk+9DaN+AqCTRNBc/PZWTfVVqb+w9P/59x+dIdF0/P+oH5mmTZFN/Dnhk/e0/T/xRagbw74RXlrDTR9UWtP8AsTTcc2yn6mj+wdM/584j9RRcdkZH2Hwba/N9l0xcf7C0HXvDVp8tvHCxHQRRitf+wdK/58YP++aDoWlYx9ih/Kht9wVjl9Q8WxyxMlhZYyMbiozVbwfp7Xd8b14fLjiyqjHUnqa6O80bS0iOy2Cux2oqnBZjWtp1pHZWccEYGFHJ9T3NJRd7sptWsiDUJhY6bPORxGhb9KyPCFnMvg3yri9EV5dB5DIpH7vcSRj6Zp/juZ10qG0hP728nWIc9urfoKzLTwW17beZLfzx7yeEOOKJPUg8z1f4J3V7qEl2fFkD3Lk5lkTLn8c1lj4C38efJ8Rabz6x9a9Xl+GdoSc6ld59dwqu3wztc/8AIUvcD0Ios+wzy/8A4UZri4Ca/pTgHIVkOAfpVhfhH4rhcMur6PKyjgtuGPp6V6ha/DnToj++u7yY+8mP5VZh+H+lySqUkuvLU/N+9OD7U+XyQHB6F8OPE+o6paWviS7sjosH7xvsjEs5/u57Z717NO0VlaLb2wWNEXaAOAoFS4hsLZYLdFjRRhVXtXn3i7UpdUuZdH06TYoG69ue0Sf3R/tGk7R2DV7nmfxW8azajcyaZorE20bbXkX+Nvb2ry8+HtccG4luIIEPOZH+Y/hXrl94WiMu3TY9iZwmTlmPrXQ6f8HPtkCy6tfMrMM+XGOn4ms46jd0fOv2TVjL5a6nF1xnfxW/o3gfxJq0m221mxQ443z4zXvcXwT8PqPmkuSf94f4VJ/wprQ1/wBVPeJ7h605X3Fc8ji+EXj5eYryym/3Z6nX4YfEWE8RRv8ASYV7Da/DGK1ObTWdTi/3Za0oPB2pw8ReJdRGOzENS5Qv5nh48BfEWLrZbv8Agamo38H/ABAjHzaKXx6Fea+gE8P66nC+JJyP9qNTUy6Lrw6+IHP/AGxWjlQXZ86f2D44iPzeHp8j0UVKtj44XgaDeAey19EjRdYb72uzH6Rr/hS/2Bft/rNauz9Ao/pSsuwKTPnuLS/Gsh50OdfdgBTpNN8U2rqbq0EQbsGBNfQQ8Mbz+/1G8f8A4HipYvCmnI250eQ+rsTScV0KUu55V4WTVQ6C4IUcYRRkmva9IM5sYvtIxJjkUWmm2tr/AKiBE+gq6owKErBKVxKWlxS4pkHyv+3B9/wZ9L3/ANoV8t19S/twj5/Bf0vf/aFfLVJjPev2NP8AkqGqf9geX/0fBX2VXxr+xp/yU/VP+wPL/wCj4K+yqpAKKKQDFLTAWkoooEJijFLRQAlJinH0opjGgcdKWlFFAxMVWu5khiLyHCj05JPoPep5ZFRCzcAVmENLMJJeo+6v90f4+9NK4gtkeWcTzLhwMIn9wH+taUfTpUUSgCpwB2psDmdVtJLvxbbSPzb2duWUf7bHGfyFdPbp5dvGo7CqM2xdRIZgHkjXaCcZAPOPzFXxNGwXbIrBhlcHqPapYkhjioWwBljge9TsM0Kig5xk+p7U0MrpA8py+Vi9O7fX0FWHKxR8YAA4FSZrC8RatFYWsk0pJVeFReS7dlHuaGwMPxbrEsBS1sfn1G5+WMdo17ufpXLyRJYwCwtyWwd88h6ySHqSa0oFkhjuNUvVH2+4OAvUIOyj2FP8PaV9vv1Dglc7nPrWb1LijX8G6Jwt7dLz/wAswR+tdpt4pYo1jRVUAKowMU+nsQ3chKe1KEqSlxii4iLZ7UuzipMUoFFwGBRQV44p+KMUAM2+lLin4pQKAI8UuKfil20gGAU4ClA4p2KBjcUAU7FGKAPlX9uP7/gv6Xv/ALQr5Zr6n/bk+/4L+l7/AO0K+WKlge9fsZ/8lP1T/sDy/wDo+CvsvFfGn7Gf/JUNU/7A8v8A6Pgr7L+tWtgCilo/GmAUUfWjNABRikNLQAmKWikJoGMmmjgj3zSJGnqxxWTqHijRNOBN7qdtAB/fcCuK8bT3Vxq2pW8Vz5MnlbLacru+zvjrt7/Uc185+K/DPibT7d7/AFe0mmtS3zXok8xG59ev6V7WDyuFdJ1J2uedVxsoy5YI+oLr4l+Dy/z69ahV6ABj/IVUl+J/g8RH7Prlu0mRwyOMjPPbrivkWUDOPamIAAOK9RZFh/5n+H+RmsXWavp+P+Z9m2/xH8GyHC69AW9CGH9KuW3jbw7MUCaraSSY5CSjAP1JFfFQO3kcfQ1d0WwvtX1BLLTV824YFvmcKqqOpJPAFTLIqCV+dr7hfXKy6L8T7TZdJ1a8tb37Lb3F1bk/Z5WuFJQkc7eat6Xpq6Vbx2tjZWttaqSQqyMxGTk9v618+eDLX/hGLK4TUL4311KABbxKwhiIPUMwBLdsgAV7l8P7qW88NxyztucSMOpIUdhzXi4vBfV1zRd0dOHxPtXytWZ0gpRSUteedpDeS+Tbsw69B9a4eZP7Q1AXUmWij+WBT093+p/lXR67MJi1uD8qj5z7+lZUe2NWc/djGaW4jL1Ub7tIV+7EP/HjXYeGLAWlkHYfvJOa5rR7U3l+pkGSzb2rvkUKoUDAAqCnorBQaUCimQJ+FFLS4z2oGJS4pe9LSuA0DNLilxS0AJijFLRSAMUUUlAC0tNzS5oAWkpM0ZoA+V/25Pv+C/pe/wDtCvlivqb9uP73gv6Xv/tCvlmkwPe/2Mv+Soap/wBgeX/0fBX2XxmvjP8AYz/5Khqn/YHl/wDR8FfZlWtgA0UUUwA0UAUuOKAEooooGJRRSOwVSzcAcmmB5X4iYS67fE8jzSPyrgPj5rvkeHND8PxP80ubiRc8gHp+mfzrrPEuq2umf2jqd8xW3jkZiO554FfOXiLXbjxJr1xql2TmU4Rf7iDoK+vwOH5nGb2j+dj55Jzqyt/WpVlOWxTMfKKCfm9MmnDNewbLRWAiu5+ENuzarql3zhIEgBHqzg8fgtcI7bFJP+TXrHg22bRDpWluP9Mm33d0o/hdkwqH6DqPU1hiXam0jObtZPqXmG5y5JJYluepr2r4VPu8MsPSc/yFeKg5OK9h+E0uNCulJ6TA/morwsyV6HzNsH/GO7BqC8uPs9u8nGRwo9T2p+SelYeq3Pm3OwYKRZH1buf6V86eyU5Sc8tljyx9TVe/OyBIR1c7j9BVi3QyyCq7n7TeEqOM7V+gqWNG74XtdkTTEctxXQVXsIRDbIg7CrGT6VInqGKQ/jTj+tNPpQIKUcd6TpR160ALml703NLxmgBaBSZo60AOopvI6jNGeKQCiikNGaYAKWm55pO/egB2aM03NL2oA+WP24vveC/pe/8AtCvlmvqX9uH73gv6Xv8A7Qr5apMD3r9jP/kqGqf9geX/ANHwV9mfzr4z/Yz/AOSoap/2B5f/AEfBX2ZVR2AKXmkozTGGaM0hNFABRRS0wCszxCzJpUpR3Q7lG5DyOe1af0rJ8THGkP8A7y046sGeC/FwPceCL+OKLc/2kSl+4XB4+ma+fUu40UN5bSEdcHb/ADr6nmEMrvHdR+bbSEpKndlPXHv6V4j8RvA3/CJeJXt0AuLCaM3NtJjHmRkEj6Edx7V9lhq3JD2a33+XX7j56nU5XK+xj6PaW+raZe3aStDcWu1ntiu75G4DbunXPFYeu6l/ZGpNaC384hFYtvx1GfSt74bApoviG4uAWM4iHX0Yn8qzr7SptX8V3PkJ5nyRAdgAEGSa8arm2JTcoysr9l/kelHDw0VvxZJ8PtYt7vxzoSX9lttTdKWLvlSe2ePXFejJNJH40hluGIcztvP4movD/hi206Fd0SzXDYySvf29K7XUvBNy2jR6+ZUkeOVU8sD5pMfeP4frW2Azb20nDEPV6J/poc+MwMlyzp9NzGORO691bFem/CiO3867uZWcTJGIo1BOGUnJ+UdSMD6V5cw26hIAdynDA+orvvhox/tVWBP7tS/Hbt/Wt8wV8OzLCP8Afo9Rv78woqxRuHc7QZAVwP7wHU/pWJKB5u1c4Ax1qW+nMuoRBmJ+bvThFulzivmD3Bkr/Z7JiOHf5Fp2g24lu1P8K81WvX8y4Crysfyj3Peuh8P23lQb8ctUsrZGyvTilo70v4VJA38aCKdSUwGkdqTmnd6DQAg96XtxQOlLQAnal/Cl+tN4oAU0lBPtSZoAM0E0dutJ2oAOgoopM0ALRSUUAfLP7cP3/Bf0vf8A2hXy1X1L+3D97wX9L3/2hXy1SYHvX7Gn/JUNU/7A8v8A6Pgr7LFfGn7Gn/JT9U/7A8v/AKPgr7Lqo7ALSUdKM1QxKWkpaACgUUUALWN4r/5A7j/bFbNYvi3/AJBB/wCug/kaqHxIUtmeWMcye5Ncd8c9YtNSv7LTrZw72NmwlYckHHAqz8StbvdA0S3lsF2S3kjRJORnZjrt9+a8i03fPeqjMXkuCVZmbJYnqSa+tjQvTdbsnb9T5uCd/JtGlp9sdN8LbipXz2Cj3AX/ABNdF4Ft0axvLsgZknO1j6BQKf4402/vNLs7fSLOW5kSRt6xD7q7QBn9a6bwLok+naBaJqkQiljG7ys5O485P6cV8nKUZYeOurf+Z9BTTVR9rG1pdkI1Wd1y5GVU9VHqa3vEV2tl4G095GI3TTbFHVmzgD+dUCzNwVZ27BRyx9K8/wDFWvXl7cWtq8uYbZ2EKr0jyctg9+nU115Vg5V6vN9lbmGOxcaELdWWbhxJqchUDCAK2DkBu4/Cu7+GmRqL9f8AVtn9K8704BYc85PJPvXpPwzQm5mcfwxHP5ivczD3aEkeZgtasTrid+qRDJPertxJ5ELOfvHhfrVGzPm6uuOwJqTUHEtxsU/InA9z3r5Rs+gSuJYQmWVFHXPJrtbWMRxqAOgrA8P22W8wjpXSrwKkJMdRRSj6UiQ+nWkpfyoPFACUhFB9qTNMA70ZpDzSZoAXNGaTmigBc0lIaKYC5oo6mlx7UAJRinYoA96QCYowPWlpQKAPlb9uLhvBf0vf/aFfLNfU/wC3GMP4L+l7/wC0K+WKTA96/Yz/AOSoap/2B5f/AEfBX2XXxp+xp/yU/U/+wPL/AOj4K+yqqOwBRRR9aoYtFJS0AFFFFABWfrtutzpVwjEjClwR2IFaHvVa/ObWYdihH6U46NCex85fEvSbnW/DiJaBpJbJ2nWIckqR82PfjNeQ6VIY7pJwMmH94QfavoXzZLeaOWFyksbBlYdiK84+M+kW+k+IIrzTIo7W31iISSxIuBG/VgvopPP419nh6t17Bre//B/zPm03qaHhvxxYSSTpJH5EkmNrNKqx475J5roY9c06U/8AIX0eM45Ju/8A7Gvnt/lcc98VY2grWEshwnS6+bPR+sVopa3+R9GrqNi9uWi1jTZJNvy+Xcrn68kYry/WIXttRRTz8/BU5BHYg9684kAB4613XgzXvtOnWGg3mnRzeXPi3u04ddx5Vh/EM9PSunD4GOCi/Z6pnJjYSrR55vY6WxBMK/SvUfh00cUFyXZEJUHLHGBzXmca+W7R8fKxFep+FreFdFt3eNC5ydxXJ6//AFq87Np8tH1Zpl0L1V5GxZTgTyzRHIK7VfHHuRU8a75FUCogeOfwq9o6ebcA9hXy57yVjptMhEUCjGCa0OgqvFwop5amZ3JcijNRZozSsBLmkLY71HnijNADiaTNJRTEHfmlpM/nQKAFzRSgUucUDEAp2PejtwKB79aQBilxiilzQAgHrS4oB5pC1AC44paaT6UDpSA+V/25PveC/pe/+0K+WK+p/wBuP7/gv6Xv/tCvlikwPef2NP8Akp+qf9geX/0fBX2XXxp+xr/yU/VP+wPL/wCj4K+yqtbALRSUvaqAKKPwooAXvRRRQAHpWZq9wIrZueoxWg7YB5rkPFF98j4PQYHvTiB59qUkVsJ5riVIoIss7ucBQPWvD/iL41XxVr9o9qhj0+zURRZ6v6sfr2r0X41QiTwRLLHMwkF0oaID7ybc7ifrXgKY2jFfc4ClGUfaPc8fDUIylKUjTvcJKTzye1OEw8sYNZ8krP8AeNMDY716HKdSo+6kyzNMoPORiu+8GWklgltqF8rW/BaFCMO3+1jtWd8J9Mtr/Xb3UL6FLi30u3NwIn+68hOEz7A849q2dQllu73zJnLu3UmsJy5m6aPNzCsoWglsdBZv5rhv7xyK9V0y4WHTrZMjKoPw715Tpa7DHk9Op9a7yKXEKjd2HTtxXzOeytGEfM6cp1lJvsb7XxcgKCSeldj4ehKwhj1NcHoyNc3a9doNem2EYjhQAY4r5+Gp7U2XgeKWmdqUHFUZj80oNMzSjNFgJM0U0ClpALS0goFAC0tNzRmgB1LmmZ96XNAD91GfSo93pSg8UWC47NLupmaM0DH7qQmmZ96UmgB2aA1Mz+dGaAPlr9uA5fwX9L3/ANoV8t19RftvHMvg36Xn/tCvl2pYHvP7Gv8AyU/U/wDsDy/+j4K+ya+Nv2Nv+Sn6p/2B5f8A0dBX2RVx2AWlpKXNMQUtJSigAoz6mjvzTGOBTAp6nP5Vux6cV5trzy3E37tsj0rqvE1+FOxeSK46Vi0hY110qPMrnJVr8rsYN7bWerwPp2pSeVbynyncjPlnoGx6A9favBNc8J3eieIL/Sr9liltZChxzuHUEexGD+Nexa5K9nqEzMD5b85/xrmvEtjc+JdU097FPOvpU8ggnBfYODn6D9K+rwknDr7rR5SqzpyfJuzgItKtFA3rJIe5LY/lVlbOwAA+xIcd9xzXdR/C7xS/S0h/7+ikk+GPiqEEtYKQP7sgNdP1qi/tr7xSWKer5vxOa8NXFvo2rCSONo7a4XybhAxIKE9efQ4Nat/E1vqUsLHJSTgjuPWm3nhPVrHIvrZovrS6o5K2sjn940SqffHFNSjKV4u9zhxHPy++nfzNi2l27fWupF+Nu3PzDjB71xOkJNcEbUPlgj5q7DTdOnurxfkIGckmvnM8jGUoxT1V/wBDsy6vKLbS3seieCLZiiyMOTzzXoMOMVz/AIc08W1nGp64roo1wBXhKPKj6BNvVkgNKBzSZ4pQaCh4/SlBHamA0ucUgH5FGaZnNLmlYB2aCeKbmkzQMdnPWg03NFAD80Z/OmZFLkYoAXJ+lLmmZpcigBxNANNzzQKAHd6XNM3UBqAHE0Z5pueaOR9KAPlr9tz/AF/g7/dvP5w18v19P/tt/wDHx4P/AN27/nDXzBUPcZ7x+xt/yU7VP+wPL/6Ogr7JFfG37G//ACU7U/8AsDy/+joK+yBVx2AeKBTacD6UxC0ppKUdKAE7VXuSwjbaOasHio52VUJboKaEzg9YRizlhzWG4RVIrotfuDK7bAAegJFcxLZSSNlyfpXRGtynPOkmZV3Y/a5Sh2MDwd3Sup8JeENH0m4W/eRZLzaVUbsIgPXA9fes1bJlA+QkZ7GpBC6Yxlfxq5Y+bjyq9ghSSd2tUegRi2AxG6/nTyiH+IfnXne+7jOVck0ovboDDFxnvmub26N25di146toruIxPLtjBycDJJrz+Hw5YIwZoTKw6GQ5A/CuvlzK+ZWyx7N2qa2s0mZQF6cH3raOPqwXLB2Rx1sN7Z3kc/aafkqkS7cdABgV1/hzScOmQxI5Jrb0jQ4igeRMewFdNbWUUKgIoAHtWLm5O7Lp4eMBltFtQD8qt4xilwBS4GaTZ02G84pecUuPSikMToaWlxQBzSAKBRS0AJQRRS0DG0tFFABSmk/CigBDxS0lFADhSZpDSc0AOzQDTaM0AOoJpvSg/SgD5a/bYP8ApPhD/cu/5w18x19N/tr/APH14R/3Lr+cNfMlZvcZ7v8Ascf8lN1P/sDy/wDo6CvsbdXxz+xx/wAlO1P/ALA8v/o6CvsbFXHYBQ3WnAntxSCl780xBk+tLk+tJ60fSgBGbjFZep3BERUHNaL5IwayL6ElvxpsNzn7mOSUjapJqax0uR3zIp2/lWtaYRwMfpWtEOBgVKXUGZsekQBeU5pzaPAT92tgDIpDwKoRiS6JBjjINZ91oaYO05x2NdJOSFO0ZOOKwL2S4ZyCSAfSpaQ1cwJdOVZCMVp6Rp+WBx8ufzpYLSWVx1+tdDZW3lKOKUUN6Fu2TYoHarWeOKiQcCpAatkij3pcUmeKUUhhiijNGeOaAEpaAaM0AGaTNGKWgBDzS8UUhoADRRn2o7UAGc0ZpD0oHFAB1oPFKaaaAAUZoWjigBc0hoNNNACjpS8U0UZoA+W/21jm78I/7l1/OKvmSvpj9tQ/6b4TH+xdfzir5nrOW4z3f9jj/kpup/8AYHl/9HQV9jnqK+Of2N/+Snan/wBgeX/0dBX2NVR2AUA/Sl/nR06UfWqEGc0ZOOaARikoAQjIqNog3UVNkdqCM8frQBXW3QEHbUoUD3FPFIQc570AGTQRntRjj2oyc8UAMK5qF7VHOSuasgep5ozzQBCkKoOBUirjtTwOaOM0CFoJOOKTilA4oGLSim0tABmg+9GeaM0ALQetJRQAtLTaUn0oAM0UmaKAF7UfSj3puaAHUdqQUUAFIetLnFJ1oAKMUHpQKADFNbpTjTc0DCijvSHigD5Y/bU/4/8Awp/1zuf5xV80V9L/ALan/H/4T/653P8AOKvmis5bgetfs1eLtE8GeOr7UfEl79js5dNkt0k8p5MuZYmAwik9FbnpxX0qPj18Nh/zMfH/AF43P/xuvl79n3wBpfxG8Z3uka3cXsFtBp73ataOquXEkagEsrDGHPb0r35/2W/BY6an4i/8CIf/AI1TTYWOj/4X18Ns/wDIx/8Aklcf/G6P+F9fDg/8zF/5JXH/AMRXHy/sy+EEv7eL+0fEHkSo/wA3nw5DjBA/1XcZ/KrB/Zf8GY/5CfiLJ6f6RD/8ap6hY6k/Hr4cdR4g/wDJOf8A+Io/4X18Of8AoYeP+vOf/wCIrl4/2X/BbID/AGn4i3Dhh9oh4P8A36rgfjJ8FPDHg3SdKTQ73WLnW9UvUtbWG4ljZGB+8SFjB4yo696G2gasezH49fDg/wDMw4/7c5//AIik/wCF8/Dj/oYf/JOf/wCIrlh+zB4PVFEmpa8ZAo37Z4sbsc4/ddM1Xm/Zp8HKwRNS14v1P7+L5R6n93RqFjsT8efhx28Q/wDknP8A/EUD48/Dn/oYf/JOf/4iuLP7NXg8f8xHXv8Av/F/8bpV/Zq8HnrqWvf9/wCH/wCNU9R8p2n/AAvr4cf9DB/5Jz//ABFH/C+vhwOniH/yTn/+Irkk/Zl8GNj/AImXiDP/AF3h/wDjVOP7MXg0H/kJa/j18+H/AONUaisdUPjz8Of+g/8A+Sk//wARSn49fDnt4gz/ANuk3/xFclF+zN4KMmybU/ECsTwfPhwf/IVWv+GXPBY66n4g/wC/8P8A8apagdF/wvr4d9te/wDJWb/4mj/hfPw7P/Md/wDJaX/4muc/4Zd8F/8AQT8Qf9/4f/jVH/DL3gv/AKCWv/8Af+L/AON0XYjo/wDhfXw8x/yHP/JaX/4ml/4X18PP+g5/5Ly//E1zf/DL3gz/AKCOvf8Af+L/AON0f8MveDO2pa7/AN/ov/jdF2B0Y+PPw9z/AMh4/wDgNL/8TS/8L5+Hn/Qd/wDJaX/4mub/AOGXvBn/AEEdd/7/AEX/AMboP7L3g3/oI65/3+j/APjdF2M6T/hfXw8/6Dv/AJLS/wDxNH/C+vh5/wBB3/yWl/8Aia5v/hl7wZ/0Edd/7/Rf/G6P+GX/AAZ31HXf+/0X/wAbouwOkPx6+Hn/AEHf/JaX/wCJoHx6+Hv/AEHf/JeX/wCJrm/+GXvBn/QR13/v9F/8bo/4Ze8G/wDQR1z/AL/Rf/G6LsDpf+F9fDz/AKDv/ktL/wDE0n/C+fh5/wBB3/yWl/8Aia5v/hl/wZ/0Edc/7/R//G6T/hl/wZ/0Edc/7/R//G6LsDpf+F9fDzH/ACHf/JeX/wCJpf8AhfXw8x/yHf8AyXl/+Jrmv+GX/BvbUdc/7/R//G6P+GX/AAb/ANBHXP8Av9H/APEUXYHSH49fDz/oO/8AkvL/APE0v/C+vh3313/yWl/+Jrmf+GX/AAb/ANBHW/8Av9H/APEUv/DL/g3/AKCGt/8Af6P/AOIouwOl/wCF8/Drr/bv/ktL/wDE0h+PXw7P/Me/8lpf/ia5v/hl/wAG/wDQQ1z/AL/R/wDxFH/DL3g3/oI65/3+j/8AjdF2B0Z+PXw87a7/AOS8v/xNH/C+vh8Omt5/7YSf/E1zn/DL3gz/AKCOu/8Af6L/AON0H9l7wb/0Edd/7/Rf/G6LsDo/+F9fD/I/4nQ/78v/AIUn/C+fAB6az/5Bf/Cud/4Zf8Gf9BHXf+/0X/xuj/hl/wAG/wDQR1z/AL/R/wDxui7A6L/hfHgHP/IZ/wDIL/4Uf8L38AY/5DP/AJAf/Cuc/wCGYPBv/QQ1v/v9H/8AEUf8Mw+Dv+ghrX/f2P8A+IouwOj/AOF7fD/HOtEf9u8n/wATSn48fD3/AKDhH/btL/8AE1zn/DMHg7/oIa1/39j/APiKP+GYPB3fUNb/AO/0f/xFF2B5N+0/448PeNbnw6/hu/N4LVbgTfunTbuMe37wGc7T09K8NxXsv7RXwv0b4b/8I/8A2JcX039ofaPN+1OrY8vysY2qP75/SvGal+YHun7HkzQfE7UCksaM2kyqBJ0f99D8ue3Tr7V7P49TSdP0D4n+K7nwzoOqatY6nbrCdVsUuAFNpYjaT97aN7EAEcnNfPv7NmP+E6vtwz/xLn/9GxV799q0LUdC8beG/GEmuQRatqMUolsdNuJi0a21qAyyJE6feiZcHJ4NIfQd8L7bw94i8W6rouseC/B5W3soLyCVPDv2CWQP979xNucqCcbxgH8a7n4YSyRfDLwh5kTPGdIs/niG7aPJTqvX8RmsPwpN4V0rxA/iD7V4z1nVGs10+O6u/D92fKgU7vLRYrVF68kkE+/Wuv8AhvZz2fw48K213DLBcw6TaRyxSoUeNxCoKsDyCDkEGqiCNOG4trliIJ42deoVsMPqOo/GsLW/BWlaz4p0jxDfi6l1HSh/oo8390p5OSnQnPf2HpXQX1lb3aFbu2huF9JYw386y38O6SRhbFYh6QSPEPyUiq3CxovG5yXlkOe2QBWLrfiPw94fhLaxrGmWCAFts1woZvouck/hTZPCegsuJdItZ+/+kbpc/wDfRNcX42+C/gzxRYSRwaZDot/g+VeWEewK3+1GPlYevQ+hFPUep2vh7XNH8T6b9v8ADuo2+oWgbYzwtko3oynBU+xAq+yEV8MajB4y+C3jhhFcSWV4PmSaL5oLyLPXB4dT6HkH0NfSvwm+OGh+NhBp2seVo/iBsKI2bEFw3/TNj0J/un8CalStuCZ6tExHFWo39ajaEqeaQAirAkliV0IOCp7VHHcPa4SbMkPZhyVp6vnvT2UOO1AmiwrKyhkIZT0Ipe9ZYMto+6PLIfvIen4elaEE6TpujOccEdwfepasSS0uaaKKAFpe1JQaQwNHeiigApKX60negAooooELRSUCgBaKKKBi9qKSjNAC96SlFIaYBR2pKKBBRRQKQBS0UUAfLn7bn/Ml/wDb7/7Qr5dr6j/bd/5kv/t9/wDaFfLlS9xnq37OBx44vv8AsHP/AOjYq+kkk289vWvmP9n+4S28a3LSNtDWLqD7+ZH/AIV9IxyBhkYINIpbHQ6Lq01hNujb5D95Oxr0DS9Xt79QNwWT+6T/AJzXkYcqeDVu1vniZdp96Yz2B481XljrnNB8UrhYb8/L0WX/AB/xrrBskQMhDKR1FNOwjLkXb15FQMAPp2rTliz9KpyRcntVpgcr478IaR430B9J1+AvFndDOmBLbv8A3kP8x0PeviT4ofDvWfh3rf2PVF86zly1pfRqfLuF9v7rDup5HuME/oCwz2FZniTQNL8T6JcaRrtol1YTjlG4ZG7Oh6qw9RQ1cTR8tfB79oHUPDywaT4xM2paQuEjuh81xbj3z99R7/MOxPSvrHRNU03X9Kh1LRbyC9sZhlJYW3A+o9iO4PIr4f8AjJ8JdV+HWoGePffeHp3xb3wXlf8ApnKB91/fo3UdwML4d/EDX/Aep/a9BuisLkGe0k+aGYf7S+vuMGs7tAmfoKyEc0gOK4T4WfFrw/8AEKBYIH+wa2FzJp87fMfUxt0cfTkdxXfvGQelWpXGJw4wearyRNG4lgbD/wAx6VNjFKpqhDrS7WclG+SUdVPf3FWs1mz26yKNpKsOQQcEH6062u2RhFdYDZwJOx+vvSa7EtGhSjpTQaWpAWijvRQAUlLSUALRSUUwCiigUgF5FJS0UwClpKWkMSiiimAlFBopCCiikoAdSUCigD5e/bd/5kv/ALff/aFfLlfUf7bv/Ml/9vv/ALQr5cqXuM9D+CMSTeKrxJELr9hfp1H7yPkV7nbXU+mFUmYyWpPDHqv19K8S+AwJ8X3mM5Fg/T/rpHXubj5jnDjoVI61DdmNG3BcJKgdCGU1Nu9K5SNptPbzbcEwdWjPb6Vt2d7Hcxh4mH0pplGmkrKcg8V0Gh+JLnTdqr+9hzzGT/L0rlFfJqVX596YHtOl6la6rbCW1cE/xIfvKfQippYs149p99LZzrNbSNHKvde/19a9F8P+J7fUStvdlYrojg9Ff6e/tTTsI0JovyqAjacHrWrJHz0qnLD1NaKQFC+tLXUrC4sNSt4rqyuF2SwSruV1PYg18ffHD4JXfguWbW/DgkvPDbNuZeWlss9n/vJ6N+B9T9kOP0o+RkZGVXRwQysMhgeoIoauJo/NmKWSGaKW3kkhuIiHR0JVlPUEEc+4NfR3wj/aGkgEOlfEFnmhzsj1VFyy+nmqOo/2hz6g8movjf8AAo2RuPEfgK1L23Ml1pSDcYvV4R3X/Y6jtxwPn3ZEYshwSecCsmrCufo/aXNtf2cN3YXENzaTKHjmicOjqe4I4NOI7V8IfDL4l6/8Pr3OmS/adMZt02nTsfLf1K/3G9x+INfYfw4+Inh/4g6eZdFuPLvY1zcWE3yzRe+P4l/2hkfQ8VUZdyrnVngYNNkRZE2sMj3qUqRUZ/GtEBFDM9sdr5eHse6/4itBWDqCpBBGQR3qk2G4IqsJZLNy0a74ifmTP6j3oauS0bANFQQ3UEsCzrKgiYcFztx9c0xtRsEcq1/Zqw6gzKCP1qUmyXJLctUU2NlkTfGyunqhBH6U6kMD6UUUUALSCiigBaBSUpwFJJAAGSScAUwFFB61zepeNtBsGZDdm6lXqlshfH1boPzrAn+K+jxzbBbSg+sk8a/1NbwwtaavGLMJ4qjB2lJHoVFcNZfE3SLlsNa3gA6tFslA98K2cfhXS6Pr2lazkaZfQzyDrFnbIPqp5qalCpT1nFocMRSqO0ZI06BRRWJsBpO/SlooAKWkooA+Xv23f+ZL/wC33/2hXy5X1H+25/zJf/b7/wC0K+XKl7jPSfgKSPGF5gE/6C//AKMjr3lxuOS3I9K8E+BP/I3XmTj/AEF//Rkde7oRncoXPbnGKzluNDSfLPyqD3IIzUDJtc3Fs3lyn7yYwrf4Vc+VuWOCOpqORGU5jBx7d6QElveBjhuG6EGr8cmRkVishlILHaB/EOop8Ny0TYk/76HQ1SY07m+jZ4HX0qeNgcbx0rMgnD8g4I4q2rZTmqQztfD3i6WzK2+plprTosvVo/r6j9a72OSK5gWa3kWSJhlWU5BrxEOQOa1ND1m80m48yyfMZ+/A33H/AMD70BY9Tmh7gVTZecdPenaHrdnrluTAdk6/6yB/vIf6j3q3cQ5zxzWkZCKSuYzkHBrwn44fBGLX5LjxD4Lhjh1k5kurBcKl4epdOyyeo6N14Oc+6yjBHHIpiMAfbt9apq4rH50SRPHK8MqPFNG5SSKRSrqwOCCDyCDxiprC5u9Mv4L7TbmazvoG3RzwuVdD7EV9dfGn4R2njdW1nRFhtPE8Y5J+WO9AHCv6Njo/4HjGPlC+tJ7K/ns723ktr6Fik0Eq7WRx1BH+c1i1YTPo/wCEv7QNvqHlaT4/aOzvfux6oAFhl9pB/Aff7v0r35Ck0aywOskbjKuhyrA9wa/OiSNWGD0+le2/BHVdatfBGpLPqk7aK1yLW3szzt6l2B6hT029OtbUKcqsuWJFSqqceaR734k8cabpKOsTJcPGxV5C22GPHXLd8e3515Hr3xllnZ4rVHuVORiM+VEff+8a4Dx5q0+o63LZMzLaWZEWzP8ArHA5dvXrgDsKwFAHSvo8NgKUEnJXZ5s6s6urdl2R1t14/wBamLbFtYlbjGzccfU1BF451qM4kWxmXGCJLdTkf571zdNcc16ChC2xiqUH0PSvDvxKSG9ja8tZbJwwzNYyEDHoV9K9q8J+MXu7VZhcDVLLODIoAmiJ7EcZ/EA/WvlG1haRx8vArqdKvLvR5orvTZ2guU79Qw/usO49q5cTgqdVaLUlSdGV4M+v7S5hvLaO4tZFlhcZVl/UH0PselTCvFvhz433XMU8rBbW5kEN7EeTFKeFkz3HTn+7/u17QRgkelfN4jDyoT5Weph8Qq8b9VuFLRRXOdAoxjkgDqSe1eI/EHxm16L13d49HtFLoi8eZjoW9S3HHbI969puEMltPGBkvGygfVTXy58QlLeDLyWMHDm2lyR/AWAP5Hj8K9TLKcZzbl5HBjZu8afRnn+q69qOrMfOmaGD+GCI4VR7+p9zWX5a56VIq5UmlVSa+lWmiM0ox2GJuiYNE7xsO6sQf0rsfC/im4a8gs9VndixC2t6vEsD/wAOWHJXPHqK5BuGx6Vc0K0e+1m2jTASNxNKzcBEBGT/AEx3pTSktSakION5H1T8MvGNzqsz6NrTB9QjQvDcYwZlHDK3+0PUdRXoVeG/DlN/jvT5wTgNIvHqUPFe418pjqcadW0DfAVZVKb5nezt+QUtJS1xHcFFHeloA+Xf23P+ZL/7ff8A2hXy5X1H+27/AMyX/wBvv/tCvlype4z0j4Dru8X3eO1i5/8AIkde6sWIPQe+OK8W/Z0tTd+NNQQAkjTZG/8AIsX+Ne5XUL28hUh8+oFRJDKoYBQGxn3FOV8DIYY7+tI+cZBPPrio1YAHtkelQBMUWRvlADY5HrVdoyUIZcY61MH+XJYZHoalDLj958wI5zTAoo7wEFH+StK0vAwCnrVcwBlIjxkdAaqsPLOU4b+7600xp23N5ZRxjkVMj8ZFY9hJLMSI4pJD6KpOPrV8uYcC4aKHPTfIvPt1rWFOc/gTZM6sIfFJI0IZpIZkngkaGdOVkU8iu98OeMI7ny7TWdkVweFnHCP9fQ15el/brndeWhxzlZQf61KJ0kQKCHDYHbFbfVK+/IzL61R25ke53MAdOmQecis2dCnPJA9K4jw14vOjbbTUGeSyB24PLw+6nuvt+XpXocMtrqVqtxYzxzwt0eNgRUuM4fGrGkakJ/C7mQ8uDx3rw39pK08O36WcsiPF4liH/H3EnyCPGRHOe+f4cZK9ele6XVvtlUtwpPPpXyL46u9S1zxpr82rloms7w2i2+3ailQBuC+rdc+mKUtdAm2tEcHLbZjLIc98GvUfhZNAvhZLO4ZYI7lpFMj8qsokJRj3A6g49favPX2ssgXqeGB42sOortPBK7fD8KEf8tJDz/vV25Suas0+36o4Mx0pK3f9GS+O9Cuba6m1QQupGFvozyY26CT3UjGT+PQ1yqkEZzxXqtlrDQIkF8pmt1BSOQY8yFT1AJ4Zf9luPpWFqfgq2vg914ZuYVbq1o52qT6rnlPocr7ivo4y5dJ/8A8yhiYtKMtH/X9fnY4mpLdUaYeacLUWrJc6PI0eqWc9sw5zImA30PQ/ga50eIXMvyQqRnp5gqXjKMZcjlqdypSkro9It4Y1jUoMU6Rhg5rmtI1oggTRSInp94Ct4SpMm+Jgyn0rRSUtUzllBxepd8NXxtdYdMFobmF4pFzjPGVP1B/rX1tolybzRNNumOWntYpCfUlRXxzpRP8AbtsFHXdn8jX1z4Kbd4N0FvWxh/8AQa8nOILljI6ME2q8o9LL82bRopKUDivBPWHL1/Ovmy5e2muL7Rb8ARSmRULejH5kz25+YHsfrX0mv3hXyx43XZ4kuR/00b+devlK5pSTPKzRNxi1vc881jTrjRL+SwvQQ68xuRgSp2Yf19DWet1EhAZlH1NenxXEGqWi2WtWcWoQRkFPNyGX2DDkV0Ty6AmlTQWHhTQrRvKJM622917Yy3c/3s8V7cq8oWTje/3HHDG01FqppJdP8jxjStMv9ZnMemwbkBy8znbHGPUt/hXf6Zpun6RYxwW8zT733XM+MPMw6Ko7KOx/Hmia4do1iwFhThY1GFH4CokyXyTzWr945q+LqVVZLlX3no/w0uPP8X6cQixRjescadEXY3HufUnqa9t7V4T8LGx4u0wZOMuP/HGr3avmcyVq1vI9jLP4Pz/yClFJSivOPSClooFMZ8u/tu/8yX/2+/8AtCvlyvqL9tz/AJkz/t9/9oV8u1D3A9z/AGP7dbn4k6pG4BH9jyn/AMjQV9IeJNAwTIgOB3FfO37Gf/JUNU/7A8v/AKPgr7GnhWUEMAQRVJXQ0eDX9pJasSwJAH45qkQrZYnbx6V6t4g8Pq6O0a5U9QK891PTmt5CCrEDoSKzlCwGQrMOvGR3HWpi6vGCuMgc0zHVQdjDjBpseVO1cZz0HeoEOB7l9vHBxUMzzESJa2zXl864toAwVXf/AGiTwKmyApBOCP4T6VFLlQWBIIAIIHIOa68DGMq8VJXObGuaoScHr/wdfwPLta1TxANSurXV7q6tb2GQpNArbAjemBxj0PQjmsR4yxy7Ox75YmvWvEGjW3iuNZN4t9WhTCy4zvUfwkdWX2+8vbI4rzTWNL1DRmP9pWzJFnAuE+eJv+BDp9Dg19lTqXVtmebh6tOqv3f3dTOEKf3akjLxHMUsqH/ZcikDBuQQadWl2dLSZp2PiLWrEEW+ozbDwUk+dSPTmu78EeMru6v0t7aVtO1p/mheF9sdwRzs2njOOing15hmtDw1Y3Gr+JNOtLLPmrMkzvnAiRDuZ2PYYH51jVhGUXzIzdKPTQ+uPA/iqPxPbSWt6IodYtxmSJeFlX/nogPbsR2P4VkfEX4cad4viWSWSWy1FFCrdwrkkDosi9HA7dCPWvMEvwPGdtdafLsX7UsEZHBbcSX6dgDj6109x491/R9UKG5jvbNv+WV1HuK8/wALLhvzzXzWJw3JVUYbPU6sHiPa03zdHY0vHPww0/xfCbmfbYeIQoX+0LSPKzYH/LaP+Ie4+YeteRR6FqHhctpOsLGl7A29hG+5SrHKsD6Ec4PIr6O0LxNZaxCrgRxyEcqSwIPpyK8o+L8OzxyLhQdlzZRnrnlSVP8AIVrli5a7v2f6EZkv3N13OMY/Kc9+adbj5gQMEHr6UxyVAzT4Dzz619EfPNXgzaivJWg8mZhPCescoDqfwPFUzpOgJI0z6FpynBLuYRwMc49KmgBbaAK57xtrCJBLpdk2+4kGJ3U8RL/dz/eNYV3SpL2k1sYYaFarU9lSbV/wXc880ydpLg25tn3Mx8naMllzwMdcgVtWkNwkjyxgrsUsytxuA68VFoL/AGTxToN1n/UajbSEgc4Eq5H5ZrqPEV6dQ8deIbo42yXNxtXGBtBIAx9BXDl2KqVbxmtj6bE04w1j1DSbZRLNfhmYQwM+3HTIznP4V9R/DeXz/h94ckPObGMfkMV8t6fdJFoxtZSVF1HsVgM/NjgH2r6a+E+U+G3h6NyGdLbaSpyMhiOtGbr91F+f6HNgL+3nzdtPRf8ABZ1op1ItKPevnz2BV+8K+W/H+F8S3HvI386+pF+8K+XfiKMeI7nrxK3869bKP4kvQ87Mfhj6mdpCNLcBI1LO3QKMmtS8kEdhsB/eTkE+gQdPzPNGgamtn4evLSBczahiKSQcGJUbLLnrhwR+Rqpdks5J64r3LOT12X4/1+h85Vs6nn/wf6+8pN1pU60N6Ui9a0Rcj0b4R25n8U20gAxBHJIx/wCA7f5mvbhXjHwcuo4PEbRS8G5t2jjPqwIbB/AGvZ818xmV/bs+hyy3sdO4o7U7vTadXAeiBooooGfLv7bn/Mmf9vv/ALQr5cr6i/bc/wCZM/7ff/aFfLtQ9wPev2M/+Soap/2B5f8A0fBX2Z2r4z/Yz/5Khqn/AGB5f/R8FfZlVHYaIpIwynIzXM67oizIzxr9RXV1G6AimB4lrGlSQSFhGWx2xWGd+CAGjAPTGMV7ZrOjpcIWRRu9+leca5ozQysVXaR1/wA96iUOwjmW3EHKBmHUkdKi6wSkNnCjI9OanlhdcqwYMTxjpVeEki6V8bvL49+RW+CT+sQ9TnxX8GVzNdiGBBIIOQa0rfWXVDHcxrOjDax+67D0bs4/3gfrWXJ1qM19i4KS1Pi7uM24uwzUfC/ha/zKpfTGyC7wKVwP+ufKn8KybnwNpe4tZeLIWiz/AMtYMkfkR/Kt2Enc20447VoRXUqxFQtu4/6aQqx/MjNQ1KPwv+vuO2GY1YaS1/rzONi8J6HBIzX2vXFzGpPyW0IUt6c84z7VpRXkNlatZ6BYjT4Hx5jnmSQ+rMeT+PTtV69fJOUjBIx8iBay7gkKcdqrlv8AFqarF1Kys9iawu411zRLa2TCx3CF5G+9K/07KP16mt3xCA2pcqQOuc1y+lgJ4o0xDksLmMEj1zzXU+JSE1QEEk5zk+ua8nHq1eFuz/M9XL0o0ZJdzu/Ax22agIoIHOfbnPtXIfEe+a78RG32LiyTy/M3ZLlvmOR2xnHv1rrPh+uUc4wu3k5zk1wHixs+LNYGMEXB4/AVGAgnWb7IMzqNUVHu/wAtTFmPPNEB6+tNm60sB+bFe0eQl7hrxPbDQ9dku1lJTT5zCYwSUmK/u2wOcZ4z0BIzXjemamtwSuQpPY9c+9euWc8lvOssDFHGQCO4PUH1B9DXM+M/CFpqEc9/pca2upoDLsj4SXHJXHY1wYzBuu+dPbob4DFww7dKStd7/wCZztmS+raYoHP22Af+RVrf1UbPFmtqOMXNwP8Ax41xOg3/AJ91ZMf9atxET9RItdxqn/I2a4cYHnzt9OTWGX/HL0PUxXwr1IXPladYv3Uqf1r6j+Dsnm/DTRnwFz5vH/bRq+ZUtmuLS2iHRFDt7Ac19OfB3B+GHh9kGA0Lt+cjVebP9wvX9GYYKzrN9k/xaOyBxSikxRzmvnT1xy/eFfMPxIH/ABUV3/11b+dfTq/eH1r5k+JQ/wCKjvP+uzfzNetlP8SXoebmXwR9TB0eZYbn96rNCeHCn5h7j3Fa11bOsropWZAgdJogSkinuO4I7qeR7isOyzuPHNbUqtPDbxmWWKFJ0kunjJBEY5KZ/vN0x6V7rutTwK6XtF59TPcFWwfpSL96pLmUTXMkioEVmJVB/CM8Cogfmq0Q29LnefDI/wDFW6V/vtx/wBq94rwv4VwtN4ssNnSHfK3soUj+ZFe6DtxXzWZ/xvkfQ5Wv3T9f0Q4U6kFLXnHphSUUpoA+XP23P+ZM/wC33/2hXy7X1F+25/zJf/b7/wC0K+Xah7jPev2M/wDkqGqf9geX/wBHwV9mV8Z/sZ/8lQ1T/sDy/wDo+CvsyqWw0FJS0fWmA1lyKydU0qO7jO4AOOhFa4prruB5xTA8m1/QzG/IwynIz0NcdqELwTE4+VzggA8da971GxjuoisiAn1NebeN9MNjp1zJtI6AN+PSujBvlrxa/q5y4ymp0ZJ+v3anmUveoj9OKml61Aema+tWx8bL42OhOCx9BxV+LkHFZ0fO7aCTir0BJTDAjHrSlsTPcpXnU1m3H3eOtad5941nSRySsEiQu3oP8aJNJXZ1YdXskVtM8yXxXpZtIpLiUXAl8lRyQoJP5YNdHr93HdXIlhdcBiCMFWX2KnkGt34b6bYWdzO1wQdUnXYkh+6id0X69z3rqdb8P2t7n7baRzHHUj5h9COa+dxmMjUrKUNUlY+kwtKVOlyvqU/h1cKEZC2TjO3uP/rc1wfjAkeM9XyCN027B9CBXaadoi6bKfsF5eW6HqhYSD82Gce1cT40eVfFVxDOQ/2dERJsYaVSM5Yeozj6VtltVSrSt1X+RjmMVKkvJmRL96li4YcU1zuIoT0r2+p5SXu2L0PLjIz2qLXr6PT4WUuDcyIRFH3yeMn0Aqh4gvrrTdFN1YAK/mrG0u3d5QPf+ma4hLh3maaaV5ZXOWkc5Y/jVJpDoYR1X7RvRdP62L0XhuAzW15CxhuYZFkyB8rlSD8w/DrWxcJJNqF1eXLr5tw7O6oMDJOSKr6ZeCRfLc8jofWrcvSs/ZxjJyS1Z3SnN+7JkunXaxtdQyPsaeIxo3bJHT8a+nvhHA9v8MfDsUq7XW3IIP8AvGvk3zPLu4mPQNX1x8LmD/D3Q3UbVaFiAew3txXnZv8AwY+v6M0wa5a7t1X+R1GOKKWg18+esC/eH1r5m+JX/Ix3oP8Az2b+Zr6ZH3h9a+aPiUP+KjvvXzm/ma9XKf4r9Dzcz+CPqc3FaTTQ2DQzGKB5nS5MZAf5QCqg9gc9fatXVbqSRILYFY7W3XbFAgwqep92Pdjkms3TJEjm2yMVibG4gZ2++O+Kt6un2XUVtLiSNZnUNEQ2UmU9Gjb+IH8x0Ir3dLq+54FRTc7dP6ev9dCoaRT8/wBTQ2R1601T83WrRMjvvhg7r4r0sxvtzIVb/aUq2R/L8q96Wvn74YSp/wAJhpCEkEynH/fLV9AqMV83mitW+R7+Vfwn6/oh3biigUV5p6gUUUUAfLv7bn/Ml/8Ab7/7Qr5dr6i/bc/5kv8A7ff/AGhXy7UPcZ71+xn/AMlQ1T/sDy/+j4K+y818afsZ/wDJT9U/7A8v/o+CvsuqjsMKKMUUwDFFHejtQAhArjfiqETwjNlgHaVFQHqTnOB+AJrs685+NCyiw0iRUYwrcOrsOilkwuf1FdOEV60V5nNjJ8lGT/rXQ8fl9elQt+lPl+8RUXGM19atj46Xxsr6wZ4tDkmt5WhBfy5JE6qCM4z2J5x9K5HT9R14TJb/ANqXIAAOGw2VPTqM139g5H2mIhXiliKujDKnuDj1B5HpXml7cvFq0sqt8+ep70Ld3PTwFpxlT5U3vqkdlZtJcXAiubhmkCeYQeCwz/jWuHAUbQAPTFcNZa5bfbbSbUraWSOGQM32eTa7L3UH3rtrV7PVYZrvw/dC4hQ/PbT/ACTQ5/vdvbPT3ryMywlWs1KL07f1+p6WG5aKs42Zct5SCCCVYcg55Fel+Etei1SJbO+KrcKMK54Df/XryaKdZASu4FSVZW4Kn0Iq5aTlJVaPgqcg14Moyg+WSszvi09UeyX+m7Wztrxn4kR+T4vcHkNBGfrxXsPg3xDFqVsttfMomxhSe/tXmfxutxbeM7bZ0ezVv/HiP6V6GWfx/kzlxy/d38zjAcinL1GKjTpUi9ea+jPFZes5zCZF2xyRSoY5YpF3JIp7EfqD2NctrnhmNBLPpRKhQWNuxz/3ya6OM5xUeo3KWds00pAJGEXu59BTsiKdSdOfuP5Hn9jMdwZTgiuk8zzIQ3qKx4LZNwJAzWzHBtt8IwbHbuKNbanozmpMqR27XN18oykSl3r7D8CwrbeCtAhUcLYwn81z/Wvk/TJUTS9UijP+mSDGO5Svr7RIPsui6db4wYbWKM/ggryc4fuQXmzXAycq0/JL/Mvg0E0lJmvBPVuOX7w+tfNfxGGfEl//ANdn/nX0kG+YfWvm/wCIGT4m1EEEETvx+NerlOlV+h5uZp+zRy0a4arGq2Z1HSYrAEIz3Eciv/zyVTlpPYAZ/E1FOtysNn9jEYNxO0TzOu7ygq7jgepHrV3UrkLbR2VugjhXmV85kuG/vO38lHAr3n5Hg3bnGSeq1Xy/r5la9eKS8na23+QXPl7/AL23sT71WPWjcB3pCcnrVIHCysdR8NpsePNDQ8FpzjH+6a+lP0r5b8F3As/GOkXbDKwThyPUYIP86+o0dZFDoQUYZB9RXz2bte2Xp+rPbylWpyXmLS0UGvKPVDtR2oNIaAPl79tz/mS/+33/ANoV8u19Rftt/wDMmf8Ab7/7Qr5dqHuM96/Yz/5Khqn/AGB5f/R8FfZdfGn7Gn/JT9U/7A8v/o+CvssVUdhhR60GimAUUHFFMA71y3xPkaPwPqBRiu4xqcdwXGRXU1ynxSP/ABQ9/wD70f8A6GK2w/8AFh6oxr/wpejPAJPvGmdvxp0nDHvzTfXOa+vWx8XL4mS2X+tcf7B/CvL9W41CYdwSD7c16Hqktzb6RLNZP5b7thkAzsBHb3xnFeZSI+5s5dicls53H1pPbQ9XLIfFN9dCInB4NXdDv57DXLCe1YiQzLEVBx5isQCp9QQapeTMx4jI9ycVteFoYrTWba7uj5nktv2rz+XvWSUuh6spRjqz0bxM62mqWEqFCbljC4HVgDw3vjpmnQHDHHPNc/qF7NqOu2c91hD5gWGAH/VR9sn1NdDapg7mAIzXk4+iuaN97E4ed02tjY0x/JvIny3B7HFT/F5ftn9h6hnc/kNbuT/snI/nWaHwwHPX61r6m0WoeG2SQsxjYMVb8jiow6VOopFV1z03E88TgYqQGpLu1e1O7JeAn5Xx+h96iU17id9UeM01oxLy4e0064uIoxJJGBgEcDnqfpXKTTz3cxmuXaV8dT2+g7Cuzt5DFICApBBBVhkMD1BHpTbTS4JryO2hUKs7bIwf4XPQZ9D0FOTsrlUZRUuV9ev6HLWSl5fu9K1Nqg8fKfY1rXfh6402eQTxNE46AiqwtiB6A9Q2Ky9spbHZ7Joo2kJGppIMeWUIOOO44r7MidHhiaJgyFFKkHgjAr5T02wWB/PuVXb/AAoRyf8AAV7V8K/Ev2+ybTbhv39v/q8/xJ/9avHzKtGtyqPS/wChtg4OFSTezS/C/wDmeiFh2ppOeO9N6ij1xXl2PTHqMHNeC/F6yey8WzSMpEV2onjOOCOjD6gj9RXvWeK4r4q+Hzr3hl3gUm8siZoSOp4+ZfxH8hXXgaypVk3s9DmxlJ1aTS3R4TYMGlWF5FjR3GGb7qt0BPtzgmor+N45nWRCjo5R1PVWHUGqyOc4cY7dKtTu1yVcgsWXY575XoT+HGfpX01z5hQ5ZXKJ+6fWmF1RSTwBT0iklcJCjOxOAFFdPo2gxWrC41HbJcDlY/4UPv6mubEYqFCN5fcdsKLqaIPC2mPDEb+4BSeVcRIeqx9z9T/KvbPh9qn2vSUtpHBkh+Ue4rzBmLOpPc4rovBd61tqQUElT1GK+YrVZVpucup7GHpqkkkesigmmxtuQN606szrDvR0pKKBny/+25/zJn/b7/7Qr5dr6i/bb/5kv/t9/wDaFfLtQ9wPev2M/wDkqGqf9geX/wBHwV9l9K+NP2M/+Sn6p/2B5f8A0fBX2VVR2GGetKOlJRVAANLSUZ9qAAE1xvxauDF4PeLjE86Rn6ct/wCy12Vc38QdIl1nwvcw2wU3MJE8QI+8V6ge5GQK2w7UasXLa5jiE5U5KO9j54lPzcU0n8/Sh3DfMM4PYjke1R5z0r69bHx04+8yzaT+X5yOiyQTx7JIn+647fiDyD2NZ58L6JIGbfdRt3CqDzVmJsPn2q0p/dtjBFK3VC9rUpP3HYwH0DTIT8nmSD1bigxw2yEQRrH7gVoXmB689KzZz8oB6d6bZ1wlKavJ3M4ErqVrnr5gJFdbFOQq5Y57gCuZtQsviKw85tsb3C729Aa6/V9Jms7hwQ3BrzcdbnjfsevhfgdiIT+xz61chvgkLx9FYcj1rFJdSc9fanCTHXpXPFI1bZeEm31xjoRkfjUD2MU77oh5JPZR8v5dqaspHOaeJADnIDY6nmuqFS2xzzpqW5WexnjPKBgO6HIqG6WQJkblI5BHUHsRWqJmyPmJ9e1SqjS/exs9at4pQV5GDwnM9Gek61ZvrvhHTNTxE9zLbJJIYzuBYj5se+evoa4CbTFs3LSjL54B7V6/4Wto9M8G2NrcFVIQuwbtuJP9a8v8VgC+kWJxtByK8N1ZSvGOx6rhormFdEEkZ5/OpPD+oSaVrUNxC5XByfSs6Xc2c5xnimJEUIPYd85qkkkJKx9PaPfJf2UU8ZyrgE+1aAAzx1ryv4X60QgtZGyhPBPY16mh3CuWaszqi7oUg96SQblII4/nUhpmDzUjPn/4g+GRo+uSyRqfsk53oB29RWTplvOrSG0DQiSMwyOT95G6g+xxXuvi7R4tSsT5iZdORXmU9p9nBiw2M49BXY8dUUeVHDPCw5r2Mm1gS0TESjd3Yip1XjLZJP6VaKYA24VvzwKYsYxgMDnqcVxSm5u8i4wUdhsYJYA4x39Qa2/DrBL9C3AzWQq7ATgGrNrJJG6lak0R7TasGhQjpipq5Tw3qhlRY2btxmuoR80M2Q/0pKUdKKBny9+23/zJn/b7/wC0K+Xa+ov23P8AmTP+33/2hXy7UPcD3r9jT/kqGp/9geX/ANHwV9l18afsZ/8AJUNU/wCwPL/6Pgr7Lqo7DENHalPtR0pgJ24pOKdSH0pgGeTRnjkUhzRnigR8+fEPw6NP8RXQtv3aynzY+PlIPY/Q1xcpkicpNGUb3/pX0B8TNLS80xZ9p8yE8FTivH5oxKpjmG9R2YdK9zC4t8qUjycTg4uTa3OfikPmcehq9CTsXbyey5qaTSYyS0DtG391uRVY6dfxcL5JUDg9K9GGIg+p5tXBzeyKd22CVAGM8896zZ2wDnpWu2nTkn7SSpP9wdfxp8WnrEd4QO/YsM05Voo1p4eSVmY1nZMSZpQVOMIp6j3r3bStPh8U+F7O8BxdrHslA7sOCT9eteTPEeRg5r0r4O3hie4sXIKyHeoPYivKxk+f3kepho8vunM674dltpGwu0j0HBrmJYJImwVJHrX0pqekQX0ZEiA56EiuD1nwawdiilwf4sciuWFfubTpHkiJk9x7VLHG38KnPQ12lx4XEByQc/TvWNe2htT9z8abxL6Gfs7FGK3VeZFOf7ua1NPlhhk8yVFO3lVPTPrispmbPt61G8jbSM8Vk25u8hpW2Om1HxFLOvLtnsM1zc9xvfJOPqc5qBFaRsYJ9xVyK06fJyfxo0Ra1KvGOUBHqaVR6DHvV/7A+eFYe2KVNPmHJT8alyHY1PCcv2e9RieeCAvevcNKuhc2qODyRXhWlQSx3KNs5969b8JzMIxHIOo9axcrmsdDq1FOAxSIcinVBRFOoZCCOvFedeKNL2SsVQcHIFekuMisLXrQTwk45AoE1c8oaPB2sPmJ5IpxUj6VdvoDFOyMeetQbOcZpGdiHHy05BkAdPepSvTpS4+XkUh2NXSLnyZVw3PY132l3nnRgE815naffGR06V1ej3JUrz9aaKiztlORTulVraTcoPrVgHNBZ8v/ALbn/Ml/9vv/ALQr5dr6i/bc/wCZM/7ff/aFfLtQ9wPev2M/+Soap/2B5f8A0fBX2XXxp+xn/wAlQ1T/ALA8v/o+Cvss1UdgEz+dHWj+VLnmmMSilpOlMAPrSAAHvSikNAFLVbNby0eGQZDDFeIeI9OawvpAqnAbHC/rXvUnIrgfHlgH/e7SQeDW9GdtDKpG6ueXhuBnGafvGMHB+o6UXEZjcrnOKhz6j8661U0OflHtjtk+mRUZiDZ+XANNOR1FLuK9yR7U/a2DlEeAcYyc+uK6/wCHFhKNVSZVOM/pWFpFmbu5VCVC5wd1ex+HLCCxtwE2lyOSBWFWppY1pw1N0KDSPHkEYyKcGGMDGKcOlclzcz7nT7eYYeMYrmfEXhe1urZti7HHQiu1PPXmq86BlqlITimfP+raUbMlXbkHpWM0RB5zXq3jvSC4Msa/XArzqa1cZBVq157GLjYsaTCjugQBifauysNAMwB2AH6VwVpNLZTB48gg16X4X1954lWWMe5FQ5lRRMnhZinWkfwuygjHHpXb2pWWNSOhqz5eRyKhsux5wNENu4JTGO9bOmDyWX2NdNPaxyDlRWXPa+U/y9M1IWNq2kDID3qwOlZdg5AAP0rSWkyhxqtcx71I9asCmSDjFAHAeItP+dpMcj0rnGj4969H1i23xsQM1xN5bmNiCOPWhkNGYUIHNNzggEVZlX5QOuKhK5OeMikIE+Vxyfat3TnwRWLChJyOPWtiwXG0mmgR2OlzbowDWvGa57S8gjFb0fAFNlo+ZP22/wDmTP8At9/9oV8u19Q/tt/8yZ/2+/8AtCvl6s3uM96/Yz/5Kfqn/YHl/wDR8FfZVfGv7Gn/ACU/VP8AsDy/+joK+yv51UdhhRRRVAFHXrRQKACg9qOh9qSgBGrE8R25nsnULmtw8iq1ymUI6g1SYmeG69amKZiFxg8gVi5r0bxXp/75jt4NcDdWxhkO4Vt7Sxi4kK5IA659aXbtPQ5p0ZAbAarwt9wyT27VDqAokNldtC4wf0rqNI8RPEwVZWOOgzXOm2iXkg1G4UY8tcEe9S5jSseu6Pr63GBKRk8Zro4pN3IrxnSbl42QF+D/ABZr0zQLzz7Zdx5+tLc0TN880xlyDQpJ+lPxSGZGp2i3EDK3JxivPNY0gwuwUZFerMnJ4rL1LTUnQ/Lz6ine4mePy6UXcfLjNdN4esTGVVFyQa159L2nBX2qxp8ZtXyBmpsSdLpsZjgUGr4rOtbhXA7Gr6tnikyxxFQTQq4wasCg0AZ6Q+W+AOKugcZo2gnOOad0oAKRhxSj2opAVLiPehFcrq1l8xwBzXZSL7VQu7USA5FUJq55zc27IxB4NQLCxPJNdfd6cCfmX6GqB0x92F4FKxNjLhi6YrSs4Sdu0Veg0vJ6Vs2WnrEORTGkLp8BVRkfjWqg4FRxLtGBU6jikyj5e/bb/wCZM/7ff/aFfL1fUX7bfH/CGf8Ab7/7Qr5dqHuB71+xp/yU/VP+wPL/AOj4K+yhXxp+xp/yU/VP+wPL/wCj4K+yveqjsMUjNHY0dqTHNMBaKDQaYBSUvWjFACZpjjjFPI5pCOKBHM+IrPzYmYdetebazZMGJx+Ir2K+h8yNhXCa1YOhdccHkU2JnnBTy3PIyOx71qWr5jUh15p2oWDLJkD6k1lujCT5uPXAqSS9cOqqSZAQPSs9pULcDJPfNRE7ecE/WnKgPYj0PY0rgbGnyDYp4Fd54Wn2uFGOeeOlefabFISA6lcetdvoSNG6lcDHbNUho9ChbKg+oqcdKp2R3RjPpVxaGUGKayg1JSUgKc9qj9utUJLAg5U8VtkZFNK+1FwMaO3dCDjmtC3LdG4qwUGOgpcd8UXAcKKB0opAH1ooooAKKD+lFACHpTSoPUU+igCq8CsTkVH9kQdRV0ikK07gV0hUdBipQuMGn4paAGgD0p1FFID5d/bb/wCZM/7ff/aFfL1fUP7bf/Mmf9vv/tCvl6pe4HvX7Gn/ACU/VP8AsDy/+j4K+yccV8EfAHx5pvw88Y3mraxBdT281g9qq2yqWDGSNgTkjjCGvff+GoPB+f8AkG63/wB+o/8A4uqTGe9/WlxXgn/DUPg//oG61/36j/8Ai6P+GofB/wD0Dda/79R//F07oD3ukrwX/hqHwf8A9A3Wv+/Uf/xdH/DUPhD/AKBus/8AfqP/AOLouB713pa8E/4ag8If9A3Wf+/cf/xdJ/w0/wCEf+gdq/8A37T/AOLouhHvdFeCf8NPeEv+gdq3/ftP/iqP+GnfCZ/5cNU/74X/AOKouB7vIOM4rM1GxWeM7lzXjR/ac8KZ/wCPDU/++F/+Kpp/ab8Kf9A/VD9ET/4qi6A7rUNJxuyp+tYFzphbKlV449K52X9pTwdJ97TNXP0jT/4us2b9oTwY7EjTdbGfSGL/AOOUXQrHSyaT8xyuD78ipINJy/QAHkjsa40/H7wdk/8AEt13n/pjF/8AHKfH+0F4ORs/2Zrv/fmH/wCOUaCsel6fpW3buU4710um2QGABxXjcP7RngtDk6Xr/wCEMP8A8dq9F+0z4Kjxt0rxBx/0wh/+O0XQ0j3u3j2JjHNWBXgY/ah8GD/mFeIf+/EP/wAdpf8AhqPwZ/0CvEP/AH4h/wDjtK6Ge9iivBf+Go/Bn/QK8Q/9+If/AI7R/wANR+DP+gV4h/78Q/8Ax2i4HvVLXgf/AA1H4M/6BXiH/vxD/wDHaP8AhqPwZ/0CvEP/AH4h/wDjtFwPezRXgn/DUfg3/oFeIf8AvxD/APHaP+Go/Bn/AECvEP8A34h/+O0XA97o7V4L/wANR+DP+gV4h/78Q/8Ax2k/4aj8Gf8AQK8Q/wDfiH/47RcD3uivBP8AhqPwZ/0CvEP/AH4h/wDjtH/DUfg3/oF+If8AvxD/APHaLge9mivBP+Go/Bn/AECvEP8A34h/+O0f8NR+Df8AoF+If+/EP/x2i4HvdFeCf8NR+Df+gX4g/wC/EP8A8do/4aj8G/8AQK8Qf9+Yf/jtFwPeu1ArwX/hqPwb/wBAvxD/AN+If/jtH/DUXgz/AKBfiH/vxD/8douB71QeteC/8NR+DP8AoFeIf+/EP/x2gftR+DP+gV4h/wC/EP8A8douB70KO9eC/wDDUXgz/oFeIf8AvxD/APHaB+1F4M/6BfiH/vxD/wDHaLgcv+23/wAyZ/2+/wDtCvl6vZf2iPijo3xK/wCEf/sS11G3/s/7R5v2xEXd5nlY27Wb+4c5x2rxqpYBRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scalp lacerations can sometimes bleed profusely. In such cases, scalp clips (like the Raney Clips&reg; pictured above) can tamponade bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aesculap&reg; Raney Clips. Copyright &copy; 2010 B. Braun Aesculap.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11426=[""].join("\n");
var outline_f11_10_11426=null;
var title_f11_10_11427="Oral lichen planus - reticular";
var content_f11_10_11427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Oral lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0F7UngYKkdMc1mXunh0IK8jnpXQxIG5JximTxggsOg64o5EWpnluvaO8shywMaciPFcrd6URvaQbsjgZwBXreq2YJZhkDH51yd9aAE8cVy1KVmbRlc881bSWvLRSArzwj7v8AfX0qDwZ4suNC1tI3TbaFgskf92uuubco4IX36VgaxpkP2pLpVIlHIOMgnuK1pzaiZTpKUj2nUNV0m+0yGezl81vLy6gZYH29a8bk8S6tovjCbVdI3Wc8aNHH5yckEYOVNTabcXyz2txoEpV85CY6MO31rTuNdlv9Qmu9fsor27cYZnA4PTJA61vGp1aMauFb0izmPh1JPfX995xJmyXdj7nJrrZtN+2XCyxEkE8svQ1X0W3srK1c21kVuJZMvNvIyn93Fek+D9Ij1JYreKRApJJdiBkelVJqa0IWHqUPjWhzM+jizggN1FiGaPfHjuPX864/XvDttqEhZIRwOo4INe4XnhcFhCjfxYBPRcnA5rnvEfhyTRL17e4AY8OGTowPpUy0VhxSl6HnXh+xmso0jkXBU4/DtWwGMrFO2fyq8LQyEvFlWHY1RvHSxheeYgHH50qcnFO5vyKUkkZepatY2t+1vIeU4zitfT7OC92uLiFYz/tcmvObhJLm7kuGOWdicVdsA4Ybd2B6da5vaXk2evGjJw5Ez1S3to0CxJMGjQccVeRFhGQQe/NefWFzMCTvf0ADVqGeR05ndT1xnqK2VbQz/s93smb2oaikJ+UhpB0THWuceSW4naac7nJ5qPaxkGX9s561aMW2IHuR1rnnNyep6OHw0aC03JIWUsVDAEc9KnjX97yMqP1qtFC2N0YDKRVtvltwBgEdag6k0tEFwUaPAAx1qnjzQofK47nvTpyVZAw68/LStOkmE2kEHApoqy2L9vHuK9Ng7VYaEeUpTg9uKq2rBdkYJbjnnpV6FGT593y5zj09qEJqwzbtKjbye4psmThG49asOfMywAH9KDGfLLDHPHNIlO25U8koCT34zTSh4UfKPWtBo9y7XOAOhx1qnh9zA5xnikUncasZAGT26CmMu1juxj+VOklJkOEAI4oJ2hc8/UU0yuUhIKKWkOPY0y3+YllGQalmbeRuB471GkQTazMcNztFBaV0WYGCHJweM5NSmWNlclAM8AHpUGd0WCMDFRMpOBuGMUCUblh2AVF29O9NSMFS59aI8GMZySelOjLFgCDz1FBWw5dyttVeR1NTZLjBAJB5qQJxjPFTRIqsMdT1oC6Io+m0AZ61Oqn7uMeuO9TRorMSQAPSnrsU8Dk0GbaZB5QwMYBHAqeIAp8oBPTjvSsgC++fSpFRVIHpzQS2MjTKguvvVpWDrgLjn8qa2Srcc8AVJFnysdD0NMh66jFVlye1SB1ZeORj9ac3KgEg56UiAqMOevFNEtXI2jLHBP1HpVS5s1YYPetJcBSMjPvTGAc5U9KpGbTRyWq6aGiOF59q8+1rTmUsdvT2r1+4j3ZAGa5HXbLeG+UY+lKUbo1hrozyG9i2k/KMistxhq7bU9MZpAke3J45rAu7FoT+9ADf3R/OstmZVaZiSfLgp1FdFps/2i3Uk/MODmsaeL0zz+lSaVP5FztY/Kxx+NawlZ6nn1aeh0kS5bGR+FX1j2BTzk1QibLA1rRKZVAGc10XIgrmxol0/lvAOI2HIrTMIKkYODVOwjCqCBhu/Fa6JujJpHXFWQzTZMBoX6dqbcR7W5prqUkVxjI61cuEE0CuOo5NPdC2dyiAF5XrRTPMAbBoqLmsWepxMQASOvc1KxBGBWdbXG5dpJPcVcj+ZeSc4raLPmpIr3MYPB6VhX1iGBZRxXRzcKOgz6VC0AOfQ02ubQalY4HULMxgMy4Ukj1rIe03qw2KyHkqa7/VrJJkIIwQdw7fhWJLYfNwPyrL2djRSuchb6KlvI72kslur8snOM+oPapYNI3OvmNvQdOxb6+tdSts8KkoOD6jNQTxOSvYjpVezb0R0Uq8Yu8lcxtTuYIYSqqPlXselYtn4m1DTZlazG2PHzKxzmrGsuGnEcWCFOWPqfSqRtfNABU+vFZN8rtE7vZusk5o7HR/ijOgKXtueRgnOQRW1qXxH0zWUiN27rLEm3JSvKntyrlTGT74qBrVhJkj9KPbTRP9n035HaS+IrC3eRrWQyKc4XFc7f3kuqSZkOFA+VR0FVIbJ2IBG31NW4YBCT8oPvWcpylozejg4U9UUxBg7WFWbeAGX5Scd6teUJCowfWp1jMWNmP8amx1qNh8MJhXByatW8cmE2sNpPTHNNgdSVZyFxnINW4RhtyAkdetO5cSWS1UBSBgjkj+tKgWQAYIAPSr0Db0COADjgHpVdrYn5gSvOCOtDJvfcRT9nYBQCPSpGMcgK9zzms6WVo5NvzcccdKt27L1OST79KCuVhLHnpkHHr1qgsuy42Hsc1p5DrgY3ZxVO9tmjbftOR3x1qWarsTRt5cm8Y2nvV0XI2qc5GQDWGeUHJ3Crtq5kX5sUJmnLoa4Ab5+R3qwhCtyQcjrVSCQmM7gBt5/wAKeZMPxyDjr0qjNq5am2leOvFVc7n+YcCo9w3tuYqvbFHyLlS+GHY+9IahYHXIdiRntUG3PyntzzTJXEbAZ3H24piOQ+45APTmloWk7Fl4yCu0MCT+VKIcZ3csD1zTI7gY2kknPXpSNKQhAHz9yDyaQWa0EZwhbfk4PFNDK6gkbajV/MYs4xkYx6UlvKnmHIJ29KEitEW1bA4PtVuJSJBHMNoK7o2PVvpWeJQN3y8euKtWZfcGcbsdPUCmKSZfgbhsYNO+4SxAxUUT4k24wjc/hVoKowPxwaDO9hYsjlmPPOKlK7cEEnIpuVAKgmnRod43kkE07ENkmWKAkDNKg+b6UpAHQZz0zTo1PBb86CSRRwcjd71IGwDgZpitt6Uj8dBgUAlclQ456e1MOWLc4Pv3pQQRkkfn/Smg5Yk/kaYJDowCORkilU9cYFRiULggjI9KGlVjwSKVxuLYkq5ByOOmaxtRhDo2cYraJ8wZU59qozw5DH9cVopEpWPP9ZsEySykofTrXE6hbhZW4Yn+devalaiSNgVH1rgNdsNrMxGAM1E49TSyaOKu4yRyuM1lOCDkcEHINdFdxgIUGelYs8fpkcVBxVYG3ps/n2qMT8w+Vq39OkJkXNcfoUwjumhf7snH410luwjkGTXVB3Rwr93I7G0I3Dn8a2LX07Vg6e4eMEda3LNxj19vWmda2C6iKluoBqTTTvV4257c1akjEsQBFUI1aGbOOAaaE9SrqFsY5GIzRWrqMIliDrRSktdC4SstRNF16KdQAw46c111jdCRRg8EetfJdn4svNLumKSZ2tgoxz+Rr03wh8TrS5CpdZt3JAy3Kk/WtVGx8yqt172h7hJKMjJBHWgSgnjnPauas9dt7uJWjkU5HUHNXre8DMCrCq5bbleRoXMe5eRk44qqLcYzzkirStvYfrUmBjnt2qmhGU0K4PQVzHiW/W1xBCCZW+8R/CK3PEGprYQsRjzm4QenvXGJbyXUxlkUsWOSW71hVqaWR6mCwvP+8mtBbWJJVIdRuAq9FaxiLoBkUiWibgMYA9KulAvy8471gkei10RmS2SPIcDGPTvVaeyTHCYOa2xGM/Jg/Ske2LgHB298UWK2Zg/ZwjdM8c0rRnbwmQe2K15oFAIwQe2eKoKpUlenpUmyVysIjGDk8DqO+KSRwMMRx2IFTTIp6Dk9adFaqGBIyvepsXZdSpbFRN8+VQnqa0om4PAH41UdCZdv3VHoKsIMAE9elNITLxDEo5OMdBTmkZmO7k/wgUyKVSMHOKajhJPVT+lARs9xrW5dsuck/mKakZEhBAzV2UD5HGMnvVaXPmHAwWHGaGilK+g+KMIT0IYcfWieY+V8/Uce1MQea3dTjGKFQbxwGQHkZ/Olcdu5TkBVOeMUy3YhuvXmrl/l33KmxegUdh9aqCLHJzU21uaRldF8SM6jLfc6etTQT8jeMiqC5Qhu1WvIIaNpQY0f7vvVJCbQ+cYOF+6elKqRojB2JlxxjsfeiV08pfLQjH8TdaqhHLZJOKbQ4u4sxV3GwbR3FOiDgMCoYnkHuKYoL7iDx6mrVqzlsTcpggYGKixbdkQnbgNzk8EU0H522jnH4/jVwwQshJVwPUYxUBhiRQwZvMB5YjjFOwlNEKgg5wcDktTkG4k8A02NzHKMlXBPTsRTp51jlZY9pUHg96Rb3FjOG+bkVeglO3KYH9Kz0kClmH3iO9CyFmG/A+gxTC1zbh+ZBnll/lV5OQD3xWLbyshAJGPrWzZSKUKEdenNVE556aijhic9O1TIcEYGKiKYPoTTlO1jkcU7CepZ4OAxPHQU9RxyevSmRkcfnUyrubBFKxDY0Dc3p+FEjHjkZPTmpWX24FIcFsdT60WGmRou7IJFMkO6UAj5R2qzyM+mKhnAaMMvJPFBSepFgBSccemagLZTCjvU65AGRjjGaryADJQH61NjSOo5ZXDdevUU8krwfunvULBm4A7VOqgx8nmmrikkU76NZFAUggVyWtWg2SHgnPBx09q7NkDKfb8KyNVtfkbr0PSrvdEx0PI9RhKu5I6dawrpSODjI9K7TXLQpuYCuUvo9pbpk81js7EVYaXMfJRww4KnIrsIJBPBFMp4YZrk5V5/Ctnw7PmOS3bBK/Mtb0nqeXWj1Oz0SbnZnrXTWvysG7GuH0ybZOOoGa7mxYSRDODnHNbWLg7o1YeVxVa8QK2cdutWbdcA5pbld8RA6gcUGhBat5sJQ8kDpRVa3cRTKcn0NFMl6HhF/wCBtTe8n8uKFoy25X3YPNXNF8PHTXkS4dZQwwUUcfnXS32pXF5KQgMcB6KDz+Jqextg65IGRyaxlXb0iclPLYJXlqLpKy2rj7MWjA7ZyDXXafqpVlEg2t6dqxLOHDeoq60LdU70RqSidcsFSnpax21hq8TKN0if99VJeazEsZMbb37Ac1xNvbNLcbPz47VuJA2FVeFA5NX7aUkQsspxldsqXSNdSmSY7mJ/yKmgjCoOOexq1HAVjaWOMuiEZYHoTTYZEyzTZAxlcdzWTR6CjpoGCF4GT3IqEI+4hj8vrV9W3JkDrzUTKNmdvX0pMhFQuI8kd6kivOoPSopI97gYIxyacyKEDY5zzQmy+WL3EuZlk7546VQZwT8qkn6VbAAOD/F1xUDoIpcn7p9KG+o4xS0ERAYwMD1Oe1SSFQNuc49adFkMABj14zUN4u0gqcfUUX0FJXYuxZFBBqFsqMAZNV2dlJKjNEMxDFmHXimkDi0XIyV60+VRhWXoagiZW7/SrdsR0NO1xXsJBKRhSeB61YO0n5lGOcYqKQAN0Ax1pvmEHJXjPFDQehawuAVGQaV0KuW65HQfzpI3VUBPRucVYUqwPGCKFESlbcoyOI5Cdp3Y4xzn61UklaRd5GM8cDitaeNZHXK9utVJYQHJxkH1qeU1TTK9v8ynfkE+tXPMXyQgjUkD7x7ULCGzxg/WmBmh3eSxXnkdQaqwNpkXJbIBxntQx+Qr0yeaJLsq5KkbsYyPSoElJOeCT3pM0iMEhDlME5NadqCRgn5iOBms8Q7T8x2k84NaFsuzljzxURTKk9NAlaQcdQPWmTEeVn+LP4VbfDD7ucVTm2gENwBnqabRMTPbJccc9qmKM4GQCOMHin2wkmkUuoIU5U45H+NXXiyqjIBHPA6mkomkp20GW8MDDZI7RN9MioJoxHIdp3Y6EdKuwrGZE345698VFcxhHKqx2/TFNrQyUtSKNuAxOCTg1oWjEHkgY9e9UYUw33RkHsavQnypVITKjnFC0KkzWyHjyv3h94UiKMjkmq6y+ZLuCEJ6A1fSPglduC2AKsxvYfGM9OvtWnBBiMORyPXrVAHyiAV69avxzhkIJ4xVJIxm29iGQYHJwfrUEjEHIOD3q3IAy54IFU5HGMdPes5KxpDURbjjBXJJ/OmqCRuGB6j0qM8c5A+tPB3OAB1HapZtaw07gMDvQU3IAev6VPIg2Akgt3GadEFwAARjtQPm0K8UIDqTjHpUjRnaTtwBVjYo4JFPVcLzxnvmqsZuRkyDk8nPpUEkO9cOCR34rYaMZyOB/OqlzFz1PTuKEg5rnBeIbEAOcdegrz/ULXDHjH1r13WrfchyenpXnmsWpR2IXIz1qZrqaLVHGzQ4yDjNM0+T7PfxOTgZwfpWjcRZY9jWbNDhz7UovqcFWB1IPlzAg+4xXa6Bcb4lwfzrgbOXzrKJ+rAbT9RXU+Gp+Qveus46Wj5TuISRgE8mpHJIwOfpVaBvlXPPvVsLxjtQzpMeb91Ocrx1FFTanH/EOveii7JlC+pwSWQEZOOat2tufLXAOPSta3tgTj19qtR2vJXGB9K5FHU7NlYz7dCjEAZx2q4seUwBz1zmppYVQ5VeOnNTW69FAA46VaWti0uo7SoD55dvTFaUzrEOMcHqTxVeH5JcAYFR6iT53YAj8KblZAo88tR7yxSXEip8kYGSFbOD9akiVQoBAOOTVCCPBwpVm69f88VeQKsbFvlc9OeKhSuayiloiwcCLHAzyfeoZ5QrBVGeOMUrS7oMMMv2INRxRqBkjH1FUZKHVkSxk5JJHcimE/uz0IHJFTF8jaO1V5YiWJXv+VCQJXZD2+Xn2ppheRCM/ianTCgqQCTUwQEDgA00hvQzEjeMlsk+1I7bwoxjvmtSWEGMEHp6VTlQgHcOCaT0GtdSlKi8kj60wKu3CmpipHVgeaZJ8g3AcLxRcckMiQq31qwhKjPWmQuCcrgn6VPCqkDu3t3qkZMXzi2A35+tJIwXJAyD39KesWX7FRUqxHbwAfWq1C6Io5RgBTyP0FWopFLcsAP5VUkgI24+U9M/41IYCvVxkcUJDcUX4iPMwXGD6CmsB83I9s1XjYbf9odKkkO7jOPU+lOWwrajXY445NVZJMLkjg989aecnPtxxUEwJycjP8qg1jEiIXuOSeAO1LIVAXaozjn0BqSNQGG7kDtRwS3IqSraiwuZOWwX71ctye4J7ECqflMpDqMD0qaOV14ztz6U0DXYtNlAQ316c1WYbx831pZ5i3Jb5jjimLuaQsOg7UXKUWTQYQkKeT6VYB+Qk8dwc1DC45GMEc1MxZ4hHuHlg7gMdD607kSTKkrnzg0IwBnmnK8ksmWIY9OlSvEMDJUZqKA+S3Qhh0HakO6LESYYenfFWMAsdvI9+tVoAzkgYJ61cSUN94fl0oM2y1aHKFF5LVdC4PfA5xjpWba8Etn6Y71pwOWQKT1wSc88VaRjJu5OiZGSWxj86miCl165HFFoA5x0/GnTKIvuH/8AXTtYm93Yc5ABAGT9aqyAE8kj8KkQsSHIBxnHPSmyqT8wbj0qXqaQ0ApGQFA+Y/rVdh5ZIPJPpTwxX6dqVsNgt2Gc1LNY+ZHJIcAZ47mprcg8NnFRCNSeufWpkBXlcge9SU7ErkZGBnHenoWJ9PWmBCTkZIqVcdMdOtUrmbLsMcTWUu5dznAVicbf8axroLuOOgPrWoGZYSvGDVaVMjlRj+VUzKGjuYt3CGDE4Oeua4PxDAQ5wuK9IniyCCvWuV1y0DK2e/epkro3gzzG8UBiMDPesqWLapyOe1dVqNsFkcLgrnHSseW2wcHg1ktCKsCDR85ljJ4+8K39FkMdwMg/TNY9qhjnVtwI6GtG3+SbB/CuqnrE8ya5alz0i0bfEvTmr6Hjn9KyNFkEkS854rWThitUzdFe9TdGfUUVPOoKn6UUDOdtkYSA46VaEbCU84wMjNWIolBXcPxp8igqB6nPI6VyJHbbUgVgc5HtTSu1w/Ge+KcI2jmz1J696WWNyC6nHOMelNuxair6FkFMq5OAOTVe+AkG5VytTIgaMozYYiq9usiO0bqduOM881LlcdNWZUto5IpgRgc8H0q8pILOTuwudnpSXSKuRg+1NfBX90TnHzeuaS0Ohvm1JYDvYHHyfyq2Y1wFDc1BaxMkWWOD1xT3dFYNjLevatlojmkrvQfNAqx5GcGqJIORt4HFWHdnBOTikjiX6/U0XItbcrGAlg2T9McUsWQTkHIq1Lhe3GPzqsTzlic96A3JcbkG0E561XlwV5BB9utKJNr4Jx6Ypj9xk5NMSiV5VDk98jnFVrhGXhR8o7ZqzGCD0570k2w5GRnHalYq7TM1jsbJBAPXB6Vbt5Bgl3OOnBwaYYw428A461JDbjjOCaEmNpNFlSxVSMEgYYjjPvViNiDnse1VkG1Thjg8Edc1NuYAEgY7HritLmfKWBEZNwUEY5IpLSBpGZcKD78Aj1qS0uSjZ4Jz+dSLErltvGeRz0phrsyOaxeCTja6dmU8GowhxnOCPWp5YNoC8DAzUUbgEg8ntS3ErkaxHcUX5Tnjng1SuoZLeX5lIYnuMVoxAOzSvIg8s52n+LFJqOqG7i6eVIDlVIyGFTJGkZSTsZikMAM8j+dPHKsWTpUasZ0w4XIOQQOVqbGQGL8n07fWoZtoPUoVRB29B0p8kW77vTuaihVl3EjkmpAz7tuSaaJtYheE7uM9sip7aP5ckcg1KuN+CvXqc1OYwFAQc96fKmNy6FRkXdkHJJ7CpAzDII4FTCPbySATUTsRlcYHqaLWJvccTvXBGAOaaVBOSBn1FRBwQeDgdqeCQATn6UhWJIhiTIwfapzwV2r15qFSuVz1PtVq3USuyYOUHT2p2JbHW3BOTx3FXV7c44qJYguM9T3NSbSAB707Gbs2XoCQuScYp0kpPAqmhcjjIFP3+uT6GmJRLUM+DhhyakuJPMXgflVMPtbJyTUhfIAA5qblcqDHT09TTwgCgscE8U0jcmcncO1ABjB5yfQ0ihqttYc/SpSx4DGoyoJ4AzVhEG0EfTkUimSwSuqgk8e/pSxfMxYqcE1GVOcBfyqzEpCYxj8aaZDsiQAD0prxYBJ+tSQAZzxnv3p7Jk5PJHvTMzMly0mMDkcYrC1eFtpIAPpXTTp8+QBz6Vm31uDGcHJx69KEUnqeXahEySvkc+mKxJ4tz5A4rstdj2MxHU+3Jrm5EyDgc4rJ6M3kroyniDHGMCrLDDKemasJHyMjn1pb9W2o2/eQOvp7VtSZ5uJhZXOo8OS5RQDiupSORgzDDKoBNcP4bmO8KDXd2NxsjII3BuGHetSVdxuiJgSM9qKeVAGR0opGlrlSKIOD/L0pfKKsM89hzVeOdlkAUHHersb7xnnjrmuVSO1poidAydxUcac/N/FVtkBU/rVeMOXxjgcA0SCOwqQjfuGcY6U4ujShXPzL6VcU8fKPxqnKieaW6H2oSEnzMnkto5FOPmx19qFsAJEwMg8YxULEgZjf5vf0qSC/MJAkGcHg1cWnuD5raE95EkKhEwXx6VjTKysS3DZ5HatdQJ7oSqcg8UzUbfIwFy5PJ9quWqCEuXRmRGzMnBNPGVU5BPoamWPaCOtKU+U9qizLbRCWJxntUb7Rnng08KCcZwDTZQRgEgigl6MqA5Ug89gaXODg5p4h69u/tQ6dNvJA59aoLkDbW5GcioHXHIGc96tP8pz0Uio9oJ4ziiwXuV7fHmDJznit/TLDzU3Lk/WsIxFDnB69a6bRbkRJtPTua0pq71Mq7aWgPpJc5AH4CqEunSoSWU+2BXVRyK54ytWVthOoJwT1xWnJfY5FiJQ3OIj8yF/mX8x1qzAS0qnHBPYdK377TEckoCD/ACqgluYD8y4IPWo5WjoVVSWhJJCrIGAyCOazL23TClM5Hpxg/wCFa8uNgwR9PWqs6Fh607EwbMp0AX5hke3H41nXEBkICEdevStuaIlCcdew/lVEx7MEgA9qiR0wlYI4xLCm5AkycdPvD3pxtiFYnkHqauwKZJH3Y2gDNWGs2dASR9BSUBOdmYuNvT+dKqM2SMr3I9avC1OeORnuKUx+WSpxjFK1jRTT2IbeLgbyBVqIIquAeq8Z5wfaqQDgkAk/0qwrKFHf29aFoKSbGyMwP3ffJFVyrSA7jgVYVvM3AnAHbtUIyGKqpKt6UNkxK5iz07VLCjP1yKegJwM9OKnACdOvvSKewqQjjJwauRopk85gTJjGSajj+fHAFXLaDdhy+F9x6UGUieGBTHnv60hXD8jFLHJtG3H4mn4DEZzV9CEu4jgBc1AuA3PSrjR5GNwphhwM9fWpZcbIjK4x/Wn9ycCgpkVIYxj5TSsVcaqtjI6GnpGHGD196d1XPcU5G3DGOCO1ILjAoUjANSqSVwO4pACoIUduvWnBQSDmkNj412kE5FSnO3jH1pqBmj5HQ4z71JEp2njn1pkMbC5BYE5/Cph8wOTgdDSjYCO5py4wemM5NBJG8YYEcnHv2qleKphK45PH/wCqr+dxOT2wBUN1GCDt/wDrU0ho43WtOimsbmZ7hI54iFWIjmQeufauFnAHXBOe3avR9YsZrjKQxlnx91ASeO9cLfWEiStG6lT/ALQxUTR102mtzLBC4xy1OljZ7ZyVIA5zV+DS3jKs4BQt1HIGadcxbUaM9MdqunpucuIjzJpFPRXMc6Eetd/ZksgzjGK89sQUkJ64Nd5pD7olJ9Oa2e5xUvhNA/d96KQNz6jNFI2RnrFtOMfjUsY2Ad81M0bE8Dn39KesYkQDOMVwI6+YRPmxycA07y8D5cg+tKibQSM/L1pzSMFA4INXfQS7Iga4EXBOD6UyTBBPHrmq1w++Rm24XHDUiuxUAHIx1pXNlT6jGDLlgflJ6E08udpLceuakIAQZ6EflVYrucleQKpOwblrTrjypgP+WbHFdGqxyZri5XETdenatHSb5knCSn5frW0J9GY1afNqjf8A7NEmSv5Gq11ZrEOcZrWa4VLYsCfXisO4uDMxJOM9q0aSOWm5ydmZ8qbckDOfaqfLMR2FahYEFeuapvH8xIrJo64vTUaIsKR7fpTJMlskfQ4qxEcAg9R2qJvvf0p2F1KVwCASBkdzmqrMCDjrnHNak8QKHHPvVR4gGJK4AOBVWBNEEM4Y7GArTtZVRxjgVn+WC27aSexqTcVPHSqTYpK51trOoC8de1advNFglRjmuKt55I3HPAPStqzvlZSo+8PfrWqdziqUDoZJIiAWYDjOfWsy/eEgneOayr26Y7tzHjoAOtUI5mLkFcgd80nIdPD21uXfMG/gn5TwKUvx1APoaoicpMAxzn2q9GyFHzgBhnp1qEdElYa7qIwNuCP1rPmbIPTd9KuTSHhCFC44IHX61VmUlc4wBz70mioIns5QhO48nGc1qpNBsJBwPeufgV8EAZ3+vUVet/LBKkuxPHsKItoJwT1LUsoVDgDpzxVF2YnOARn6VoJbFzgjJq8+mExBlXNDTZKqRgc7s3Z6gntnrQqNv6jHrWs1s65AVRj2qnMu0HGOOhIqWrGynzbEUmU+UnnHaoty5x/F2pcs5Y5BNSLF8nJJNIaVhqxgdhnPNSKpAJ59qj2lScE+mTViAZwSSQOOO9KwMWNfnCg89Sc1aVm6HkjuKijOHwBmpWPYDaeuaFoS9R+/nkGpgSB+NQxgNk8bhSgHPUmmKxZjl/PrTuT06VADg4qYY44yO1FxWJFGWHHanOmBxQGwAM8nripFztBHPvQGxBkjGce+Kakh3EHI7cdqfcYA5ByT2quc7/lJBzWZqlctIw3jJ4qViQMADNVoQWcdM1cILYzwOxFAmkNWUkDAwe/+NWYRuU4JJHrUcVuMcjvjHariKEOTknHIppESaGoMdVGe3vTjGJPugg9DUiouPmbGT0pvm7ZtqD2BJq7kK72IJAw9DzxxVeVivzHpnFXpSWUjj1I9az5ZQsuXDFAcFc9aCopsq3VwI498QeOfOAyPjjuK4DxEXe5QSNIxBOS3I59K76+i8xG2DFcbrcLqpDY2g5xjvUy2NqNkzOijZFV0fevcN/hU5tUmuRvbYjd26CqlpJsJSMHOQRkZrVugyFSyhhjt3pw1RnWumc3bQjz5owfu5rp9CfMQrm7iMx6iwwRu6Ct/QPlyPet2cNLdo6BR64/CinL97pz3oqTQZvJIC9BSIcMOuPWmAlW68VaSLcpK/wD6q4UrnU7IfGOpxwe1RTx8fXtVlcMuVPTg1DI37zGOvJptW0Ii9TLuFCod27ntTEYEgBCG/kKuXKBwR3HJ96rqAg47ioOmLuhJIzIevA4prIU4PA6ZFWI8gkn070skZlOcYU1aJ5n1MmVFYksMk0kACTIG4UkDd6Vo/ZB0Ix39KjkgQNg8fStEPmT0OvjiT7KE/hAHNYeoIMnYcVHp+pLCiwTuWhPCnutOvGTdmB96+3euhtNaHFCEoSdyosbDB55qTYHGOlQ+bKhwcED2qxBJ5pIAwx71BvK5HIm0HA4JqnKCGJAwOla6wnaQ3JqpdWpyCgPPNNomMkV4VDR4bPHSo2UE8jJ6c1ehtXck9DinPbFXGATx1NMLq5mMgA4AGDxTGXnP6VckTaThePSo2BChiD0popO4yJASOwNbWlaejXCtkEHtmsqNQT161o2MzxSBsjiriZVL2dmS6lYmFsBSQDjntWY0eFJAz+FdQ0q3UeJAA4Gc1jyjbMR274ptIypTdrMyzFvYBVw3vV8xPHCvyZ46movN2uWUcg9fWrQuDJHg9+eOgqTWUpaFJoxnkEn0pjjA6Z+tSNweTlegOKZKmQGABPqKC0xkRHmqCQM55rWtLcBAwYAc8YrKjGZV38L64rehULbAE/KOeKImdSTS0J7Xy1Kgn5vU81pJdRxL+8ZfYZrm57gQ52sAfXvVUztIMMST2zT5rGXsefVnQXrxy8oQc9qyZrYngDikt/NCZYnZWtaRLKFB5zUv3jRP2SOdNvtO3HNPWJguT2PWty8sgHO3O3qPaqLxGMMrcCpasbRqcxlylsEY4+tJFnORu+tWpE4wfxyKkigYKpQfhipNL2Q2AYGejetK2S3Hf8quW9nJImAuR71MNMZRknAPpRZsj2kU9SnFkZ461PGhIycA9xTpUVDtXO4VCqyZB9TyaBN3JvLxkhjuqSNcsNwp8SqPvtVtYUf7jZNFr7EOdtyBVJOQeKmVTtPWpVTaVBA2nr2phz/eFAKVys8ZbGT78U3ySc7lwCe9XViyCeM0qxsxwRmpaNFNoqQIqtg5+grQQbYmRhw+Dkjnj0qNIMHdtJxVti7iMFiQgwo9KaREpXZXQFWG0GrggLgOufpTljGwnBB7mnwQSjLNkDp/9enYylK5HJERknBbFQlfm3YUf0q60eSfQDrTFjAXqQfeiw4z0KZiJ6P19qZ9gDlt/B2/KSeuOtWT98qoxSSndGMcY9aEVzPoZrMEQqoBXGNxNcZ4iO4sBySOx4rr7lCcl3O09hXLaxCu1+DnPWk9jopRSldnKW032e53MCcdcela94DbQRSPtYSfNt9PrWY0cfnr5pJUnnHGK1vEcSi3hWMYAjBGe9TBuxVa3MkYV8T9pt5W2FWAOFOcCtfTJU+0sIuFOMZrnbkjClDnBxgevpXQ2VidO1OG1vruCN3UGUglhBns3vjH51ve6PN0jNo6VD3B49KKsXIkN9suHR5AFBdcbSuOCPbFFA+dLcozxOkhZBle3NSRyttAPFTr8y4B69B6UjR7R8wrlS6nZzXVmTrwoYAe4qOUDBwfxqtHMwBVc5FSJ86lec54odmTy2IiCX464/OmFS7dMZqw0ZUZbipUhwNxBye9RbU0UkhkcI2gsKSUbRwPw9aLiQIhweO1VQXIHJIP6UN2Eot6sinG5s7zjvVMuxJBFW5yQwxgcd6qP8x/TrVJm0UQTgtgLjiktp2RtoJ3ClcBOCTk55601VLHIzz61SfYbWljUhO9Mg/N3qe2YB+RzVG1c9R3/WrQJDg1qmc8kbEMyEAsMjvxVr/R5UG1lXnvWXHKuMAc9vehJPm5/lWnMcrp9i/sjQ5UjmqFzcJvKY6DtUszgR5HesmVmaUjILd6TY4U2xly+0/KAc+lQO5xjJxirGwyE4HaoZUXJGeTSZ0xsJC7FAD0zxxVyK4IJQDGeM1SgxkqcgdMk1KxHyhWGad2hON2a9nMpwC2MHvUNz/rS2QATgc9ar20bE/OckenrSXBaKUBupGVJ7029DNRtLQeIs5/PFMwUYkkEd8CiKck5Gc+4oDZPPPrxQVyu+owsTk8EGmxsWOBxnrU5AC4xz61AgIbng0DGnekgPbrV+K4byNmCKqycuAOR61JgkDaeeoI4pJg4pkMv7wjcRx3qzYWjyuMAnPT/wCtVWSNjzz6nNX9PuDbHcQGX60yZ+6tDQgjlXKyqQMYAIrTssIny43AUyO9WQKCMg96nkhIG8E4zVo4pTvoy0iiRQSAfU4qteWSNGcED3xVq3JEZKHB/Sk2mQ4bIbseuabREZNPQw/7PDHAJPuKsxweRGML9M1teQ0cW4AD8KyLy4Yh9vODUNWN41JVHYhaZkGAOlMbUGk+UgD1pq7m3Atkj9aj8g56Aenes7s3UY9SdUDuSFxnrSyxYGAAAPzqBboxN8ykn1xQtw0r5PQ+tDsPld7jghI+lOiyrA7guOwpn2hQCMcn1oB+YdfXjmo5i0rlwsrEBsA/WnNE23IY4ql0JKN19K0IZVaMDkHvVXuJxcdgT9DSGTqA2G9e1LgnIyCBwfakK4xjv0pMEiH7S69WweOversEwDAt9cVVlhznkZqcIuxQB09+lCKko2NYSJ5WD169KVbsoRkgg+tUoW2lhnr1Gc1HOyxcjuKcpHN7PWxpyyRlTgkVVnuCuCg+UDk9aoi4yoI5xTVdixAyc9RUOVzSNK25aSQjnaGB5z6UnnYyCQVJx9agR84wvynj8aZKxDAjqB1xTTL5L6DLhd5IUfnXOa2gVWUjpXRuCq785PesPWzmEkAZ9hTZVN2l5HDyMPtaggbe+R3qe8Vvs27khODk9B7VWvFxcfMOCeOa0LmFZrbapBJXJANTE3q9GcvJJiP5MBlfdnvmu1s47HWbhNRuNO1eKefDSrBFuikbGCwY9M1xDfJMy4DbWBx0B9jXod5BrNxqzz2mpwi1cKY4VvVURDA+TAOOK1i9Dy62lS6ZW1x7qLW/tscDRQlFja3bOUQDC/pRWheRzLKUvJRLNtGXD788cc0U3KxtCNloTxNhtvA9qnd18vYR16VlM0iEsvTvUsdzuxkgEiuaLOiUOqJTH8wOPyp8bYG04yelMzk5GcD1pRtOecE9xTaE3ckLNJndwauQgrGuRk9DWdEz7wvvjPrWnbvtQh8ZXrmmtSJLoVbuASH5ag2tkdBntirU7AEYIA9BVVm7D061nJamsb2IZVVVPc9zWdcJg5HT09avzDdx6c5qNoDncxySO9JXNYu2rMc/M5IByBinZJQZPPpVyRFUkgcZ4qs8RLFjjPqKtM0vzBHJxn8/ar9u4yCDn1rLiU7+uD61bhjZZM/MAe4rSLInFdzYRUKAg5Ixj6075c5zkkYwapb1XjIye4NAJlbGDgdQOTVs5+TqTsxeNlBxj8azpmKOMA7jwDSyTNC53Z/DtTfPWVeB8w/WpuaxhbUktpCkuetSOTIzYXBHpVbzFXt0HINJb3C7jkjPpVpicOpdtofMI2sNvQ8Yq7b6U5ZSEwfTPX8aNNhjdi+W46c1t285hf5gOvT1rRJHJWqyWkTONsY8Kqd+grP1kAMCAcY59q7CYRT2xMY+b0Irnr21aUsApAP44olEzo1bvU5yMlTuOWFXIQzHcqkg8/QVXuLZrecHAZe9aFuQ8RVGG4jkAdazirHbJ6XQ+IJPH1wB1I61DPAI32jO31qzBaHaW5RgO3FWrfOVaRcgckHvVWMOa2xnxWzOQJMAdQ3XipniULjIyDwfWrs/lSAGEY4x70PGPs/UEgd6LWE6hj4LEso+XpU0MMu8YyVzyMVpabCJn2uigZzgcV0VtYQq4deMDketNRMq2IUNGRabp8ZtkdeQeas3UgSNkwRkVcchID5QwcflWY6bxjJJx9a02OGMueV2UraVlJXdgjtWtYstwgb0ODisG4DxuSQVHYirGm36xMQW56ZPeovY6alPmjdG7eTpHCUOcEda5e9kQv1z9O1atzMJAVwcEZ4rnL18SH5eOlKTNcLStuW7cgS5yCvbiri4zywP07VjQzDgA8gdAMVNFNtbcT9CKzvY6pU2aLIkiMvrWeU2Ag4wD+dWbeQyHO3p3pZ9nJxyOpND11FFuOjIJMdduARTRwAOcdzTiRjajc5zj0p4YFiD1/nUNGqYW4LKFbIIPHar0CBM7ueeMVCpToefUntVgEhsA/gKa0Ik2x6Y3NjoaTJVvRaa33RjOaSZgg6jp1obElcdKPM6LzjqDUUMjB9jZBHQ0iysMbWIPtSBt7ZbkjjnvUXLUbI0rccFif8A69VLpjIWUjBFTo28KFB45+lNkjZyS3XrmhkR0d2UrdNufU9BU4BwxGc9yKeqBc87Qf8APNPiU7SCcqKRo5X1CKL5Sc5AGaikIVyME1OrZOCcDoT60ToGJ54rRIzvrqRnAU56VialH8koDAcVvsvyc4GKw9bVsHsB0ptExepwGqAJIwHT+VFs5exXcfunb747UaxxKx29etUrC5IhliPJU7x6/Ss1ozoq/CFpc2VndXBv9OF8HACAylNuPp1q/peqaI0wCeHEU5/5+Wrn7mdZp+FxTtKz9qX3NbR2PPnFOaZ6NK0UhElrAIIsDEYbdj8aKke2WG3ixcQy8DIQnjI+lFKRtG1tBszjG08gU0hCoOKYVY4znnnNKpKqQwzWCN2rbCQuEfY3Q9DUpyrY25HfFJhNy5AyOhp4kwefrxVpEN32HLgscHNTRlmwDyfUetVOG5Ax+NTo7Ag9MetANEk0bL8xI9xVSQknapPXnFWLmYSr+7GCOwplvbsck9etTKPYuLsrsh6qMg8dakdgsfXnFPYFSVGOahlhLHoOec0rFpplCR9zMRxj1qGRSAOnTtViSDaSGOfYVCy9BuNJm6t0G2ceZgTxk10V1bxxwoQByBk1zQLRnhsCtK3v90QjnPIHBrSD6GVWDdmiOdDztGc8dK2tDt1bd5oUjAGR2rLFvNMwaNgB2INaVnbTQnO85PJx3rWK1Oeq1y2TKWvWfkTFk5VucCsEkqx7V3U9ut5Hh257cVzmq6S9uS684HXFKcOpeHrJrlk9TJaTzQQPvjqPWls7aeUgeXz0BNMt8RXCl+QOorqbKS23q4YA+/pRBX3Na1RwWiGWUMsDHkcjkVeMb7ecrzzmnSXVrtLKAX9qz7nUCqnbya22RwWlN3sbtnOsIC4yB3FTR3FuXJJBU9cVyUd43mglvl7jtSG9YTHHTP50cxLwxt6jbLJIBFtcGqj6YYjvAZSh6YxmqMN+Yr/aCSh9a6e3kFzAdhBIGeeSPakrMJudJJdDn5LlzhSp3gelEdxhACSP1q9e2/RkGGxyPSoBagoeOo7UmmaRlForpcKrEZbOcn2q3JcxiHcQM4496z7i2MZJBPHJrNnmlRCBzz07Vm3Y1VJTN+C5EIZicccgVLFrzx52ncp7kYxXO292ZBtkU5zxTp2woYLlvyp84nh4t6o7az1oSrkjg8detJdXYV9y8D1FcPDPLHl1bG05yRW9p8rX0IDDjHpVqd9DCeFjDXoakU63ClXUYaqc0XlTYXBxxnFH2ZoHGG+ntU0qn7Nub7w6n1pscdHpsyeQ+WqtjJ69az5gspIHX1qWCbzQQ55XoBSOuzcyn8MVLVzSC5WZnRyjAg5+9U4XB6g56c1FI3z5zz7cYpQ4z8x5J61mzsd7FuEsCQM06c5QqxI7YqGGUq3GcA8kVZceYSSe2eKDJqzKcEbgMc8ZqYTliABk+9I2VUADj0oU5yFAqTRK+pOJD6AnqKsLOojxg564qAKvk7s8j0p8RAXqOeBQLlRcSUMucfnSNGG5z15qNF4yDg465p5IVTtOTikZ27EY+U4z36AU0NtK9DyaaVG7PJJ7+lPiALkYOcdak1toXYSeGIPsfSpUcu3oD0qJX2Lhvzp4cbMt+oqjBq7HNEDuyAFPvTtuEIyG9qgkwiABzg01JPK43c+56imHK2iU4yCVwwHFWghkjzgA5796gjIaRCzZGc4rRinj5wuMVaRnUbRQkVgx3fdAyaxdXXMRbGQe9b97Kn0PsaxtTOYWw2RjinYyUnc8214DexHSuUu3ZG3K20joRXXeImCuw61xWoP8xrCS1OxyvEktnM9zGflBbg+gr0C20rT9O1HVZ3s5JYNPEdvGkzHFxO3VuO2OgFeY6VIWvfLALFxjHqa9SaKaCCMXWtXc9zpk8KyRhQY4S3oTyzKK2g7o86o7yRvanbR21wI4VKI0aP5Z52bhnb+FFGpxyRXbrJMZ2cCQSnq4IyD+VFEjppq8VqNvIpLSZ4ZVCyL1AOeaoyGTgsBitQRLdRxzbly+flzkg56H3qveL5fAUfU1HKaqV9OpTdTjA61HKWU5c4HtTnmCkAoc+tJdyCWLbgDNLYaV2OhcugK4ZfUVJ5jNg84Xg1S00PArJJjaemDThcbWYA4X1NCelyuXXQsrmFy5Y7fSrYnLsPK+6R27GqC3KyLscc+tSxyojDYcMO9MTjfcs7grjceT2q1CVI4OTWeQHfdk1cRWxuA6UJEyQ27iiwWJwTWPMdp+Xn0rQvJDJtHGBzWfNtwflyKmSNqWxWcKzgEkn+VSoiKTyc+/pVbHzckfhVlV3DB5X3NI6JCi4aPoTkHGOlTpfyq2DIV/GqxQKcKoI/WmPxll59M1omZuEX0N221d4wAwDc+laS3tvdYR3xn1HWuLjlbccn8e1W4nlLABeBzkVopHPPDReq0NPWtJjhXzIyDk1hFpIsgEqe5rblu3e2CMS23pkZNZM5BbaVx3pSXY0o81rS1KqTNzh2/A1Iru+W3YxTZSqjjg06MDywMgdzxUXN2kRmeZS4HI/nUL3cqk7gCoP41MVznPT6VG8Qwemf6UuZhaJJYXRafLkEN0zWvFcSWz+ZCxHc81z8UWZMZ59K0EZ/JyDnA5q4SZjUgmdVp9+t4OSFfuD3rUjhBDYBBx2rhrW5EUgdSA9d1pkyX8HmRkBlHzCtYu551em6eq2MbVJVZNgUKy8FvWueuCePQ1ra8WN2QeAOlY7yEArwD0ORWM3qduHjaKHW0DyCVQAJVGVH96mq/mDb3B5B45pvz4CI5TI7e1QF5lkLPgue+etRc35SWTfyOdpIyBXV+FlxG24cYrn7SRZcLIMYrqdOKpEvljO30ranucmKl7trGlJHnHAx71XuYT9nIxjjqKsmfKBiBipA6SxZH4itWeepNM5Z4ZbUSS4DAc7c9fpVp5BHGgDKwdQ3ynPWrF/CxDY5HcGsiQFcFQeO2MVnsejTftNx8qGVjswR6U0DYCCvQc1Jaum47wFOPXvSsVHIOSetS1c3TexC7oqgR53d81Ys93lbiTz05quiIZR5g+UcgVeh8rzhgAoP0pIJtJWRHdPgDbj+VQLKSvPFTTvncFGfSq8a5IDZGallwRdhbcBipnVoSvy7gPWqqkISAcfSpvNJIBPy9OuaQNdifzc8r+VKMsAM4H61TmkCLj9KElkCDP3TxkUhKJcc7Y8Ej0qOB23/MOD0NMfdjoSO+aaGIOMcUilHQvmXAG7oTSSklRz8vYCq0OCwViACfyqzIdqBAQB60MiyTI3uMLtK89PxqZeRncCQOmKqsgKlQcY5z60+AFACW78e9IbSNC15QvkgnoBUiSMjkdf9mq9vJtUqxOaR5GXcFIyT1rRM55Rux1wzeZnOAffpWfqjhUZeBxzmrUR35G7n61navGUjcuTk1oloYP4rHn/iFwGauJviDkg5z3FdX4jbJPSuJv5eSARWE9zaWkR2kMTqSlSQQOMevavXrOSS4WdtS8Nav9ounjkuGgGI5GQcNyMjPevHvDyk3cjuD5ajBHrXq2oW+qanqf27R9WhOnEL5DfaxH5CgD5WUnII/WtILQ4Z7o6LVHuJZhPd2z2yuAqKykAADAAz7UU0arBeWmq5ukmgLRxw/NkySqBvdV7L1oqmjroe9HXQqW92q3I7Bm+atsmOaMdDnrWBHaMUJK5CnqP51p2bgQZ4z35qdjWtFbxI7m1Ukk8Y6CqC2rMeWGfSrk7PuY/kc0yzV1lywH40tCbuKuZM6SqzBsjnp6VXkZlxkEj3rf1o5yygZx2FYTq0ibT97uT/KpkrG1OfMrsRJgrjPT1HerccodeBk+orNNu6YXBwKmjaXavBAHGanU0aT2NWF9uOea0oZyMANwRWHCX3qOlXtrBcg8/XmrV+hlKKZZdQScc9xUFxAGjBI5qWIsyEHhgM59ahmfapBPWhijuUDDhzjJX0qTyvl4bHHepzGWXKrUcYKvySPUClY157oiZyoxj6VWkIZxkce1TXBO7A2+5NIE3DsTnrVIpPQfapGMYXn3rWsbUSDjCg8EZzVK2gVCpbn3NdLpMKgZx15zWsUclepy6ojbTB5A7E9jWJc2xQk4AxXXp8smSMt781Bqun/aIhNBjcPvDFVJHPSxDjK0jiWgXcAxzSvBkcDn+VaDwFZNrYzVaUNG3T5T1rCx3xncpvEV6+uMGq8i4YgZGOxq8JAwJAX61WuHDcjggc1OhortkdsAWzjk9atbVUk847VThYq2OT74qfft6kU0yJJkE6gg/Lj3FavhfVms71UlPyOMHPSsthyxz26VAgxJkZNHM07ilBTi4s7TxLFkxyRgFSeMVzrqPOGUzzzWtpV4Li18iY5wOM1SuojHMVycdjVz11RjRvD3GUmBQnHAJ44qGdhsDY6e3SrJTcwIzio7lQy7cEVizpT7kEEhyMNz1465rr4PMjt0cfxAe1cWcxurAjrwRXWWl4Lq2VSQNo9a0pMxxMW0mjQE5OFJ4q7aSDcFbk9qzIipGDzgc4H9aXzTG6/OAQcA+tb3OBxTNy7QPCxII4/OuenVd5498VtT3I+zK3UVi3JAlJXBGMilI0w90VmAViR0PtVi3hEj5Bz7elQMA7nI44zViBhHnv6GkdbbtoV75ArAY4HU0yCUIwG0H3zirF9+8PXntis1VIk2sDn1qXuawScdS3LyMjGDxmgPsXDADvmmEt0BxnmrMkReDK8tjFSXexEkhkOQ3X1q0GVF+vSqkUWwKHOCO/pVh4m2jGOfxqRtojOWfn7h+U561bs0G7DZ2jp3quq7GHc9KlVsMcDj2pLcUnfRFqWNdh2n86obmDlTgjGatqWeM5baBzgd6gG18g549BTeoo6Cb5Dg4+7U29+SwG4UMD5eVUYp8a7zyc46UuUd1YAzMPugA8VOilx972FPCDZuUdBkCkTJJ4+Y96OUycuw2Q4+Rcc9PrUauQh3Lj29aWSMlgOd1Ls2r/j2qopkyaSJLYKDubG0D86xdfuhggcg+lXriZgMA8Driuc1q4HlsRitVsYKF5cxxPiKcBm+tcPqEm6Qg10fiCcsWIP4VyNy5ZuvvXM9WVVVkdHoyBZjApAQYG76969PnTRrA6zEnh+2kOleVkylt8yEgMxP1ORXlfhzM5mOPvEKBXqLvHpupgXfiV/t9vELaRfsfmJt67Gzw2M962jsccle39fkZniPZZ6+z20UcELRRSRJGMAIyggH355oqnr032nUpplvGvN+D5zR+XnjoF7AdKKo6KbaijrbCaQI65L57e1W9NYLcNG2MMM89zVSw8yBCygknvUxQorM/BBBU+lS0ddRJ3NaWEed83UYwKbPCinfu7jIzxU8KK6xzNLlWQMSgyfcD3pNT8tmIt4jGh6JuyRxQcV7uxkXTb5ARkjuKie0QzKynA/StNY4lVgVAYd/WqF9OFcqq9OMdKRabvZCXFsImIA5FRpEGB6fyFQidZbgCSQxrnqTnbUTSscqhz70JpmiTJ/JVSDnJ7e1Sox3Dcc1ni4YEEggCp4ZVf5+49aNC2n1LUjeW4AJ560kuCvJA781XdySxPJqu0kgfGSV9DUtjS1NK3OFxkYpJ1/izjvxVWF8Y7ZzmpXlypwQRihMLakBjy2Wxz7U+GL5yASM+1MMgZwp4J71qWaKWUseaqOopzshkMLSSBcg46cVu27C2VFzzjnNVI4xC/BznkUsspPB+nNabHFNubsbMcy5DAkqfSrdpOsUpDn5W4rCtZihAAyD2q7Mr+YrMpVDz9ad2c8oW0ZFrFp+9ZkGYzyCB0rnLlQHbI47g85rto5R5O2QBgR0rHvtOjlO6LBJ7A9KUonRQrcukjjiNpJAGD2FQn5ySOAOxrYvbMozBhjHBFUFhxknGB0GeawasenGSepX8vYRk0hBzzyPpU5AY4YkrUbDC8A4zjNIPUruwIyQfcUgXIyOKftzk4/GnbW6DJzQG2gtrcGKRSWAFdCmy6iUuBu9a5WYlUyAc9zWhp16Q6tnP9auL6MyqwvrHcu3MJgYAqePaqU77ugPHqa6d/L1C1BTG7HpXNX1q8Enz4570SiTRnzaPcoSjgdcnqav6SzwHcRlSO9UFyZwCDg4rfhjzEuUBFEFrc2qtJWHm8AbkEGmB/M/A5z1qQ2SyKMflSratEpx+lanNeHQ1IpFksc9CKoOd3bJPeo2u/Jj2HkH86kQma3SRFIAoYoR5dRrsQMAU6NgHBPFIi7vvAhfrViWABVIPHp60bGt0tGMmVXYHP196ZIuxSW471KVWFdzfMSOB6VRnd5RzwvpQVDUjeXKZ6Z9Kf8AaiV2nA9BUDfuzk1XaU5G1efes27HWopovmXcwySecVOk7lgqjjHGaqwhXHOMnrVuPCqCOlQ2TJJaBhicnk/nUgbAwBwRnNL5gCEAjb1qPqTwNvuanUhMkjY792eFHAqclZCrBNpaq3LHaoHPU1oWlu7gEqB7iqV9iZNR1FtgSpypAHHHepEjJb5c8da1bK0MilcHaenarAsPKcFxtXOfpWqicssTFOxSiticBfTt0qybLaoYnir73FvCp2DJrGu9RaQkDhaeiMYynUeiEfy4gTlSe9Zt3cgZVRkng4qO6dgeSCDWbeyEFcH8qV7HXClfcLmchDg8fWuX1uYFHHfFaV5M5HH4VzOq3BZCp4I7etDloa8ljjtdcFjnt2ArNjg83T2uCoDhtqt68elO1+UiZhuI9jT4nhXSbdN2JcbnIPvWC1OPEM0fDkapZyGXcNz43egr0fWr2xh1N4pNBF4UVQt5JM4a4G0Yc4GD9a4/wnpi32nkG+tLMJ8wa4Yru57V3cM2s4GfF+nlR0/edP8Ax2tkcztp/wAH9Dk9SmimumeC0FnGQAIQxbb75PPPWil8SvO2qSNc3sV9LtXM8RyrccD8OlFO50QSaO4t4JTKiYWJXJIJPH41Yt1Em+GU5OPlPaq24PbEEMSMYBxkHvVy12CFJZDhh8nWg6JbXILK4NpMwQkrnBQ8j61uS3EElnEFRQy8lx95s9qwn3RyNtXg9/WrFjMkiGM/6zOPm7UjGdO/vFnhgxP4Vl3EYLFmNb76bdR2Ru/If7MePMPSsW68sEh8qTUsiDTfusyrqIEkgYPaq0SPuwoyPWtVgrL8uDxioVPl5BUc1K0N+ayKWcPhuPSnFtowB+NLPGHYHuO1Eifuh0YD9KGykyaFlyNx6etWQkT4KgHvWahVvkH3h1qWPKMApOPrSTuJo1DCMZHcYqAQNuAXJx6ChZycKTtP6GpI8qSAePXNUSm0M8nL5I5HrVlEIXIyMc0wsVPBz60NLtXGMnpmqVkLVl22lMksSPyOg961JLMPgbSAP1rl0vBFKh9OciuittYimCqSVOMHNaKSZz1qc1rEeYkjkxyCvIx3qZ7xQmGzxzjtVaZ1l3CM5JHBHNZk/mI2DnH1obsZxp83xHRRTrMoKNVJ76WCfaFBXJJHtUGl7tpx93qSe1WJzA4YySAEdTRfQOVRlZkWqFLq18+LAI4PaucbJjJOWOeMVeurxViaGMlwTy1ZquVBUE9e/pWM3dndRi4xsIFO7DcAdPemzMqpznmpQ6sQc802dRjOQag1vqVQecjvxmiQ8Hg/Sm5wvLcD2qY/NGOhPrTQNoqSgsCB39qihDREKe5wKvcg4H61FKuVZcHJ6HFK5afQuadem2fIPPf0rofMiv4wcAtjHSuK81Qfmzx1qxa6m1nKCuSDWqmluZ1KHPrHc3biww5YAAD14q5p/lglJAAAPzqsmtRXFtkr83cGqUs7MOOAelVdLUx5ZzVmaN3dJC21CMegqudUBjAC5NZFwfTr6etEJBU5xuA59qXMaqjFIuyzGbOFx9abZXLxAxZwG6elV1mG05zzUMuTh1OSPejqaqCasbizlnAUjNWJLncm1zux2FYkMh2gkcjnNaCMJQr/AKVSZMqaRaRxsDcYFQSgkEhutPLKqbAnHc1EoMmQAMn1ouOC6lPJ8zaQT9aaF5YghcdqlZWSUsRlMVEzr5ijjOehrKTOpPQtRKQq9MVccELzgCoIyeOPepTllGetQYyYo29MZUj1pXAA5GRj1xSiEgEjrjHIqNlwApJwfXtQSnclt234JJGPbrW7pQaTaA2F9DWJDGXI6KFra0uQqQowQB1q4bmFd3jZHV2yxRQ84Jx61l6nqOA21uMYqrc3X2ZSC3JGAKxJ5jKxycCtJS6HFQw/M+aRNNdnnG7HWqzOzsMk7fQU1VBxzk1LGMDDZ4NZ8x3JRirIZMcBQ3HPpVOZVKnIx6VfmUOAevOKq3OCQPTrVApHO3/yM2DwfWuQ11iqMy8nsDXY6ggySDlRmuL1ybaHHGB0qZI0c9DgdXkZ5m3Z65+lRpISh2nqAMUmpybpnOQfYUukL5twiEZ3HmoieZVleR3ukaZdXdmkdpazTlFBYRoW259cVqJoGqiP/kF3mf8ArieaqW01xbhFtJpYS+B+7crn0ziu1ms7K1ivBda/rJeyZEuWjPyqW7jnkA1v1CU3BHA3sctnOYbmF4ZhgmN1KkA9ODRV3xVbrb+IJoUluJlVUKyztuaQFQQ2f7pB4oqZG8HeKZ3EVxGF+4m/HUcGmyXLlmGeOozVPYRkZ57AVYRWO3OMUXudSSWo63dwjB8lGPBPap4VLKzxtkKeo6j3pvlsVKkgZ6DtS2+IVZQRzwSKBOzWh2/g/UopLWeG9m227R+Vcea/8R6Mo9K47UwEuHAIZATg+tRHej+ZGenb1HpT7xCRtUdRnNKT0OanQVObkupUDllb5eR1zSEZGOvpiiIgISfSmuhMYbpnoai5tZXGRMM4OKkkj+Q/L0qKMkvnHzZqwT8hwQ2aaIloygECElc49+aUSAOo7461NtQt8vr1z3pvk7T2wDmlsXzIliXOdpyDzVuJmDjb0qjGSjjB4zwKt+aOORkdqaZMrj5iGHzHjNVJ2IXA7n6VaYgr8xonAki3DBoY4MygpYjqD1pdso5RuevGatIgLHIOakaMgDru6/QVBtzFWK6uIGDBiCKvJrMpZWniVwOPSqbx7iOcjpmoJGCDbnr0pqTXUHCMuhsf2qeRGAo9AarozTOS2Wz71RSInIB+lWrMOjMuOMfnT5rmfLGGwMrBjs5FVnUbNysT36dD2HvVp9zP0II9O9Vpgd6lSBz6VBpFjduHBBO49PSnyOW+XIBNQkY+XgDrk9qBluBgDNNMtoGXaSCM/QU+AlgFVckjAFMlBO3BB4q54fQfaHDD5gpxVR1ZlN2jctw6VvRdz/N3B7Usmmyqp+XcopJZnDYBIKnNallcBwDknPODWqijmlUnHU5G6gML7iDjPNV3iRgC2Tz2NdPrlqrQu6iudXkYxwBwfWs5RszspVOeNxsSGLgcgdqtCTehB6+tUnb5goB6flTkcR8Zx7etQnY0auSzuVXDcZ71CkrqzAEe/vU0rLIg2j5u1UpOMevcUN6lQVy7bTB1CkHnrU7soBVcY/lVCBmRgTyKt/Kyn2/WrjIGiS2bemCeR71vaUsckeD94dq5yF9smGHB5q9DcG3mEiOBk9qtSsZ1IuSsjoY7IsfmUUeQiqSwOPaiw1DzlAYgMP1q9lZc4wBitOhwuUou0jB1HIwAGC1nRRky78Z7GtPUWXfhSWxVS3AHXqTWEtz0KcvdLEWW3ZAAHAqaDAdeeOgFLEAqZI+9SeYA4wME8A0GblcuyKCox1I9ai8oMM8DHrURZmQjORSh1C5Yj6UrIzSfQtRfKNpHynvVuG4SEcAE1kCYkHB46inMx4/iz6UKQnDm3LlxcmeQlh1NQMMMcdPWmK2OoOaemXPzD6UFpKIQuOhOBUjF+AvQ96RYsMSw/KpGGCCAB9O9UkRKaELcEFskVRm3E/e49avsuBz1NUL9ggAUjB5qtjPnMfUQERjnII7159rz/Kw9a7rVJFWJi7c153r04IYj3olsTKdjjL3/AFrDjOfzrV8Kw+bfFsDCLmsa9Y7iQa63wbDi0MhAy54rOC10OS/NM6GUY2kHBGDkV1M1zdf2ukOp6bbhtVt0S4hafy/MOflkJ/gbgVzs7FJAQASuCPwrV1pdG1m9lv5NZ+xGfDTQSwMzq2MEKRwRxxW5pV6XMbxNc3M/iCf7XbfZJIgsItxz5aqMKM9+O9FN16/i1PWWntlkW2SNIIjJ99lRQoZvc4oqGbUlaCvod5dRKCCj7twyccY9qah2qd/JFOTbJGMHnrjp2pCoYEUHV0JA25SDx3pqKXdiPmUcH1pqdAM5FSxtszgnJ/WgWy0JFJEZDLuA5GRSWx3s0Z68kE0ySQlvQAYIp8O1n8zIGw5+ooauQ9NRXsmjt1kZlxISu0H5hj1HaqzK23y8Hb1BravLN0Q5ySefrVSNTHgMCR39qzJUrq5TMO0bl69Kqz5jzt6GtKZgoAx+NULoDOAMkjjilcFcgRs9hilyNg5Ix3ojUp1GKf5qgkMAQTTB+RHIoVgByDzk0hyzKpH4irO1AvPIPH0pjhRwfrmmJSHrnaBIc44FSM67Dj8MUxUy/Uk9jU32YbSDzRuCkiGM5I55FPYq0g+bPHI9aeLYqdo7cZpTa7Aw7n17VD0KuitIASM/gMdainhVpAFGDjHNXGTyzwd3rUBIOMDK85qS02QNGyqrMcEHByKlVyrFQSRjjHenTHEITkgdPaoOSevToRTuVvuW5Jdo3bMjviq0pLKSOT1zU0aFgR0z1zTym0YA+U8g0EpqJQKgkc5PamKVJIbgjv3q1s+bb90exqErtOBjNI0TuRzgHO3geuM80umXPkXaEnrwfeopZGRwCS3GB61Xc8nJOSePSqTs7oOW6szqZ4YpkMkUoyR0z0NOQLaxxvIRjvtrlDPIq4ViD39MUG7l2qDISB1HpWntFuZfV29Gze1e8WQfuz9BWJGMNyTzyM1FHc7jh+g4BJqQvujz3HeocuY2hDkVkNKlXO85yeoqOZAAWDGpMsQd7Ak8nFRxndHgDj3qGjRE6KcLwMevWmTqGkz27AVOqYO1Ohps64bcOfamhJ6kQQgcd8cU6PcFAOcg/hipCcLjgeuaWHaM7/0oQ7kTMBOuOn60g35xklf1p0wG4EYJyOlAyeT0zTvqadDX0Ob/AEoKRk9CK6ySL90WTIOOua4zR2UXo3DJzXZ+d5aAAMMitqex5+K0mrGDdhkYjGD3OKZCBxxkVPqk2W3E9+lVA5dSRxx61L3N4axJ2l67cY9PSpEOF+c9e1U4gWYnAqZmwBnkjtUg10RO0nJPrULNk/XmoHlO7cW4PQCjzN5GBmkxxjYsoxwAMA+gqTeN2M9qYikqCw47UqoT1HGaYmyaM8g1ZhxnuTUKxgNhQcdcVOhG0MVpoxlIkHsOc0qpukAAHHSmx53Z5I9u1WoEbBdTVpHNOVhs8YKEkYxWPfoJVIPG3pWveSkRYI5z61z19cnazFgc9van1Jjdq5zutsfmGeenrXnevysNwCHn1rudTvNgJ28EVxuq3HnKVwCCe9RJpsJuyOJnLPKAB14r0vw/aiC0tojnKqCa43T9PE+rwhQCoO5hXoFqNm9umBinBWZlRV22SfbJooriJGCxT4Enyg5wcj6fhXV3c+r29xHBN4r0eGVwpCPb4IBHGfl4/GuGmlK4YHkHIzXTSWNh4ieXV5LPXYzLhp0t7YSRuwGCUc9jirewVbN6/kZ/i/TL63+26leX9pfS2+yO58gbGiyMKSuBx7iisvxZ4ktbi01aCGCaO+1HyrVY2+7Bbx4xk9S5xiitqcI21OGtiqilyx6HcocYAPXsamTjk1WVSpO6rEbkD2HHNciZ9H0HlBjOcU9xsjwxB703I5JokZcBsg1ZDYxNzEtmpmCqjbckkdvWqkUnzEL0A5FTKDkc9jx+FBL13OxkbzLaInBO0ZrLvIhn5OD6Vp2MXnaZBIo4aMYqvPB83zdR6USRxxkk7GJIoR18xTtzzjriq9wigBlxtJzkH9K1b6EAY3EA89KyJJAm6HPyP2HT61m0dEXcoXD4UjIyO1UNxZvvH05NWriMLJtPIxxVRU8tirnJNSzRWSNC1w0ZAJI9zQTwQfXrS2TgkgYA9DTLgkSMMbSapme7LFsSW5PTvWhg4Lbs47CsmKTcw2cH+ZrWhlDKR69RTWpE+48PgBSDn6VFM49cH69KeQCec4AxTmjDrx1oaYospliTgHPrTNgBz0HfipmjKEbqjYndwcAc/Ws7G6d9iOXBwTg59OlMKkMFJyMdhUjg4yR9BTJPT8qRSdieKPC5Xr70juyttIUD2pIpCMZ6Y6GptqyDdwe1Mluz1K0h4DdDVSUEAk5zVqZTvyCCKrT7sMeveixpFlCbCsSN2R6daa5ypxgYHHsamAZuWXnvUTxFlz8v19aDVMglU4JwRxTYyMFTj1606QE5wMHrVdVcuNxBxxjFS2WnoKobvjiliVySMH069aMbGycEZqcMG4BwQOpoQ+g1wyxsGzmmRAxsBxzUqA7AWXcwNWI4lMfzgc80xOVkPtySnORimu3AwM0g4DZPfIoTaDyMUJ2JJEjJBbAIIximE+UwB/lU0TgZ9/So7gkyZXHHrTuC1dmMkwME9fShMqhOeCfTrQU3ICfryKll27O2cY44ppXNOboSaT816MdQQeK7iZl+z8kDjiuK0NVa/VR9c10GoSlQBuH4VrT0iceJXNUUTPumLluhHtUEKmNMuePrTZHG5tvA9RTZHJTYuDxUtnRFaWLNvKWPqCcA1Ky7vOAVg8Y5Ykc+1UYWZfk9DVyEomeu4nJqETLTUiK7WUN9085zU8cfTaBgdqkSHfJnHynsatqqoo4560zOVSxHH8oye3r2qXKscjj3FVpGJ4POSc4FPHEeOAeuKaZPmWonyCucEe1NPm7xj7tRMCNpT8h2q/bjai7jTRjOSiLGdi/7RqwCI0wSfUioVUGQuScDke9RyzjJOODVt2Rg/eIL+T9yWx09e9c5qMw2k8c9a072cSKUTOO+a53UpAAw6jtUs1SsjndYnJyARjFcheMWdgWCjB5xW9q0xDEPgAd65i5n3TKkfzMxxis+plWeg/Sp3trlfJBLEgMxruSxW3UfxEc1g6LokkUqy3GOuQK2pGySfSunToZYWM4wbnuyncMAw3AlQRuA7juK6/XbHX9R1M3mhzSSacyqbR4JwscKgDAIyNpHfNcZJhmPUVFK4jjK5YAjnk4pbsuUdOa5J4paLUvHd1NHIkwSONJZYx8kkwQB2HtnvRT/ABtALPWdml2vlxLa27kRrhQWjBJ/E0Vq4SnqjgpVqVFcr1PRZI8qSOCO5p0OGQHr7VoCMbSrDk+gqlNiGQKBjNczR76nfQSQ/LUCgAEHPNTOQwznFQmPDFh9etLU0W1hkeBICD26VcRyiEHgjtjtWa5YS5BxjvV1M7RJ1U8GtEYSO+8OJv0K15ByCB+fSpNQhbG4jHv2qn4Ru1GjLEwwVc45963Lt4jaHzWCccFjjP0qrXPIlPkm7nMROyOxU43KUIYA4B9PyrP1TSZ0MtzDHvtVwRKBgc+1XGuUtZzLE8bnOfmGehzVC5vJJt4ErgMeVXgH8KzcTrhP3rxZi3EeSCeuapzDeQDHtCnrW/Hplxcf6qJuT95uBU0vhe+a2Dq0bsP4ATmlysuWJpxdnI5+2ZPmGefXFF0FcA+3c0yaN7W68uZDG46qRVoCNhyoHHNFr6GqaWqKFu4hwwwR1I9KvxzNkNGwI/nVS4hHzFMGmw/LtGMNnoam9tCpWlqbUcocDgr61MJfmXHBzx71mKpPI4IHIp8DkEq46c81VzNRNV2EqkYwR1qhNGNxA704P5eWLZUfpTfPSQZUZ9ah6lxTQ3+EA8kdxTmC9D2pjMpBHUVBJIw6dql6GiVxzyKGC54qRMkgjp7VTaRSNvG7OBVm3cjC5prccloSzv5aHAqjKxkPGOPbiprmTfKAWxzVdyFbC8DNK4RVldkOCUZTw1CIccYIP8PpStuJyCMA9T2pZM7WyPpzQaXKjghcDBPTp2qJ0AOSpDNzkdqtOxUD1qMruz2pDTYgjygPBNG0EbiMselIMbenbk5p0Ss4JByQOMUXHcY4YNkAgnoAani6c8gjP1pWQ8lwR2xTYycEHg/SgZI6gruHA9PTiq4UAhucH9fpUgbGQowDTGO3jAGf0oGtByy4bg9vypoLFs4OKMhVIzk4zxQHAYgcZOM0DJ41xGCSd3fNVJZWDE5GPSpZZSqkA4ArPJJJIOQTnFPYuKvqbmg7ozJLjpwOauTMzsWOSPftVK0Z4LZVx15IpwlEj43Ee1a7Kxk1eVyY4KHdn8KqGZixChR2p/faTjPWhIlzjoahlXSHwoc5DDJPJFaMMYHORjrj1qnAFBwBwe57VeRyF+ZcjtSMZyLUXypz+FI0u5DnoOw71WnmCkKOM96iAOMlunHWgzt1ZdikRyBkEeookADgjkfWqsbNklQFHp0qVEZjkngd6qK01Ibdy7GhIBfp2A61aiAkYAH5aqo2ANxwD3q7AwCcYAq0c8rpBcyiKPHUdMCufurshWJYqOwrZuG3NngEVjahHuVsgYpPUqk0tzImvCG2k8449aw9SuixYhjx1qzqR8o5U1yeq3xCsu7BPX/69Q3Y1bW6MvWLnLMCx6596TwtZG81MPIPkj+Y/Wsq7maWTgbm6fWu/wDDlktjpisVxI/Joirs5n70i3O2wHbj0qlLkpwO9WLhsk8/hUD8AknA/pW5cuwWetXugxzS2EyxNJgPlFfOOnWiTx74ilRWjvI+f+ndP8KrafbWWptfzahJN9gsEVpEt8eZKzNhVBPT3NbQ8O2U2mtqGhvM1vF/r7afDSQehyPvL71fwrzOC6rzdtthdC8R6lLHf/2jDDcS3ahWlZAOAMDgcdKK1tW0yCx1IQWysI/Jifk5OWUE/rRTU5LY6qeGp8qaR2MCuRhhx29aqara/uw6jtzx0q/bXau+0gA+3erU4V4W4yT61ibKbi7nIRPkbWHToTSsvzDaecYqS7tzHI5xwO1NUFlArNnbGVyqRhzkCrcRJUA8j2qu6jOemOTT43KuASQM1SdjOaN3S71LWzZNpMu47CP6028upp23TyFmPTngVRu3EKoR3Geaitpmlcrzk9MnpXTFaXPnMXUvVaLkaeY3XOPU1tadDGFBK5b1PesyCIqMsBke9XbK4zIFxg9MHtStdnPKbsb1oY04bnJrWjxgEEYrm2kChW5z6g9atW17tBDtkY4BOKuxg1cu6ro9pqkYFwgDj7sg+8PpXC654evNLfzS3m2w/iUcr9RXaxagTkM1Trcxzqythgww2e9RKCep1YfF1KLtujynJOCTkHqPSo3QgBsZx0NdJ4m0I28puLJT5J5Zf7n09q5zcwGN2faueUWme9SqxqR5ok0MjBAX+92yalM4ZR6iqXmISB0p4AbHB69TRqbKPUtllMbYP1zSKFZODjntTABj5ucelIZCr/KR9allxEk3I2ASVz1py5YkZ4J6Uhf5huHbrVpIFIBXqO+aViuaxl3cJTJHemwysOM4IHer9yrbTkYNUHUHJx83qTxU2saJ8yHOw7/e6g9qRZi68jGT3604plNpbJ69KiCspxg4Bxz1oDQm2FjkDqOlLgFRnt1zUbSNHg4GOwprvwRjKn8MUEO7FcDacYyenpUOQoKn7w61JHhkO7kDpTGUc/KMjqetA4kIyDxj/GlhbaWZSCCOfamHCn/ZqRQoAHf0pGhMpyoDE5+vWl2szggEY96ZtwnGM9/emvI3qeKGESRsAgtyR1xUbAFDvADduKeSFQMD15xUTscHcRQO5GGAxlgM0b/mz/MVXkxj5ep4zSp1G7kjpmmUTzOGTkcelQRqplQAnOakkbGcnA/rUlknmSbh1XJz71RXNZF+5k+UEemKrRvjDFuM4psjFeTnI9OlQeYC2WPGecU29SUtNC/EzSOR+VXLe24y+Ko2LjzC3b0Na0cgbJ6fWjcyldDMgSdBtzVh5gi8nGelRSShVyBz1qlNI0wBfc2TwPSkyLXJ5JA8mSScDmgzbAT3I6YqFiAPUd6siIna+Tt6CkN2QluzuyKAck5Oa2IsIoDnJ9BWfCwQ84NW45NynaQfwq0jCpqyYKshXceO1WHYINpPaq0S+Wgdm596heUyE/zpmdr7CTM2cq3XpWdeXG2MAHnv71LckBuTnvWVeSbSfQZGaaEzC1yf92QDz14riNSkLSHnIPGa6fV5kIbAFcfdhpbgRxEkseMVnLcU5aFrw/pYvb9GBHloQSDXeXRCKEHbjiqmgWC6bYLlf3jDJpzkuxYnk1aVghGyITzz+ZrE1/URCvkQnMrkDjtWhq97HY27MT8zDisPSbKS7n+1XI5Y5A9PStoqy5mcuJm5v2UN+pteCjcaS0zi3juorlNk8EqlkkXOecdCD0NdPoclxp90Li2VkblSpQlWU9VI7ipPCeoTaLdCWEnyn+WaMfxr/iOxroP7Z1TzZPLvrvydx2FwM47Z7Ur31ZtClyLkS0K1876jfG7eJYCyKvljoMDHGaKdc3E1xIZrmUySEAFyOTiiqRvFNKyN2NYmKdj61faRDDtWs/YIwM8Ke5qaLjIJ4/nWJD11M+7QlmAxz29azYiwbafvAelbrx4l2sOvQ96zLy3aKYECpehvCXQqzp+8B5xTRhuh5q06b0zjOagZG/hHI7Chmq10M7xjfPp+kpcqgkKHpnHBribTxzMZwXCxA46DOfwrrvGkEl5obogJfAUEdc9RXkr6fLGcSrsCHOCMV003dWPlcyjKnW9T1S18S3W1SzRyB16LlT+Vbuk6vBJF5sj7T0w5wQa8egvpI1HJ2+pq02quInJX5R97nrQ3ZmNr9T1u48S2NtuLTkso6L8x/Ss6Hx1aS3XlxLMJS21Qw+97/SuBhkeW23hPlPIXofxqTw9bGXUlmcEhM8n1o529xuKij0+DU7q6mALEL7V0mmmYEFnbJrmdFiUyKxGR2FdlZHlcgZPYClqwckkW/Kllj2swYHjBGc1xutaS1rIWEZER7+ntXodtEMArip7izjniIdAwxzxQ431NMPjHRl5Hi88WOcYFFs/Ynj37112t+HXiZntRuU/wE/yrkzGYpCCpyDggjpWdrH0NKtGrG8R6tyPQ9BT9m/7vAFQMCWyoqbcce+KTRrckgh4DMTgHtVyIL0YgE9B3qCaIGxkbzNjABgv97tU8JDoro7HjrjkkUtgbuOlAAVcAkisy6G1xkYFapy8ZLcMrEcDA/Cqd0AwySM4oauVB2ZnFiPl3de9SQldpwc9qZOGUDPPHamxyKQBismjV6oWQZGDjHeomADYGfrTy2SwUNkdc01yx69O+Klhqgj+U8Eciq8rcBQcetPUkKQO564qN+TxgkCpuxxWoy3GZFJJqeRNr4WmIoK4OBU4w33Qc/WmkD3F2KFxkg96ciDkcDPQjvUfmdVwATSvkcgYA65qhXYyQhBtPGPaqrlpAMAEd6ldg7E5zzk1XkOVZeoPpxSsUiJl2yDdwKJm3YAOTUUhYIuCST3NEMmM8cnmhFruSq+TyCPpWnbERwN0G7isdSSx960wNtsqk9quIpdhlw+4gBuKrMPm54oc7TtJwc81NFCWjG4nnpUvV2L2VyezUnnIz6+taaOuQD1qpEEjjAGc/SoJZmBBU496rYyfvGm7kjG78KqzysrgADAHA9frWc00jSD5s4qbLFST0HU+tLcEuXctQOZ5lGMYPQVqBmdtitx/Os6wVQ2cnmtKBSHOQMnvVxRjUmmyZYQAoyD25q5CixKRwM85FVuRyoJIqUErGc8HvVo55ybEumDLgGs6e48hfu9O9SSuNxbOQe+ayr6Xk8nHp2qblRViw10siMSetY2p3YbKhxioLm8IQ7eFrFvLgjOWye1O+hnJK9zP1abdkKelT+E9MMs7XVwuEH3QRVW0t31K8Eag7AfmNdaQltbrDDgADH1qUru5MFzO4t1NlsKeOgArM1G8jsrdpXIyOgpuo38dnEZJT83YVzcKT6vdiaXPkg5VT3raMftPYzxFfl/d0/if4D7OCfVr37TchhGD8qmutsbZEVVA4HtUdlaeWoGAB0FbVrak4wOOvWiUrhh6KprXc3/CFt/x+PBDHLfJGDAjgHPPzEDuQK3orvXS+0RTu39x4Bj6HisTR7CLZNcXU0kVvbAMxjHzkk4AWtC+ll/s9rqwvrqe1T5ZEdyHiPbcPT3oQ52cv8yr4hiSPU5FhVFG1S6IflVyPmA/GiotWhS01DyIixXy0fJ5OWUE0U7m0Je6jSt7lZo/Kf72OKWAlJQH5BHHNY8QcsGDEN1Na8f72EjGWHOfesjWcLLQsOVZyCT7VPcWyS2ufasouyOGOcdD9auvd/ucLz6+1MxaeljNC+W7BuKQhEdWxlc5I9atbBOpK4z9KjePC881Njbm1KF5Gs9vJE3KsMjHByORXC6/ptm8JnDSxlmO3+LcR716CyZGD+NcrqthIs7xI0ccbt/rH5wf6D3Fa0nrY8zM6XNFTR5yyKFbKgZ4AJqOAIbhYy3yg/OvrjtmtDX7V428wLgKdpZeh96woVkDkA4XORg1s49jwlO0uU6Z7lGjKs3UYA9Kv+FHlnvPKcfPuJyD2+lYulRhywIB57Vt6WTYajFOoY84AHc1j1sddSDlBTPUdNUIAo5wK6TTZFOB0P9a5C1mkjkKTRmKRfvIwwR9a39PvI3lCdGHaujlSRwt3Z2VjkEda1jBtRT1DDI5rnracKFKkhTxW/ayg2xBJ2nkD1pENtalW4gE0bKyk96898YaQYJjdRLx0cf1r0v7/AE5PrWfqECXKlZEDLjBFYzXU78HiXTl5HjDKQ/XI9qazHsMY6CtrXdNbTr5oufLb5kY+npWYYwYztGGHXNZ7n0tOakk0SWT+YAjjI71pyFQoaPb5a/dwCMfSsNHeFtyjGO9Xre96KwG0nNIpxe6JmZ25bHPTmq0g2rnjOanumVo96Yz6VRkd+AwJH505KxcCGVsNzjA71G4G7I5FLcmMHBHPTA71C524C8gjH41kza2iFJ6g+ueaapLkAEj2oBABIzUbMNgK53VFh2HsWHpj1poOxtwNRNKcY3fn2pfNO0/dAxikgsx8Z+YkjnripQGJ3Hgg1DAxyP0p8hIII5GKoh7jZHw+SfmJ5GKlSQMdpPUcmq0j5Xd0+nFMjfaTntQDJXQqS3UZqCZgQdv15pryszHkH1FV5nODxtHoKNykR3DEuM9KauQDtPNIHJHzA5pVO4AdAeDQjS9ie0XzbhAxwCe1adwAGwMelUrLEUwYk/Wr8gyc8n3xVrYhu7KeN74bgGtB8Q+WEAwE4PrVfywe/X3ps8hwQOwx1pLQJSvoO8/MnPPambWOWJx6VDEGLfP933q63BUKVwKSTbBuwQw7UBHNTrGrkAdKYrlQMng96kh/ejgjjrVvTQwbbJVJDqiDP9K0oUYsAc5FUrNFMuQOF5xWpGwPpz2ppGVSVtESRRc8dqLngfMePSn7ggJIHtWTqF3hs5O09aZim5Mg1OZQdi8e9Yd5dlUO3GcdadeXLSkqM+xrGuHZSdzdByalGzdlqR3E+VPH51lv5lzMEUZZuKn2vdSlI8keta1nbR2UeWI345J7U7XMUnJ+RPY20dhAAn3zyTWLrWuQ2Pyj5n9Kq+IdcaONktTuc1zFpZ3F5epLcoWQsC2fSumnSW8jhxONcfcoLUL3U3v75Gl5XIwor0PR7Zfs8ZVcDHTFW9a8PaDLDYyaXEqyhcvt4yO2fer9la+UFC8BaKrWyDA0Zpuc+pJBb42sRn2ratVRIwQMVUjG7Ax0q0oyPestD0GWLS+Fo0qSRJNbzLslhckBhnI5HQ1Xs7qWxuDLBtIYFXjblXU/wn1qawsVuZHkmDmGPGVT7zsThUHuT3q9FBC9xPbyabbqIQS/kykyADqVJOGI7iixDlFXuihqV4L2/NyIvJBRU8vOcYGOtFJqFqbS6MW7zFGCjgfeUjIP5UU0jWKVlbY1JLTnCjae4q7Z2pVW6mtvX7eKG9YRIFHWqgJWFtpxzSUUZ+2k4mZPalJBu+63GPSoJYHjyhxjHFX71iyHJ6AUsqholzzSa1FzMx4mKuCB04q1IuQHAx6iqzjDt9avIoKjjtUo0b1uVpIxIrEDB61geJLGS5sF8p9jq4HJwD9a6qRQrLgAcGqF8oa3lBGcVUdzOq+aLizyfxDHcRui3e0SMO33T7isBoSscpZdxAyuelei+Jo0eycsoJUAg+lcbqn/AB5t04HFdM9GfNwjdNvoZ2kTxqJERmDDgZ5BPsa9L+G+kafe6zHNr9y0NtEQAIxwZD0Uk9u5rifDkEUU2I0AH2R5vXDgcGte0uZke0ZXIadd8n+0T1P6VLXQzjUk0k2dJqEw03xpqFp9p+1QOxZJB93cOCBW9YyK7q46gda86uwFbRZF4eSV2Y+p55ru9H6flVR2sS37x3OnsGWME8Dmuitx8iOCflztBPHPXFctpvRB2xXRRnJH4U0iZs0VYA8gDPvUbsCc+tMbhVph6fiaiaKpbmB4wtBPprsE3yRkOpUZ7/4Vwj8fdwCRke9epagM28mf7uK8pcfJJ/suQPasFufQYCTcLDHXOe2euareVlgQeOpqy5JGT1I5pIfuVJ6kXoTWsZeNwCSetREY3Jz09KvaeBk1XuVHmvxTa0HF+9YyrhQfm7Cqxl2nnn09qvSgbj9KpbF3His2jpWqGBvlO5jz61H5gL89MUNxJ+FQofmNILCy8Kew9aYrhQQRkHt2NLJ16mpAilVyKmw2OhPAByPapCSSVHQVVxh2AzigsxkGT2oM5KxKwO3bnoc1A5xwD9cd6lbo31qBzyT3waBISBh82OuaZKo2nIznvSW3JqWT7hoQFR1K4BJA706NTIBgihuYcnk06z/1oHtTC5OFAbO6r8N2u3a3p1qlOMLkdc1BKSrccUXsyrXNYuNx8us+WQ+btGST+VPsWJU5NSKBvHA5q9ydgRHxy/WpIpArKOvbFSSjCxY9Krof3wFK2pDdy025hgflipYlK9BjNQxjMpz7VMhIJx61TRDdtC3HIY154Pc5qS3nYOGJ+XOKqS8KT6mlU/uxTRD2NG9uwsXX8K5y+u9/3cAD1q3fO3lnmsW65jOfWkyYxsQXNwFfPAH1qmY3um+bhT60sQDyHdzz3q24xjHH0ppWE9dw3QWMPG3gfnXKa1rMt1J5VsSF9ab4jnlEoUOduelM0KJJJV3qDyK6KcUlzHlYvETlU9itEWNL0l5GDy8/WussLBI1Gxee1PsYkA4Uda2baNcrxUSk5bnZh8PCnHQLW1AQHHNW1hyPQGpQAOgqVeSaSOlsgU7BgGmtO4OBT5e1Q9TzQKOptaFehWkiZ0idnSWJnOFEiHgN6AgkZrYt7VYpmmis7i3c5w07r5UWRgnd/F1OK5BgNp4p0Ppk49M0yZ077Pc39Tjt71ig+a3RFjXPBYKMZ/Gis6CVwANxxRTISa0TP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A reticular white plaque is present on the buccal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Carl Allen, DDS, MSD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11427=[""].join("\n");
var outline_f11_10_11427=null;
var title_f11_10_11428="Neonate body stalk malformation";
var content_f11_10_11428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neonate with body stalk malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11428=[""].join("\n");
var outline_f11_10_11428=null;
var title_f11_10_11429="Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus Haemophilus influenzae type B hepatitis B conjugate vaccine: Drug information";
var content_f11_10_11429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus Haemophilus influenzae type B hepatitis B conjugate vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11562067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Infanrix Hexa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11562071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial, Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11562136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Vaccinate preterm infants according to their chronological age from birth. Children 6 weeks to 2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     I.M.: 0.5 mL; repeat in 8-week intervals for a total of 3 doses. Vaccination usually begins at 2 months, but may be started at 6 weeks of age. Do not administer to infants &lt;6 weeks of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Use in children previously vaccinated with one or more doses of hepatitis B vaccine:",
"     </i>",
"     Children who received 1 dose of hepatitis B vaccine at birth may receive a 3 dose series of Infanrix Hexa&trade; beginning no earlier than at 6 weeks of age. Use in infants who received more than 1 dose of hepatitis B vaccine has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Where immunization against poliovirus is desired, Infanrix Hexa&trade; may be administered instead to infants scheduled to receive concurrent Infanrix&trade; (diphtheria, tetanus and acellular pertussis vaccine) and hepatitis B vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Booster immunization:",
"     </b>",
"     I.M.: 0.5 mL administered at 18 months (in infants who have received a full primary vaccination course of each component of Infanrix Hexa&trade;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing delays should not interfere with the final immunity achieved with Infanrix Hexa&trade;. Regardless of the time that elapses between doses, it is not necessary to restart the vaccination series.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11562140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infanrix Hexa&trade;: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg], HBsAg 10 mcg, type 1 poliovirus 40 D antigen units, type 2 poliovirus 8 D antigen units and type 3 poliovirus 32 D antigen units,",
"     <i>",
"      Haemophilus",
"     </i>",
"     b capsular polysaccharide 10 mcg [bound to tetanus toxoid 20-40 mcg] per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate (trace amounts), polymyxin B (trace amounts), polysorbate 20, polysorbate 80, and yeast protein &le;5%; Pediarix&trade; vaccine used to reconstitute Hib forms Infanrix Hexa&trade;]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11562077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11562137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.M. injection only, preferably in the anterolateral aspects of the thigh or the deltoid muscle of the upper arm. Do not administer intravenously or subcutaneously. Do not inject into the gluteal area (suboptimal hepatitis B immune response) or areas where major nerve trunks may be located. Fractional dosing (use of reduced volume) is not recommended.  If more than one vaccine is to be given by IM injection use separate limbs. Rotate injection sites when completing vaccination series.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Acetaminophen may be used when needed to provide comfort; however, routine prophylactic administration of acetaminophen to prevent fever due to vaccine use is not recommended. There is evidence of a decreased immune response to some vaccines associated with acetaminophen administration; the clinical significance of this reduction in immune response has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11562125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with other vaccines.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11562072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active primary immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b in infants and children 6 weeks to 2 years of age; booster immunization (at 18 months) in infants who previously received a full primary vaccination course of each component of the vaccine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11562066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Infanrix Hexa&trade; may be confused with Infanrix&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11562117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      All serious adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Irritability (83%), sleeping increased (63%), fever &ge;38&deg;C (100.4&deg;F) (56%), sleeping decreased (51%), crying abnormal (43%), fatigue, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site: Redness (49%), pain (43%), swelling (36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Loss of appetite (49%), diarrhea (36%), vomiting (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever &gt;39.5&deg;C (103.1&deg;F), nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site: Induration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction (including anaphylactic and anaphylactoid reactions), angioedema, apnea, bronchospasm, collapse, diffuse edema of injected limb, inflammatory cellulitis (without bacterial infection),  lymphadenopathy, seizure (including febrile seizure), shock-like state (hypotonic-hyporesponsiveness episode), sudden unexpected death, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11562075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of vaccine or formulation; encephalopathy of unknown etiology within 1 week following prior vaccination with a pertussis-containing vaccine; moderate or severe acute febrile illness or acute infection; children &gt;7 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11562076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Apnea: Apnea has been reported following I.M. vaccine administration in premature infants; consider respiratory monitoring for 2-3 days following administration and/or consider risk versus benefit in infants born prematurely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Reactions from previous dose: Carefully consider use in patients with history of any of the following effects from previous administration of whole-cell DTP or acellular pertussis vaccine: Fever &ge;105&deg;F (40.5&deg;C) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; shock or collapse within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acute illness: Use is contraindicated in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Guillain-Barr&eacute; syndrome: The National Advisory Committee on Immunization (NACI) recommends using caution with repeat administration of any vaccine associated with the onset of Guillain-Barr&eacute; syndrome within 8 weeks of immunization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatitis B: Use for completion of hepatitis B vaccination series in infants born to HBsAG-positive mothers and previously vaccinated with hepatitis B immune globulin or born to mothers of unknown  status, has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neurologic disorders: Use with caution in patients with personal or immediate family (parent, sibling) history of  progressive neurologic disease, or conditions predisposing to seizures; where appropriate, consider deferring immunization until health status can be assessed and condition stabilized. Antipyretics may be considered at the time of and for 24 hours following vaccination to patients at high risk for seizures to reduce the possibility of postvaccination fever (may occur within 2-3 days).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Poliomyelitis: Defer administration during outbreaks of poliomyelitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the NACI recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids); may have a reduced response to vaccination. May be used in patients with HIV infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Premature infants: May be administered to infants born prematurely beginning at chronological age of 6 weeks; decreased immune response may be observed and the degree of clinical protection is unknown. Infants born &le;28 weeks gestation may be at greater risk for apnea; monitor respiratory function closely for 2-3 days following vaccination, particularly with history of respiratory immaturity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Aluminum: Formulation may contain aluminum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Neomycin: Formulation may contain neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Polymyxin B: Formulation may contain polymyxin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Polysorbate: Formulation may contain polysorbate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12608708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11562073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11562074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11562139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs/symptoms of hypersensitivity for 30 minutes after administration; respiratory function for 2-3 days following vaccination of infants born prematurely. Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11562132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunity to diphtheria, tetanus, pertussis, hepatitis B, poliovirus (types 1, 2, and 3), and",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type B by inducing production of specific antibodies and antitoxins.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11562126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset: Immune response observed to all components 1 month following the 3-dose series",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, 2006. Available at file://www.phac-aspc.gc.ca/publicat/cig-gci/index.html",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11429/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ome&ntilde;aca F, Garcia-Sicilia J, Garc&iacute;a-Corbeira P, et al, &ldquo;Response of Preterm Newborns To Immunization With a Hexavalent Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B Virus-Inactivated Polio and Haemophilus Influenzae Type B Vaccine: First Experiences and Solutions To a Serious and Sensitive Issue,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(6):1292-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11429/abstract-text/16322149/pubmed\" id=\"16322149\" target=\"_blank\">",
"        16322149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11429/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11429/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16462 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11429=[""].join("\n");
var outline_f11_10_11429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562067\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562071\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562136\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562140\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562077\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562137\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562125\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562072\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562066\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562117\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562075\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562076\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299217\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608708\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562073\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562074\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562139\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562132\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11562126\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_10_11430="Cladribine: Pediatric drug information";
var content_f11_10_11430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cladribine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"    see \"Cladribine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/22/19813?source=see_link\">",
"    see \"Cladribine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite (Purine Analog)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"      see \"Cladribine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents (details concerning dosing in combination regimens and protocols should be consulted):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute myeloid leukemia:",
"     </b>",
"     Limited data available: I.V.: 8.9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days for 1 or 2 courses (Krance, 2001) or 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 30 minutes for 5 days for 1 course (in combination with cytarabine) (Crews, 2002; Rubnitz, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Langerhans cell histiocytosis, refractory:",
"     </b>",
"     Limited data available: I.V.: 5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours for 5 days every 21 days for up to 6 cycles (Weitzman, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Hairy cell leukemia:",
"     </b>",
"     I.V.: 0.09 mg/kg/day continuous infusion for 7 days for 1 cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (due to inadequate data); use with caution. The following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 30% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer 30% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (due to inadequate data); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V.: Further dilute prior to use, may be administered over 24 hours as a continuous infusion, or as an intermittent infusion over 30 minutes or 2 hours; dependent upon indication and/or protocol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     24-hour continuous infusion: Further dilute dose in NS (Adults: 500 mL); the manufacturer recommends filtering with a 0.22 micron hydrophilic syringe filter prior to adding to infusion bag",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     7-day supply, continuous infusion: Further dilute dose in  bacteriostatic NS (Adults: 100 mL); add to CADD&reg; medication cassette reservoir; the manufacturer recommends filtering with 0.22 micron filter prior to adding to cassette/reservoir",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F152325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, chlorpromazine, cimetidine, cisplatin, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, diphenhydramine, dobutamine, dopamine, doxorubicin HCl, droperidol, enalaprilat, etoposide, famotidine, furosemide, gallium nitrate, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, idarubicin, leucovorin calcium, lorazepam, mannitol, meperidine, mesna, methylprednisolone sodium succinate, metoclopramide, mitoxantrone, morphine, nalbuphine, ondansetron, paclitaxel, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, teniposide, vincristine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light. A precipitate may develop at low temperatures and may be resolubilized at room temperature or by shaking the solution vigorously. Inadvertent freezing does not affect the solution; if freezing occurs prior to dilution, allow to thaw naturally prior to reconstitution; do not heat or microwave; do not refreeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     24-hour continuous I.V. infusion: Dilutions for infusion should be used promptly; if not used promptly, the 24-hour infusion may be stored refrigerated for up to 8 hours prior to administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     7-day continuous I.V. infusion: Dilutions for infusion should be used promptly; if not used promptly, the 7-day infusion may be stored refrigerated for up to 8 hours prior to administration. Reconstituted solution is stable for 7 days (when diluted in bacteriostatic NS) in a CADD&reg; medication cassette reservoir. For patients weighing &gt;85 kg, the effectiveness of the preservative in the bacteriostatic diluent may be reduced (due to dilution).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of active hairy cell leukemia (FDA approved in adults); has also been used for acute myeloid leukemia and refractory Langerhans cell histiocytosis (LCH)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cladribine may be confused with clevidipine, clofarabine, cytarabine, fludarabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Leustatin&reg; may be confused with lovastatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, tachycardia, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, dizziness, fatigue, fever, headache, insomnia, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, erythema, hyperhidrosis, petechiae, pruritus, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, constipation, diarrhea, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, myelosuppression, neutropenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, muscle weakness, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Abnormal breath sounds, abnormal chest sounds, cough, dyspnea, epistaxis, rales",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aplastic anemia, bacteremia, CD4 lymphocytopenia (nadir: 4-6 months), cellulitis, consciousness decreased, conjunctivitis, hemolytic anemia, hypereosinophilia, hypersensitivity, myelodysplastic syndrome, opportunistic infections (cytomegalovirus, fungal infections, herpes virus infections, listeriosis,",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     ), pancytopenia (prolonged), paraparesis, pneumonia, polyneuropathy (with high doses), progressive multifocal leukoencephalopathy (PML), pulmonary interstitial infiltrates, quadriparesis (reported at high doses), renal dysfunction (with high doses), renal failure, septic shock, Stevens-Johnson syndrome, stroke, toxic epidermal necrolysis, tuberculosis reactivation, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cladribine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; not adequately evaluated. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Dose-dependent myelosuppression (neutropenia, anemia, and thrombocytopenia) is common and generally reversible",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients with pre-existing hematologic or immunologic abnormalities; monitor blood counts, especially during the first 4-8 weeks after treatment. Cladribine therapy is associated with fever (&gt;100&deg;F), with or without neutropenia; more commonly observed in the first month. Infections (bacterial, viral, and fungal) were reported more commonly in the first month after treatment (generally mild or moderate in severity, although serious infections, including sepsis, have been reported); the incidence is reduced in the second month. Due to neutropenia and T-cell depletion, the risk versus benefit of treatment should be evaluated in patients with active infection. Administration of live vaccines is not recommended during treatment with cladribine; may increase the risk of infection due to immunosuppression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Serious, dose-related neurologic toxicity, including irreversible paraparesis and quadriparesis, has been reported with continuous infusions of higher doses (4-9 times the FDA approved dose)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may also occur at approved doses (rare); neurotoxicity may be delayed and may present as progressive, irreversible weakness; diagnostics with electromyography and nerve conduction studies were consistent with demyelinating disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Acute nephrotoxicity (eg, acidosis, anuria, increased serum creatinine), possibly requiring dialysis, has been reported with high doses (4-9 times the FDA approved dose)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; particularly when administered with other nephrotoxic agents or in patients with renal impairment. With high tumor burden, tumor lysis syndrome and subsequent hyperuricemia may occur (rare); consider allopurinol and hydrate accordingly.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Weekly (7-day) infusion preparation recommends further dilution of cladribine with bacteriostatic normal saline which contains benzyl alcohol and may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; use should be avoided in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3016299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects and fetal mortality were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of reproductive potential should use highly effective contraception during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (particularly during the first 4-8 weeks post-treatment); baseline and periodic renal and hepatic function tests; body temperature (fever); bone marrow biopsy (after CBC has normalized; to confirm treatment response); signs and symptoms of neurotoxicity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A purine nucleoside analogue; prodrug which enters the cells through a transport system and is activated via phosphorylation by deoxycytidine kinase to a 5'-triphosphate derivative (2-CaAMP). This active form incorporates into DNA resulting in inhibition of DNA synthesis and early chain termination. The induction of strand breaks results in a drop in the cofactor nicotinamide adenine dinucleotide and disruption of cell metabolism. ATP is depleted to deprive cells of an important source of energy. Cladribine is cell-cycle nonspecific and kills both resting as well as dividing cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients (8 months to 18 years): 12.7 &plusmn; 8.5 L/kg; penetrates CSF (CSF concentrations are ~18% of plasma concentration) (Kearns, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: ~9 L/kg; penetrates CSF (CSF concentrations are ~25% of plasma concentration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients (8 months to 18 years): 19.7 &plusmn; 3.4 hours (Kearns, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: After a 2-hour infusion (with normal renal function): 5.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (18%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crews KR, Gandhi V, Srivastava DK, et al, &ldquo;Interim Comparison of a Continuous Infusion versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(20):4217-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/12377965/pubmed\" id=\"12377965\" target=\"_blank\">",
"        12377965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kearns CM, Biakley RL, Santane VM, et al, &ldquo;Pharmacokinetics of Cladribine (2-Chlorodeoxyadenosine) in Children with Acute Leukemia,&rdquo;",
"      <i>",
"       Cancer Research",
"      </i>",
"      , 1994, 54:1235-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/7906999 /pubmed\" id=\"7906999 \" target=\"_blank\">",
"        7906999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krance RA, Hurwitz CA, Head DR, et al, &ldquo;Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(11):2804-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/11387351/pubmed\" id=\"11387351\" target=\"_blank\">",
"        11387351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, et al, &ldquo;Dose Escalation Trial of Cladribine Using 5 Daily I.V. Infusions in Patients with Advanced Hematologic Malignancies,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(1):188-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/8558197/pubmed\" id=\"8558197\" target=\"_blank\">",
"        8558197",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liliemark J, &ldquo;The Clinical Pharmacokinetics of Cladribine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1997, 32:120-131.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/9068927/pubmed\" id=\"9068927\" target=\"_blank\">",
"        9068927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez-Galindo C, Kelly P, Jeng M, et al, &ldquo;Treatment of Children With Langerhans Cell Histiocytosis With 2-Chlorodeoxyadenosine,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2002, 69(3):179-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/11891804 /pubmed\" id=\"11891804 \" target=\"_blank\">",
"        11891804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubnitz JE, Crews KR, Pounds S, et al, &ldquo;Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St Jude AML97 Trial,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2009, 23(8):1410-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/19242495/pubmed\" id=\"19242495\" target=\"_blank\">",
"        19242495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stine KC, Saylors RL, Williams LL, et al, &ldquo;2-Chlorodeoxyadenosine (2-CDA) for the Treatment of Refractory or Recurrent Langerhans Cell Histiocytosis (LCH) in Pediatric Patients,&rdquo;",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 1997, 29:288-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/9251735/pubmed\" id=\"9251735\" target=\"_blank\">",
"        9251735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weitzman S, Braier J, Donadieu J, et al, &ldquo;2'-Chlorodeoxyadenosine (2-CdA) as Salvage Therapy for Langerhans Cell Histiocytosis (LCH). Results of the LCH-S-98 Protocol of the Histiocyte Society,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(7):1271-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/10/11430/abstract-text/19731321/pubmed\" id=\"19731321\" target=\"_blank\">",
"        19731321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13164 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11430=[""].join("\n");
var outline_f11_10_11430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708674\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046381\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046375\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152263\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152250\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046385\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152325\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046377\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046384\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152326\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152324\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046388\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046374\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046373\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299054\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219339\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152259\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3016299\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046380\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046372\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046387\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13164\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13164|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=related_link\">",
"      Cladribine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/22/19813?source=related_link\">",
"      Cladribine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_10_11431="Overview of craniofacial pain";
var content_f11_10_11431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of craniofacial pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11431/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11431/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11431/contributors\">",
"     Charles C Ho, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11431/contributors\">",
"     Sajid A Khan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11431/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11431/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11431/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/10/11431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis and management of patients with craniofacial pain can prove daunting even to experienced clinicians. The causes are myriad, and misdiagnosis and mismanagement are common.",
"   </p>",
"   <p>",
"    This topic review will provide a brief overview of craniofacial pain, focusing on central causes and neuralgias. Primary headache syndromes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=see_link\">",
"     \"Headache syndromes other than migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROPATHIC PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain can be classified as being nociceptive (caused by a damaging or potentially damaging stimulus) or non-nociceptive. Neuropathic pain is non-nociceptive, can vary widely in clinical presentation, and can be caused by either central nervous system dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by peripheral nerve lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/1\">",
"     1",
"    </a>",
"    ]. The distinction between neuropathic and non-neuropathic pain has clinical significance since neuropathic pain is somewhat less responsive to opioids and more likely to respond to other drugs, such as anticonvulsants (among others) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropathic pain can be stimulus-evoked or stimulus-independent (spontaneous) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/1\">",
"     1",
"    </a>",
"    ]. Neuralgia, by definition, is a form of neuropathic pain that is characterized by the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal, brief (seconds to a few minutes), shock-like or lightning-like pain that follows a peripheral or cranial nerve distribution and can spread to adjacent areas in the course of the attack",
"     </li>",
"     <li>",
"      Typically, there is no objective neurologic deficit in the distribution of the affected nerve",
"     </li>",
"     <li>",
"      Attacks can be provoked by nonpainful stimulation (allodynia) of trigger points or zones",
"     </li>",
"     <li>",
"      A refractory period follows attacks; the duration of the refractory period shortens as the disease progresses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of neuropathic pain are complex. A nerve injury can induce peripheral and central changes that contribute to persistent pain and abnormal sensation. Through different mechanisms (inflammation, nociceptor activation, tissue injury), primary afferent fibers and central structures become sensitized. These processes are terminated under normal circumstances as tissues heal and inflammation declines. However, they can persist if primary afferent function is modified by disease, even in the absence of inflammation. While permanent loss or injury of primary afferent fibers (deafferentation) results in peripheral neuropathic pain, direct damage to central nervous system structures results in central pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CENTRAL CAUSES OF FACIAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central causes of facial pain are reviewed here briefly, and discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link\">",
"     \"Central craniofacial pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current International Classification of Headache Disorders contains five distinct entities of central causes of facial pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anesthesia dolorosa, characterized by persistent, painful anesthesia or hypesthesia in the distribution of the trigeminal nerve or one of its divisions, or of the occipital nerves. Anesthesia dolorosa occurs most frequently as a complication of rhizotomy or thermocoagulation performed to treat trigeminal neuralgia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link&amp;anchor=H6#H6\">",
"       \"Central craniofacial pain\", section on 'Anesthesia dolorosa'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central post-stroke pain, characterized by unilateral pain, dysesthesia, and impaired sensation involving part or the whole of the face that is not explicable by a lesion of the trigeminal nerve. It is attributed to a lesion involving the trigeminothalamic (quintothalamic) pathway, thalamus, or thalamocortical projection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link&amp;anchor=H7#H7\">",
"       \"Central craniofacial pain\", section on 'Central post-stroke pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Facial pain attributed to multiple sclerosis, characterized by unilateral or bilateral facial pain, with or without dysesthesia, attributed to a demyelinating lesion of the central connections of the trigeminal nerve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link&amp;anchor=H8#H8\">",
"       \"Central craniofacial pain\", section on 'Facial pain attributed to multiple sclerosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent idiopathic facial pain (previously known as atypical face pain), described as persistent facial pain that does not have the characteristics of the cranial neuralgias and is not attributed to another disorder. This is a diagnosis of exclusion; potential structural lesions, such as craniofacial neoplasms or abscesses, among others, need to be ruled out. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link&amp;anchor=H9#H9\">",
"       \"Central craniofacial pain\", section on 'Persistent idiopathic facial pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Burning mouth syndrome, described as an intraoral burning sensation for which no medical or dental cause can be found. Oral mucosal diseases, such as herpes simplex, and aphthous stomatitis, among others, need to be ruled out. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link&amp;anchor=H10#H10\">",
"       \"Central craniofacial pain\", section on 'Burning mouth syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEURALGIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We define neuralgia as paroxysmal pain in the distribution of a particular nerve. The pain is typically maximal at onset and may be described as lancinating, \"electric shocks,\" or as \"jabbing.\" There may be a single sharp pain or repetitive pains in succession. The pain can last a fraction of a second, or endure for several seconds. There may be a refractory period after the severe pain during which pain will not occur. Some neuralgic conditions have trigger zones (areas that when stimulated provoke an attack) or other triggers.",
"   </p>",
"   <p>",
"    Careful history often reveals other types of pain occurring, such as continuous aching, burning, or throbbing. Inquiries must be made about all the sensations that occur, as some patients mention only the severe exacerbations. Response to treatment may provide a clue to diagnosis but can also prove misleading; \"diagnostic blocks\" in the setting of facial pain do not necessarily define the site from which the pain arises because of the overlap of cranial nerves V, VII, IX, X, which converge on the spinal trigeminal nucleus and the tractus solitarius.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glossopharyngeal neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glossopharyngeal neuralgia is defined as paroxysmal pain in areas innervated by cranial nerves (CN) IX and X [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There are numerous analogies to trigeminal neuralgia, with which it occasionally coexists, although glossopharyngeal neuralgia is much less common.",
"   </p>",
"   <p>",
"    Glossopharyngeal neuralgia is characterized by paroxysmal, severe, stabbing pain involving the ear, tonsillar fossa, base of the tongue, or beneath the angle of the jaw [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, the pain can occur in the distributions of the auricular and pharyngeal branches of the vagus nerve as well as of the glossopharyngeal nerve. Bilateral involvement has been reported in 12 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/9\">",
"     9",
"    </a>",
"    ]. Typical triggers include chewing, swallowing, coughing, speaking, yawning, certain tastes, or touching the neck or external auditory canal (rarely the pre- or post-auricular areas).",
"   </p>",
"   <p>",
"    The pain typically radiates upward from the oropharynx toward the ear. The duration of the severe paroxysms is seconds to minutes, but there may also be a low grade, constant dull background pain. Several dozen attacks can occur per day, sometimes awakening the patient from sleep. Some episodes may also be associated with strenuous coughing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hoarseness.",
"   </p>",
"   <p>",
"    Like trigeminal neuralgia, glossopharyngeal neuralgia can occur in a pattern of episodes lasting weeks to months, alternating with longer periods of remission. Severe attacks have rarely been associated with",
"    <span class=\"nowrap\">",
"     bradycardia/asystole",
"    </span>",
"    resulting in syncope, presumably because input from CN IX into the tractus solitarius has an effect upon the dorsal motor nucleus of CN X [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with trigeminal neuralgia, there are \"idiopathic\" and \"secondary\" forms of glossopharyngeal neuralgia. Secondary causes include demyelinating lesions, cerebellopontine angle tumor, peritonsillar abscess, carotid aneurysm, and Eagle syndrome (in which CN IX is compressed laterally against an ossified stylohyoid ligament) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Vascular compression of CN IX and X can occur at the nerve root entry zone by the vertebral artery or posterior inferior cerebellar artery.",
"   </p>",
"   <p>",
"    The evaluation of a patient suspected of suffering from glossopharyngeal neuralgia includes a careful history, especially inquiring about the presence of trigger factors and nocturnal awakening.",
"    <span class=\"nowrap\">",
"     MRI/MRA",
"    </span>",
"    are indicated in virtually all patients to rule out a mass lesion or vascular pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]; plain skull films may reveal an ossified stylohyoid ligament (consistent with Eagle syndrome).",
"   </p>",
"   <p>",
"    Medical therapy of glossopharyngeal neuralgia is essentially the same as for trigeminal neuralgia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link&amp;anchor=H12#H12\">",
"     \"Trigeminal neuralgia\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, application of local anesthetics to the oropharynx may prove both diagnostic and therapeutic.",
"   </p>",
"   <p>",
"    Surgical treatment is considered for patients who fail medical therapy. Possible procedures including intracranial sectioning of CN IX plus the upper three to four rootlets of CN X at the jugular foramen, or vascular decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/11,15-17\">",
"     11,15-17",
"    </a>",
"    ]. The latter is a relatively safe procedure with good short-term and long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of glossopharyngeal neuralgia includes nervus intermedius neuralgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nervus intermedius neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nervus intermedius neuralgia is a rare disorder characterized by brief paroxysms of pain felt deeply in the auditory canal. Other terms used are geniculate neuralgia or Hunt neuralgia. Clinical aspects of this disorder are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6917?source=see_link\">",
"     \"Nervus intermedius (geniculate) neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Occipital neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occipital neuralgia can be a cause of headache in the occipital region. It is described as a paroxysmal jabbing pain in the greater, lesser,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    third occipital nerve distribution, sometimes accompanied by diminished sensation or dysesthesia in the affected area. Tenderness overlying the nerve affected may be present. Clinical aspects of occipital neuralgia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=see_link\">",
"     \"Occipital neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Third occipital headache is similar to greater occipital neuralgia, but much less common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26568?source=see_link&amp;anchor=H2#H2\">",
"     \"Cervicogenic headache\", section on 'Etiology and anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postherpetic neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute herpes zoster (shingles) often causes facial pain, especially affecting V1. Postherpetic neuralgia (PHN) is variably defined as pain, which persists anywhere from one to six months after the rash has healed. PHN most often represents a continuum of pain that never resolved following an acute episode of herpes zoster. However, PHN rarely has been reported to occur in patients months to years after resolution of the initial event.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, diagnosis, and treatment of PHN is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Raeder paratrigeminal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raeder paratrigeminal syndrome (also called paratrigeminal oculosympathetic syndrome) consists of constant unilateral burning facial pain with hypesthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysesthesia in the distribution of the trigeminal nerve, most often V1, along with ptosis and miosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/18\">",
"     18",
"    </a>",
"    ]. This syndrome may be caused by trauma, middle cranial fossa mass lesion, syphilis, and sinusitis. As an example, a restricted lesion in the middle cranial fossa can directly compromise trigeminal nerve fibers and cause neuralgic pain or sensory change with ptosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    miosis, but no anhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Superior laryngeal neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superior laryngeal nerve is a branch of CN X that runs adjacent to the carotid bifurcation and innervates the cricothyroid muscle of the larynx. A lesion of this nerve produces a weak, hoarse voice. The nerve may be involved by local disease of the carotid artery or injured by carotid endarterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, the patient suffers from paroxysmal pain in the throat, submandibular region, and under the ear, similar to glossopharyngeal neuralgia. The episodes last seconds to minutes and may occur spontaneously or be triggered by coughing, swallowing, or speaking. During severe paroxysms the patient can temporarily be rendered mute.",
"   </p>",
"   <p>",
"    On examination, hoarseness of speech and a trigger point superolateral to the thyroid cartilage may be noted. The differential diagnosis includes glossopharyngeal neuralgia, nervus intermedius neuralgia, and carotidynia. Local blockade of the nerve is diagnostic, and some patients respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and or other drugs used for neuralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Neurectomy in selected refractory cases may be curative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Trigeminal neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigeminal neuralgia is one of the most well-defined and common causes of facial pain. The pain of trigeminal neuralgia tends to occur in paroxysms and is maximal at or near onset. The pain has been described as \"electric shock-like\" or \"stabbing.\"",
"   </p>",
"   <p>",
"    Clinical aspects of trigeminal neuralgia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cluster-tic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"cluster-tic syndrome\" is a combination of cluster headache with coexistent trigeminal neuralgia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/7,23-25\">",
"     7,23-25",
"    </a>",
"    ]. It is characterized by three types of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One component resembles the pain of trigeminal neuralgia and is paroxysmal, short lasting, and severe.",
"     </li>",
"     <li>",
"      The second component is more like a cluster headache, although of variable length, with autonomic phenomena (lacrimation, tearing). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"       \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The third type of pain is a mixture of the first two and may be provoked by trigger points or moving the neck.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cluster-tic syndrome usually affects patients between 20 and 70 years of age. It may exist in chronic or episodic (remissions and recurrences) forms.",
"   </p>",
"   <p>",
"    Patients with cluster-tic syndrome require treatment directed at both cluster headache and trigeminal neuralgia in order to achieve remission of headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. Medical therapy usually consists of a combination of drugs used to treat trigeminal neuralgia and cluster headache and is often unsuccessful. It is reported that if surgery (microvascular decompression or trigeminal rhizotomy) relieves the neuralgia, the cluster-like pain may be lessened and become more responsive to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cancer pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer is a rare cause of facial pain. Extracranial bony or soft tissue metastases may impinge upon cranial and upper cervical nerves causing headache or facial pain. In addition, occult lung neoplasms may cause referred pain in the periauricular region. Facial pain due to cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Carotidynia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotidynia is pain that appears to emanate from the carotid artery. Rather than a distinct entity, carotidynia is now considered a syndrome that encompasses many varieties of pain, including carotid dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dental pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental pathology is a common cause of facial pain. Specific inquiry regarding prior dental procedures should be made of all patients with facial pain. The presence of provocative factors such as chewing or heat or cold sensitivity may provide useful clues. Trigeminal neuralgia also has been associated with ipsilateral dental pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Giant cell (temporal) arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell arteritis (GCA) is a chronic vasculitis of large and medium sized vessels. The craniofacial features of GCA are reviewed briefly here and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although systemic illness is characteristic of GCA and vascular involvement may be widespread, blood vessel inflammation most frequently involves the cranial branches of the arteries that originate from the aortic arch. The most feared complication of GCA &mdash; visual loss &mdash; is one potential result of the cranial arteritis associated with this disease. A new type of headache occurs in at least two-thirds of individuals affected with GCA. The head pain tends to be located over the temporal areas but can be frontal or occipital in location. The headaches may be mild or severe. The course is also variable; the headaches may become progressively worse, but can subside before treatment is started in some cases.",
"   </p>",
"   <p>",
"    Nearly one-half of GCA patients suffer from jaw claudication. In some cases, a trismus-like symptom occurs rather than fatigue of the chewing muscles. Tender temporal or occipital arteries are found in approximately one-third of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Posttraumatic and postoperative pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial pain can occur after trauma, including bullet wounds or other head injuries and surgery. Facial pain may occur after maxillofacial surgery, orbital enucleations, sinus, and dental procedures. Dental procedures can trigger a variety of syndromes, including neuralgia and facial migraine.",
"   </p>",
"   <p>",
"    In all cases of posttraumatic facial pain, a careful search must be conducted for underlying pathology, especially dental problems. Some patients manifest constant burning pain, occasionally with tingling and stabbing but without the trophic changes, edema, and redness that are characteristic of reflex sympathetic dystrophy (complex regional pain syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11431/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of posttraumatic facial pain can be extremely difficult. Blockade of the stellate ganglion may be effective in patients who complain of significant burning pain. Brief lancinating pains may respond to agents useful for neuralgias.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    , for example, can reduce pain and lessen associated depression. Other agents useful for treating migraine headaches have been employed empirically for symptomatic benefit. Posttraumatic facial pain generally resolves spontaneously within several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Primary headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine, cluster, and other headaches (such as paroxysmal hemicrania) can present mainly in the face. Many patients diagnosed with \"sinus headaches\" in fact have migraine. Careful attention to details of the history and examination should clarify the diagnosis. Questions revealing a family history, trigger factors, or the presence of an aura point toward migraine as the etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, cluster headache and other short lasting headaches may present with pain principally in the face rather than periorbitally or retroorbitally. The clarification of the duration of the episodes, along with any associated autonomic features (ptosis, rhinorrhea, lacrimation) is diagnostically helpful.",
"   </p>",
"   <p>",
"    Jabs and jolts syndrome (primary stabbing headache) can occur in isolation or as part of another headache condition, such as migraine. The pain is typically of very brief duration and of lancinating quality. Like trigeminal neuralgia, it may occur in volleys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before declaring a diagnosis of dental or sinus disease as the etiology of facial pain, positive evidence must be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Temporomandibular joint syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporomandibular joint (TMJ) syndrome is characterized by chronic or acute musculoskeletal pain with dysfunction of the masticatory system. Many patients complain of headache or facial pain; in some cases, the disorder presents only as a headache without the patient being aware of a TMJ disturbance.",
"   </p>",
"   <p>",
"    The typical headache associated with TMJ syndrome presents as unilateral ear or preauricular pain that radiates to the jaw, temple, or neck. The pain is deep, dull, continuous, and usually worse in the morning. (See",
"    <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=see_link\">",
"     \"Temporomandibular disorders in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1409?source=see_link\">",
"       \"Patient information: Trigeminal neuralgia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/1\">",
"      Harden RN. Chronic neuropathic pain. Mechanisms, diagnosis, and treatment. Neurologist 2005; 11:111.",
"     </a>",
"    </li>",
"    <li>",
"     Kanner, RM. Pharmacological approaches to pain management. In: Continuum: Pain and palliative care, Miller AE (Ed), Lippincott Williams and Wilkins, Philadelphia, PA 2005. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/3\">",
"      Bruyn GW. Nervus intermedius neuralgia (Hunt). Cephalalgia 1984; 4:71.",
"     </a>",
"    </li>",
"    <li>",
"     Peter, C, Watson, N. Trigeminal neuropathy and neuralgia. In: Neurological therapeutics: Principles and practice, Noseworthy, JH (Ed), Martin Dunitz, London, New York 2003. p.1849.",
"    </li>",
"    <li>",
"     Goodwin, JG, Bajwa, ZH. Understanding the patient with chronic pain. In: Principles and practice of pain medicine, Warfield, CA, Bajwa, ZH (Eds), McGraw-Hill, USA 2004. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/6\">",
"      Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 2005; 65:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/7\">",
"      Headache classification subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/8\">",
"      Rozen TD. Trigeminal neuralgia and glossopharyngeal neuralgia. Neurol Clin 2004; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/9\">",
"      Rushton JG, Stevens JC, Miller RH. Glossopharyngeal (vagoglossopharyngeal) neuralgia: a study of 217 cases. Arch Neurol 1981; 38:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/10\">",
"      Elias J, Kuniyoshi R, Carloni WV, et al. Glossopharyngeal neuralgia associated with cardiac syncope. Arq Bras Cardiol 2002; 78:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/11\">",
"      Bruyn GW. Glossopharyngeal neuralgia. Cephalalgia 1983; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/12\">",
"      Fini G, Gasparini G, Filippini F, et al. The long styloid process syndrome or Eagle's syndrome. J Craniomaxillofac Surg 2000; 28:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/13\">",
"      Soh KB. The glossopharyngeal nerve, glossopharyngeal neuralgia and the Eagle's syndrome--current concepts and management. Singapore Med J 1999; 40:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/14\">",
"      Hiwatashi A, Matsushima T, Yoshiura T, et al. MRI of glossopharyngeal neuralgia caused by neurovascular compression. AJR Am J Roentgenol 2008; 191:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/15\">",
"      Laha RK, Jannetta PJ. Glossopharyngeal neuralgia. J Neurosurg 1977; 47:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/16\">",
"      Resnick DK, Jannetta PJ, Bissonnette D, et al. Microvascular decompression for glossopharyngeal neuralgia. Neurosurgery 1995; 36:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/17\">",
"      Patel A, Kassam A, Horowitz M, Chang YF. Microvascular decompression in the management of glossopharyngeal neuralgia: analysis of 217 cases. Neurosurgery 2002; 50:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/18\">",
"      Mokri B. Raeder's paratrigeminal syndrome. Original concept and subsequent deviations. Arch Neurol 1982; 39:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/19\">",
"      Goadsby PJ. Raeder's syndrome [corrected]: paratrigeminal paralysis of the oculopupillary sympathetic system. J Neurol Neurosurg Psychiatry 2002; 72:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/20\">",
"      Bruyn GW. Superior laryngeal neuralgia. Cephalalgia 1983; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/21\">",
"      Schmidt D, Strutz I. Superior laryngeal neuralgia. J Neurol 1981; 225:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/22\">",
"      Brownstone PK, Ballenger JJ, Vick NA. Bilateral superior laryngeal neuralgia: its successful treatment with carbamazepine. Arch Neurol 1980; 37:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/23\">",
"      Watson P, Evans R. Cluster-tic syndrome. Headache 1985; 25:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/24\">",
"      Alberca R, Ochoa JJ. Cluster tic syndrome. Neurology 1994; 44:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/25\">",
"      Mulleners WM, Verhagen WI. Cluster-tic syndrome. Neurology 1996; 47:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/26\">",
"      Pascual J, Berciano J. Relief of cluster-tic syndrome by the combination of lithium and carbamazepine. Cephalalgia 1993; 13:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/27\">",
"      Solomon S, Apfelbaum RI, Guglielmo KM. The cluster-tic syndrome and its surgical therapy. Cephalalgia 1985; 5:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11431/abstract/28\">",
"      Jaeger B, Singer E, Kroening R. Reflex sympathetic dystrophy of the face. Report of two cases and a review of the literature. Arch Neurol 1986; 43:693.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3355 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11431=[""].join("\n");
var outline_f11_10_11431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROPATHIC PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CENTRAL CAUSES OF FACIAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEURALGIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glossopharyngeal neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nervus intermedius neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Occipital neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Raeder paratrigeminal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Superior laryngeal neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cluster-tic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cancer pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Carotidynia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dental pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Posttraumatic and postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Primary headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Temporomandibular joint syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=related_link\">",
"      Central craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26568?source=related_link\">",
"      Cervicogenic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6917?source=related_link\">",
"      Nervus intermedius (geniculate) neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=related_link\">",
"      Occipital neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1409?source=related_link\">",
"      Patient information: Trigeminal neuralgia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=related_link\">",
"      Temporomandibular disorders in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_10_11432="Emergent evaluation of syncope in children and adolescents";
var content_f11_10_11432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergent evaluation of syncope in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11432/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11432/contributors\">",
"     Brian Coleman, MD, MSE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11432/contributors\">",
"     Jack C Salerno, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11432/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11432/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11432/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11432/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/10/11432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is a sudden, brief loss of consciousness associated with loss of postural tone from which recovery is spontaneous [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/1\">",
"     1",
"    </a>",
"    ]. Up to 15 percent of children experience a syncopal episode prior to the end of adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the etiology of syncopal events in children is most often benign, syncope can also occur as the result of more serious (usually cardiac) disease with the potential for sudden death. Life-threatening causes of syncope can often be identified by collecting a detailed history of the event, a family history, performing a thorough physical exam, and using relatively few ancillary studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the serious and benign causes of syncope. A targeted emergent evaluation to distinguish between the two is described. An algorithmic approach to the emergent evaluation of the child with syncope is also presented (",
"    <a class=\"graphic graphic_algorithm graphicRef53383 \" href=\"UTD.htm?0/49/784\">",
"     algorithm 1",
"    </a>",
"    ). The evaluation of adults with syncope is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=see_link\">",
"     \"Approach to the adult patient with syncope in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is a symptom that can be classified according to the underlying cause: autonomic, cardiac, metabolic, or a condition that mimics syncope (",
"    <a class=\"graphic graphic_table graphicRef60014 \" href=\"UTD.htm?36/49/37660\">",
"     table 1",
"    </a>",
"    ). The vast majority of cases of syncope in the pediatric age group represent benign alterations in vasomotor tone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Life-threatening conditions that cause syncope are generally cardiac. They include primary electrical disturbances and structural heart disease. Common benign conditions that cause syncope include vasovagal syncope, breath holding spells, and orthostatic hypotension. Toxic exposures, hypoglycemia, and anemia can also cause syncope. Conditions that mimic syncope include seizures, migraine syndromes, hysteria, and hyperventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link\">",
"     \"Causes of syncope in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION AND DECISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the evaluation of a child with syncope is to identify life-threatening conditions, as well as conditions that are associated with the risk of significant injury. A cardiac etiology for syncope is particularly important to identify. In one retrospective series describing 480 children diagnosed with syncope, 21 of 22 patients with a cardiac cause were identified with a combination of history, physical examination, and ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history is often the most useful tool for identifying an etiology and directing further evaluation of a syncopal event (",
"    <a class=\"graphic graphic_table graphicRef74638 \" href=\"UTD.htm?0/42/683\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/9\">",
"     9",
"    </a>",
"    ]. In a large retrospective series describing children who presented to an emergency department with syncope, the following historical features were significantly associated with a specific etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged upright posture &ndash; Vasovagal etiology",
"     </li>",
"     <li>",
"      A trigger for the event &ndash; Vasovagal etiology",
"     </li>",
"     <li>",
"      Exercise-related syncope &ndash; Cardiac etiology",
"     </li>",
"     <li>",
"      Recurrent syncope &ndash; Psychogenic and cardiac etiologies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Preceding events or precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circumstances immediately preceding the event should be identified. These include the child's position and the activity in which the child was engaged. Children with a vasovagal cause of syncope typically have been upright or changed position just prior to the event. A trigger (such as pain or emotional stress) may be the precipitant in some cases. Syncope that occurs during physical exertion is very concerning for a cardiac etiology, whereas syncope after exertion may occur with vasovagal syncope or cardiac conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/8,10-12\">",
"     8,10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=see_link&amp;anchor=H2#H2\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\", section on 'Timing of referral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some triggers are associated with specific primary electrical disturbances. As an example, for patients with long QT syndrome, the triggers for the most common genotypes are acute arousal (or startle) and auditory stimuli (ie, a fire alarm) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/13\">",
"     13",
"    </a>",
"    ]. Children with familial catecholaminergic polymorphic ventricular tachycardia can develop arrhythmias in association with emotional or physical stress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of syncope in children and adolescents\", section on 'Primary electrical disturbances'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Description of the event",
"    </span>",
"    &nbsp;&mdash;&nbsp;A description of the event should include the child's report of symptoms prior to the onset of syncope, as well as witnesses' description of the syncopal event itself. Vital signs should be noted during and immediately after the event if possible.",
"   </p>",
"   <p>",
"    Children with neurocardiogenic (vasovagal) syncope frequently report symptoms before the event that include dizziness, lightheadedness, sweating, nausea, weakness, and visual changes (blurred vision, tunnel vision, slow visual loss). Shortness of breath, chest pain, or palpitations prior to or during the event are concerning for a cardiac etiology. Patients with orthostatic hypotension or vasovagal syncope may report that symptoms recurred when they tried to sit up immediately after the initial syncopal event.",
"   </p>",
"   <p>",
"    Abnormal motor activity (ie, tonic clonic movement or posturing) can occur at the end of a syncopal event, and most often correlates with neurocardiac syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/9\">",
"     9",
"    </a>",
"    ] although arrhythmia should also be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/14\">",
"     14",
"    </a>",
"    ]. The duration of such activity is usually brief, and recovery is rapid. In comparison, prolonged motor activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recovery time are consistent with a seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A past medical history of congenital heart disease (corrected or uncorrected) or arrhythmia should immediately focus attention on a potentially serious cardiac etiology. Previous syncopal events suggest a vasovagal, psychogenic cause, or (less commonly) a cardiac etiology.",
"   </p>",
"   <p>",
"    Other elements of the history should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant medical problems (ie, diabetes)",
"     </li>",
"     <li>",
"      A menstrual history",
"     </li>",
"     <li>",
"      Access to medications or illicit drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of early cardiac death (less than 45 years of age), sudden deaths including unexplained accidents involving a single motor vehicle or drowning, known arrhythmia (long QT syndrome), and familial cardiomyopathy increase the concern for a possible cardiac etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/10\">",
"     10",
"    </a>",
"    ]. A family history of vasovagal syncope may be present in up to 90 percent of children with this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination should be performed, including vital signs (with orthostatic pulse and blood pressure measurements) and cardiac and neurologic examinations.",
"   </p>",
"   <p>",
"    Measurements of blood pressure and heart rate to identify orthostatic hypotension should be taken while the patient is sitting, then after standing for two minutes. Abnormal values include a decrease in systolic blood pressure by 20 mmHg or an increase in heart rate by 20 beats per minute from sitting to standing. However, the recurrence of symptoms, such as light-headedness or even syncope on standing, is more significant than any numeric change in blood pressure. The presence of orthostatic hypotension does not rule out other causes of syncope, particularly long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac auscultation should be scrutinized for the quality of heart sounds, evidence of gallops, rubs, and for murmurs of outflow obstruction. Findings specific for a structural lesion include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The characteristic findings of aortic stenosis include a systolic ejection murmur and ejection click. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link&amp;anchor=H2#H2\">",
"       \"Valvar aortic stenosis in children\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Valvar stenosis may be associated with coarctation of the aorta. Thus, four extremity blood pressures should be measured. A difference in the systolic measurement of 20 mmHg (arm greater than leg) is significant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link&amp;anchor=H1088178828#H1088178828\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Blood pressure and pulses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with hypertrophic cardiomyopathy, maneuvers that affect the degree of obstruction cause a change in murmur intensity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An increase in intensity, due to enhancement of obstruction, is seen with the assumption of an upright posture from a squatting, sitting, or supine position, the Valsalva maneuver, during the more forceful contraction that follows the compensatory pause after a ventricular premature beat. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=see_link\">",
"       \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A decrease in intensity, due to attenuation of obstruction, is heard after going from a standing to a sitting or squatting position, with handgrip, and following passive elevation of the legs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic murmur of hypertrophic cardiomyopathy is an outflow murmur that decreases in intensity with increased venous return to the heart (during a valsalva maneuver or squatting).",
"     </li>",
"     <li>",
"      Signs of heart failure (ie, rales, a gallop,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatomegaly) are consistent with cardiac disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An age appropriate neurologic exam should be performed to identify focal deficits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link&amp;anchor=H10928992#H10928992\">",
"     \"Detailed neurologic assessment of infants and children\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;History of the event and physical exam should be used to guide ancillary studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     ECG and echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG is widely considered a standard part of the syncope work up, despite its low diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. A patient with a normal ECG has a low likelihood of arrhythmia as a cause of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/1\">",
"     1",
"    </a>",
"    ]. However, ECG abnormalities may be variable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subtle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/18\">",
"     18",
"    </a>",
"    ]. Consequently, a cardiologist should be consulted whenever there are worrisome clinical features regardless of the ECG findings (",
"    <a class=\"graphic graphic_table graphicRef74638 \" href=\"UTD.htm?0/42/683\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ECG findings that should be noted include (",
"    <a class=\"graphic graphic_table graphicRef70090 \" href=\"UTD.htm?1/14/1259\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsinus rhythms, excessive bradycardia, atrioventricular block, and age-appropriate intervals of the cardiac cycle (hand calculated) (",
"      <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"UTD.htm?12/50/13095\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37687?source=see_link\">",
"       \"ECG tutorial: Basic principles of ECG analysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signs of myocardial injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"       \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A corrected QT interval (hand calculated), with attention to T wave morphology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis of congenital long QT syndrome\", section on 'QT interval'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Findings suggestive of Brugada syndrome, including pseudo-right bundle branch block (RBBB) and persistent ST segment elevation in leads V1 to V3 (",
"      <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Findings suggestive of preexcitation syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef76226 \" href=\"UTD.htm?35/41/36506\">",
"       waveform 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21171?source=see_link\">",
"       \"ECG tutorial: Preexcitation syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several abnormalities, most notably epsilon waves, may be present in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) (",
"      <a class=\"graphic graphic_waveform graphicRef60781 \" href=\"UTD.htm?41/5/42078\">",
"       waveform 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular hypertrophy and strain patterns (",
"      <a class=\"graphic graphic_waveform graphicRef69040 \" href=\"UTD.htm?41/58/42922\">",
"       waveform 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef67622 \" href=\"UTD.htm?43/21/44378\">",
"       waveform 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"       \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=see_link\">",
"       \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergent echocardiography should be reserved for those patients with strongly suspected cardiac etiology due to the presence of an abnormal ECG, pathologic murmur, history of cardiac disease, or exercise-induced syncope, and made after consultation with a cardiologist [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who may require a more extensive cardiac evaluation (ie, additional ECG monitoring, a stress test, or tilt test) can generally be referred to a cardiologist for an outpatient evaluation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Indications for referral or admission'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Laboratory tests and neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children present for evaluation hours to days after the event has occurred. In the asymptomatic patient, extensive laboratory blood work such as serum glucose, electrolytes, and complete blood counts or neuroimaging are rarely helpful. Although evidence is limited regarding the utility of testing in children with syncope seen in the emergency department, only 6 of 238 diagnostic tests (2.5 percent) were useful in establishing an underlying cause in a series of 123 children evaluated for syncope in a neurology clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/9\">",
"     9",
"    </a>",
"    ]. In this study, neuroimaging (ie, computed tomography of the head",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging) were normal or nondiagnostic in all patients.",
"   </p>",
"   <p>",
"    The following laboratory tests may be helpful in some situations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A bedside glucose determination for children who present immediately after the episode",
"     </li>",
"     <li>",
"      A hematocrit for children who are at risk for anemia",
"     </li>",
"     <li>",
"      A urine pregnancy test in post menarchal females",
"     </li>",
"     <li>",
"      Urine toxicology screen for drugs of abuse in patients with altered metal status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the patient with prolonged loss of consciousness, seizure activity, and postictal phase, a routine outpatient EEG should be considered. Neuroimaging may be indicated emergently for children with focal neurologic deficits, persistently altered mental status, or a significant head injury as the result of the syncopal episode. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Indications for referral or admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overwhelming majority of children who have had a syncopal event from which they have completely recovered and have an unremarkable evaluation can be followed as outpatients. Those with concerning features, such as absence of a significant prodrome, associated palpitations or chest pain, a family history of syncope or sudden death, or recurrent episodes should be referred for further cardiac evaluation (",
"    <a class=\"graphic graphic_table graphicRef74638 \" href=\"UTD.htm?0/42/683\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=see_link\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Follow-up consultation with a neurologist should be considered for children with prolonged loss of consciousness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of focal neurologic abnormalities that have resolved.",
"   </p>",
"   <p>",
"    After discussion with a pediatric cardiologist, admission to the hospital for further evaluation and observation may be warranted for patients with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evidence of cardiovascular disease (ie, heart failure or arrhythmia)",
"     </li>",
"     <li>",
"      An abnormal ECG (ie, a conduction abnormality)",
"     </li>",
"     <li>",
"      Chest pain with syncope",
"     </li>",
"     <li>",
"      Syncope with cyanosis",
"     </li>",
"     <li>",
"      Apneic or bradycardic spells that resolve only with vigorous stimulation",
"     </li>",
"     <li>",
"      Abnormal neurologic findings",
"     </li>",
"     <li>",
"      Orthostatic hypotension that does not resolve with fluid therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ALGORITHMIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic approach to the emergent evaluation of syncope (including a focused history, careful cardiac and neurologic evaluations, and selected ancillary studies) can identify a cause for most children (",
"    <a class=\"graphic graphic_table graphicRef60014 \" href=\"UTD.htm?36/49/37660\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74638 \" href=\"UTD.htm?0/42/683\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef53383 \" href=\"UTD.htm?0/49/784\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Abnormal cardiac evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with a cardiac cause of syncope can be identified by a combination of historical features, cardiac examination, and ECG findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/4,21\">",
"     4,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Abnormal ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal findings on ECG, that can sometimes be subtle, may identify conditions that can cause ventricular arrhythmias (",
"    <a class=\"graphic graphic_table graphicRef70090 \" href=\"UTD.htm?1/14/1259\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Ancillary studies'",
"    </a>",
"    above.) These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prolonged QT interval is consistent with the diagnosis of acquired or congenital long QT syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"UTD.htm?26/24/27008\">",
"       waveform 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"       \"Clinical features of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A short QT interval (QTc &le;0.30 sec) suggests congenital short QT syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H9#H9\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Short QT syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis of congenital long QT syndrome\", section on 'QT interval'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Findings suggestive of Brugada syndrome, including pseudo-RBBB and persistent ST segment elevation in leads V1 to V3 (",
"      <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Findings suggestive of preexcitation syndrome indicate the diagnosis of Wolff-Parkinson-White syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef76226 \" href=\"UTD.htm?35/41/36506\">",
"       waveform 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several abnormalities, most notably epsilon waves, may be present in patients with ARVC (",
"      <a class=\"graphic graphic_waveform graphicRef60781 \" href=\"UTD.htm?41/5/42078\">",
"       waveform 4",
"      </a>",
"      ). ARVC is a progressive disorder, however, and these findings may not be present in young patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other diagnoses that may be suggested by ECG findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of left ventricular hypertrophy or strain are consistent with hypertrophic cardiomyopathy (",
"      <a class=\"graphic graphic_waveform graphicRef69040 \" href=\"UTD.htm?41/58/42922\">",
"       waveform 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"       \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=see_link\">",
"       \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right ventricular hypertrophy can occur with tetralogy of Fallot or primary pulmonary hypertension (",
"      <a class=\"graphic graphic_waveform graphicRef67622 \" href=\"UTD.htm?43/21/44378\">",
"       waveform 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"       \"Evaluation and prognosis of Eisenmenger syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A pattern of myocardial injury may be seen with congenital coronary artery abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link\">",
"       \"Congenital and pediatric coronary artery abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bradyarrhythmias such as complete AV block can be identified on ECG (",
"      <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"UTD.htm?12/50/13095\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link\">",
"       \"Bradycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Abnormal cardiac examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with known congenital heart disease may have abnormalities consistent with their diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical repair. Findings such as a systolic ejection murmur with ejection click (valvar aortic stenosis) or an outflow murmur that decreases in intensity with increased venous return to the heart (hypertrophic cardiomyopathy) may indicate undiagnosed structural heart disease. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Normal cardiac examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a normal ECG and cardiac examination are unlikely to have a cardiac etiology for their syncopal episode. However, children with worrisome historical features may require further evaluation (",
"    <a class=\"graphic graphic_table graphicRef74638 \" href=\"UTD.htm?0/42/683\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'History'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Features that help to further distinguish noncardiac causes of syncope include the duration of the episode, orthostatic changes in heart rate or blood pressure, abnormalities in laboratory studies, an abnormal respiratory pattern prior to the syncopal event, and inconsistencies between the history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Prolonged loss of consciousness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who were unconscious for more than several seconds should be evaluated for a neurologic disorder, such as a seizure or migraine syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes of syncope in children and adolescents\", section on 'Conditions that mimic syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Transient loss of consciousness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of consciousness for less than several seconds in a child with a normal ECG and cardiac examination likely represents noncardiac syncope. Clinical features and laboratory studies identify some specific causes for the syncopal event. Vasovagal (neurogenic cardiac) syncope is usually diagnosed by the presence of consistent clinical features and the exclusion of other causes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities identified by laboratory tests that may explain syncope include hypoglycemia, pregnancy, and anemia.",
"     </li>",
"     <li>",
"      Orthostatic hypotension is the likely etiology for syncope in patients with postural changes in heart rate and blood pressure and a normal ECG. The underlying cause of these changes (such as volume depletion or medications) must be identified and treated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link&amp;anchor=H20#H20\">",
"       \"Causes of syncope in children and adolescents\", section on 'Orthostatic hypotension'",
"      </a>",
"      .) Although orthostatic hypotension has also been associated with long QT syndrome, the ECG is abnormal in the vast majority of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11432/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A toxic exposure may be suggested by history (such as symptoms among other household members with carbon monoxide poisoning) or identified by a urine toxicologic screen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link&amp;anchor=H21#H21\">",
"       \"Causes of syncope in children and adolescents\", section on 'Toxic exposure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of an abnormal respiratory pattern prior to the syncopal episode suggests hyperventilation or breath holding as the etiology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link&amp;anchor=H23#H23\">",
"       \"Causes of syncope in children and adolescents\", section on 'Conditions that mimic syncope'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of syncope in children and adolescents\", section on 'Breath holding spells'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with hyperventilation are frequently adolescents experiencing some type of emotional stress. They may describe additional symptoms such as chest pain, lightheadedness, paresthesias, and visual disturbances.",
"     </li>",
"     <li>",
"      Breath holding spells occur in younger children (typically 6 to 24 months of age). Loss of consciousness develops in association with breath holding. A cardiac evaluation is indicated for children with a family history of syncope or sudden death or with episodes that are prolonged, frequent, or precipitated by startle or other nontraumatic stimuli.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with syncope related to hysteria (somatization disorder) or a conversion disorder are commonly adolescents. Expected physiologic signs (such as sweating, pallor, or changes in heart rate and blood pressure) are often absent. In addition, patients may disclose details of the event that indicate no loss of consciousness and generally suffer no injury during collapse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link&amp;anchor=H23#H23\">",
"       \"Causes of syncope in children and adolescents\", section on 'Conditions that mimic syncope'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who engage in the choking game purposely attempt self-strangulation or allow strangulation by another person with the hands or a ligature to produce a euphoric state caused by cerebral hypoxia. The plan is to release the pressure just before loss of consciousness, but failure to do so can result in death, particularly when the game is played alone using ligatures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3864?source=see_link\">",
"       \"The &ldquo;choking game&rdquo; and other strangulation activities in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the emergent evaluation of a child with syncope, a diagnosis of vasovagal (neurocardiogenic) syncope is typically a diagnosis of exclusion for patients with consistent clinical features (such as precipitating events and a prodrome). Children with concerning manifestations such as absence of a significant prodrome, associated palpitations or chest pain, or a family history of syncope or sudden death may require further cardiac evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"       \"Reflex syncope\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is a sudden, brief loss of consciousness associated with loss of postural tone from which recovery is spontaneous.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the etiology of syncopal events in children is most often benign, syncope can also occur as the result of more serious (usually cardiac) disease with the potential for sudden death (",
"      <a class=\"graphic graphic_table graphicRef60014 \" href=\"UTD.htm?36/49/37660\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link\">",
"       \"Causes of syncope in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A combination of historical features, physical examination, and ECG findings typically identifies children with a life-threatening cause of syncope (",
"      <a class=\"graphic graphic_table graphicRef74638 \" href=\"UTD.htm?0/42/683\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70090 \" href=\"UTD.htm?1/14/1259\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation and decision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An algorithmic approach to the emergent evaluation of the child with syncope is recommended (",
"      <a class=\"graphic graphic_algorithm graphicRef53383 \" href=\"UTD.htm?0/49/784\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Algorithmic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/1\">",
"      Kapoor WN. Syncope. N Engl J Med 2000; 343:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/2\">",
"      Lewis DA, Dhala A. Syncope in the pediatric patient. The cardiologist's perspective. Pediatr Clin North Am 1999; 46:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/3\">",
"      Steinberg LA, Knilans TK. Syncope in children: diagnostic tests have a high cost and low yield. J Pediatr 2005; 146:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/4\">",
"      Ritter S, Tani LY, Etheridge SP, et al. What is the yield of screening echocardiography in pediatric syncope? Pediatrics 2000; 105:E58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/5\">",
"      Zhang Q, Du J, Wang C, et al. The diagnostic protocol in children and adolescents with syncope: a multi-centre prospective study. Acta Paediatr 2009; 98:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/6\">",
"      Bo I, Carano N, Agnetti A, et al. Syncope in children and adolescents: a two-year experience at the Department of Paediatrics in Parma. Acta Biomed 2009; 80:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/7\">",
"      Pratt JL, Fleisher GR. Syncope in children and adolescents. Pediatr Emerg Care 1989; 5:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/8\">",
"      Massin MM, Bourguignont A, Coremans C, et al. Syncope in pediatric patients presenting to an emergency department. J Pediatr 2004; 145:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/9\">",
"      DiMario FJ Jr, Wheeler Castillo CS. Clinical categorization of childhood syncope. J Child Neurol 2011; 26:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/10\">",
"      Gillette PC, Garson A Jr. Sudden cardiac death in the pediatric population. Circulation 1992; 85:I64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/11\">",
"      Driscoll DJ, Jacobsen SJ, Porter CJ, Wollan PC. Syncope in children and adolescents. J Am Coll Cardiol 1997; 29:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/12\">",
"      Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol 1985; 5:118B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/13\">",
"      Moss AJ. Long QT Syndrome. JAMA 2003; 289:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/14\">",
"      MacCormick JM, McAlister H, Crawford J, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. Ann Emerg Med 2009; 54:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/15\">",
"      Reuter D, Brownstein D. Common emergent pediatric neurologic problems. Emerg Med Clin North Am 2002; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/16\">",
"      Atkins D, Hanusa B, Sefcik T, Kapoor W. Syncope and orthostatic hypotension. Am J Med 1991; 91:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/17\">",
"      American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of patients presenting with syncope. Ann Emerg Med 2001; 37:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/18\">",
"      Goble MM, Benitez C, Baumgardner M, Fenske K. ED management of pediatric syncope: searching for a rationale. Am J Emerg Med 2008; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/19\">",
"      Tanel RE, Walsh EP. Syncope in the pediatric patient. Cardiol Clin 1997; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/20\">",
"      Prodinger RJ, Reisdorff EJ. Syncope in children. Emerg Med Clin North Am 1998; 16:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11432/abstract/21\">",
"      Massin MM, Malekzadeh-Milani S, Benatar A. Cardiac syncope in pediatric patients. Clin Cardiol 2007; 30:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6464 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11432=[""].join("\n");
var outline_f11_10_11432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION AND DECISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Preceding events or precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Description of the event",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - ECG and echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Laboratory tests and neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Indications for referral or admission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ALGORITHMIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Abnormal cardiac evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Abnormal ECG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Abnormal cardiac examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Normal cardiac examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Prolonged loss of consciousness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Transient loss of consciousness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6464|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/49/784\" title=\"algorithm 1\">",
"      Emergent evaluation of pediatric syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6464|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/49/37660\" title=\"table 1\">",
"      Causes of syncope children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/42/683\" title=\"table 2\">",
"      Historical features life-threatening pediatric syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/14/1259\" title=\"table 3\">",
"      Life threatening ECG features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6464|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/50/13095\" title=\"waveform 1\">",
"      Third degree or complete AV block with narrow QRS escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 2\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?35/41/36506\" title=\"waveform 3\">",
"      ECG sinus rhythm WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/5/42078\" title=\"waveform 4\">",
"      12-lead ECG epsilon wave and T wave inversions in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/58/42922\" title=\"waveform 5\">",
"      LVH tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/21/44378\" title=\"waveform 6\">",
"      ECG of right ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/24/27008\" title=\"waveform 7\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=related_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=related_link\">",
"      Causes of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37687?source=related_link\">",
"      ECG tutorial: Basic principles of ECG analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21171?source=related_link\">",
"      ECG tutorial: Preexcitation syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=related_link\">",
"      Suspected heart disease in infants and children: Criteria for referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3864?source=related_link\">",
"      The &ldquo;choking game&rdquo; and other strangulation activities in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_10_11433="Donor insemination";
var content_f11_10_11433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Donor insemination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11433/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11433/contributors\">",
"     Elizabeth S Ginsburg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11433/contributors\">",
"     Serene S Srouji, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11433/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11433/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/10/11433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artificial insemination refers to the introduction of semen into the vagina, uterus, or oviduct by a means other than sexual intercourse. When the procedure is performed using sperm from a man other than the patient's partner, it is termed therapeutic donor insemination (TDI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic donor insemination (TDI) has been in use longer than any other artificial reproductive technique for treatment for male infertility. In 1987, over 170,000 women in the United States were treated for infertility using donor insemination, and in 1990, it was estimated that TDI produced 11,400 to 23,400 pregnancies annually [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, TDI was primarily a treatment of male factor infertility. However, the indications for TDI have expanded such that it has become an alternative approach to fertility for some women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/5\">",
"     5",
"    </a>",
"    ]. The procedure can be considered in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Couples in whom one or both partners are carriers of a heritable disease",
"     </li>",
"     <li>",
"      Couples who are serodiscordant for sexually transmissible viral infections",
"     </li>",
"     <li>",
"      Couples who fail to achieve fertilization with in vitro fertilization IVF or intracytoplasmic sperm injection (ICSI)",
"     </li>",
"     <li>",
"      Women without a male partner",
"     </li>",
"     <li>",
"      Couples who are incompatible for red cell antigens (eg, D, Kell) associated with hemolytic disease of the newborn and with a history of a severely affected infant",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Male partner infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the male partner has azoospermia, severe oligospermia, or other severe semen abnormalities resulting in infertility, the main treatment options are: (1) adoption, (2) TDI, (3) ICSI, and (4) remaining childless. Many couples choose to have ICSI with or without testicular biopsy as the initial approach to treatment of infertility due to severe semen abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the high cost of ICSI forces other couples to undergo TDI for financial reasons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heritable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for heritable disease in offspring should be considered in couples in whom either or both partners are affected by the disease or when asymptomatic carrier couples have an affected child. Depending upon the genetics of the disorder, such couples may opt for TDI from a noncarrier or phenotypically normal donor. Preimplantation genetic diagnosis with selection of unaffected blastocytes for implantation and prenatal genetic",
"    <span class=\"nowrap\">",
"     amniocentesis/chorionic",
"    </span>",
"    villous biopsy with termination of an affected fetus are other options. These options are only useful when laboratory studies can identify the responsible gene or detect a diagnostic marker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serodiscordance for viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who have sexually transmissible viral infections, such as hepatitis C and HIV, and a seronegative partner risk infecting the uninfected partner with their semen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/7\">",
"     7",
"    </a>",
"    ]. One option for these couples is TDI from an uninfected donor. In one survey of serodiscordant couples, 48 percent of respondents stated they would prefer TDI to timed unprotected intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Failed ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;TDI can be successful in infertile couples after failure of different testicular sperm retrieval procedures (ie, testicular sperm extraction, microsurgical epididymal sperm aspiration) or after fertilization failure by IVF or ICSI. In one study, as an example, 19 couples at the Oregon Health and Science University who failed 32 ICSI cycles chose to pursue TDI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/9\">",
"     9",
"    </a>",
"    ]. A total of 61 TDI cycles were completed and 16 of the 19 couples conceived within seven cycles of donor insemination. The pregnancy rate per cycle was 28 percent, and an average of 3.2 inseminations were required to achieve a pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Absence of a male partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report by the Ethics Committee of the American Society for Reproductive Medicine affirmed the right of single, gay, and lesbian persons to have access to fertility services [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. TDI is commonly used to achieve pregnancy in women without a male partner, such as single women and lesbian couples. In 1979, physicians reported that only 9.5 percent of TDIs were performed on females without male partners; however, by 1990 that number increased to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In addition, a survey of assisted reproductive technology clinics revealed that 74 to 79 percent of clinics offered services to single or lesbian women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/14\">",
"     14",
"    </a>",
"    ]. The number of single or lesbian women who perform self-inseminations is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with subfertility due to tubal factors, uterine malformations, active pelvic infection, or anovulation are not good candidates for donor insemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although TDI has been an established medical practice since the early twentieth century, little surveillance or regulation was placed on the practice until 1979, when a landmark survey of TDI practices in the United States was published [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/12\">",
"     12",
"    </a>",
"    ]. The study showed that physicians usually selected the donors, and that most physicians used medical students or hospital residents, while 10 percent used donors from military academies, husbands of patients in their practice, or friends. Screening was often limited and consisted primarily of the physician asking if the donor had any family or personal history of genetic diseases. Only 29 percent of physicians screened donors with biochemical tests other than blood type, and these tests were primarily for communicable diseases. In addition, 50 percent of respondents rejected donors who had a history of a sexually transmitted disease or drug use; 50 to 70 percent attempted to match donors with the recipient's husband in hair color, skin color, eye color,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    height, while 8 percent did not attempt any donor matching; and nearly one third used multiple donors within a single cycle. Most physicians limited the use of a donor to six pregnancies, while 10 percent used each donor for nine or more pregnancies, and 88 percent had no specific policy regarding the maximum use of a donor. Only one-third kept permanent records regarding donors and children from donor cycles on record.",
"   </p>",
"   <p>",
"    Since this study, the field of sperm donation has been revolutionized with increased regulation regarding selection criteria and screening for sexually transmitted diseases and genetic disorders. In the United States, the American Society of Reproductive Medicine (ASRM) 2013 Guidelines for Gamete and Embryo Donation provide the most recent detailed recommendations for evaluation of potential sperm, oocyte, and embryo donors, incorporating current information about optimal screening and testing for sexually transmitted infections (including HIV), genetic diseases, and psychological assessments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/5\">",
"     5",
"    </a>",
"    ]. The document includes information from the US Centers for Disease Control and Prevention, the US Food and Drug Administration, and the American Association of Tissue Banks. In 2009, the Ethics Committee of the ASRM published a report on the interests, obligations, and rights of the [egg or sperm] donor in gamete donation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/10\">",
"     10",
"    </a>",
"    ]. A synopsis of these guidelines, and additional information, are described below. Federal regulations for gamete and embryo donation in the United States are available at the following online sites:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       www.fda.gov/cber/tiss.htm",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       www.fda.gov/BiologicsBloodVaccines/default.htm",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       www.fda.gov/cber/rules/gtp.pdf",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Donor requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is clear that for ethical reasons, no individual associated with a facility performing the TDI, including the physician, can serve as a donor in that practice.",
"   </p>",
"   <p>",
"    Donors should be of legal age (&ge;18 years old) but ideally younger than age 40 years; however, many sperm banks limit the age of their donors to under 35 years. The upper age limit is meant to limit the possibility of aneuploidy related to paternal age. Proven fertility is not essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=see_link\">",
"     \"Effect of advanced paternal age on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A psychological assessment by a mental health professional should be performed on all donors. The emotional, psychological, and social aspects of sperm donation are addressed as part of this evaluation. Donors are also required to complete questionnaires regarding their attitudes or concerns about transmission of information to or future contact with biological progeny. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Legal and ethical concerns'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Donors are limited to producing 25 births in a population of 800,000 people to minimize the risk of inadvertent consanguinity; however, specific guidelines and limitations vary among countries due to differences in population size and cultural and psychosocial influences [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Donors should also be informed of their responsibility to update their records with future changes in their health status.",
"   </p>",
"   <p>",
"    Donors are advised to abstain from ejaculation for 48 to 72 hours prior to producing a specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/16\">",
"     16",
"    </a>",
"    ], and the specimen must be evaluated within one to two hours. Compensation for donation varies according to the sperm bank used; it is generally $60 to 100 per specimen.",
"   </p>",
"   <p>",
"    If the recipient prefers directed donation with a known donor, the donor must still fulfill the above criteria and undergo the screening procedures required of anonymous donors. In addition, legal issues such as parental rights must be addressed prior to insemination. The cost with a directed donor is typically less than with an anonymous donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donors should be made aware of their responsibility to give accurate medical information. A complete medical history, physical examination (see",
"    <a class=\"external\" href=\"file://www.sart.org/\">",
"     www.sart.org",
"    </a>",
"    for male donation physical examination form), and routine blood tests including blood",
"    <span class=\"nowrap\">",
"     type/Rh",
"    </span>",
"    testing (and possibly a complete blood count, liver function tests, and a chemistry panel) are performed to identify healthy men without evidence of sexually transmitted diseases or known or suspected heritable disease . A complete list of screening questions is available online at &lsquo;&lsquo;Uniform Donor Application&rsquo;&rsquo; at",
"    <a class=\"external\" href=\"file://www.sart.org/\">",
"     www.sart.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A complete sexual history is taken to exclude men who might be at high risk for HIV or other sexually transmitted diseases (",
"    <a class=\"graphic graphic_table graphicRef59652 \" href=\"UTD.htm?28/39/29307\">",
"     table 1",
"    </a>",
"    ). Evidence of urethral discharge, genital warts,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genital ulcers precludes sperm donation. The United States Food and Drug Administration (FDA) requires that donors be screened for risk factors and evidence of several communicable diseases, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HIV, HTLV-I, HTLV-II",
"     </li>",
"     <li>",
"      Hepatitis B",
"     </li>",
"     <li>",
"      Hepatitis C",
"     </li>",
"     <li>",
"      Human transmissible spongiform encephalopathy TSE (including Creutzfeldt-Jakob)",
"     </li>",
"     <li>",
"      Treponema pallidum",
"     </li>",
"     <li>",
"      Communicable diseases associated with xenotransplantation",
"     </li>",
"     <li>",
"      Chlamydia trachomatis",
"     </li>",
"     <li>",
"      Neisseria gonorrhea",
"     </li>",
"     <li>",
"      West Nile virus",
"     </li>",
"     <li>",
"      Severe Acute Respiratory Syndrome",
"     </li>",
"     <li>",
"      Small pox",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The list of test methods approved by the FDA for this purpose is available at the following online sites:",
"    <a class=\"external\" href=\"file://www.fda.gov/cber/products/testkits.htm\">",
"     www.fda.gov/cber/products/testkits.htm",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     www.fda.gov/downloads/BiologicsBlood",
"    </span>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Vaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm091345.pdf.",
"    </span>",
"   </p>",
"   <p>",
"    Potential donors also undergo a genetic evaluation. In the United States, the American Society for Reproductive Medicine (ASRM) has published minimum genetic testing for sperm donors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/5\">",
"     5",
"    </a>",
"    ]. The FDA does not mandate an extensive evaluation for heritable diseases. Most sperm banks advertise that a three-generation family history is taken to evaluate for any heritable diseases. The donor and his first-degree relatives should not have any major Mendelian disorders, major congenital malformations, familial disease with a major genetic component, or known karyotype abnormalities. Although some sperm banks perform a chromosomal analysis, this is not required. The low risk of chromosomal abnormality in these men was illustrated by a large retrospective study that determined the karyotype of over 10,000 normal fertile sperm donors over a 25-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/17\">",
"     17",
"    </a>",
"    ]. Thirty-eight karyotype aberrations (0.37 percent) were diagnosed, including 21 balanced chromosomal rearrangements. The frequency of chromosomal aberrations was similar to that in the general population of newborns.",
"   </p>",
"   <p>",
"    Genetic testing of high-risk groups is performed. In the United States, guidelines for ethnicity and population-based genetic screening are available from the American College of Obstetricians and Gynecologists (ACOG) (www.acog.org) and the American College of Medical Genetics (ACMG) (www.acmg.net). If test results reveal a heterozygous state, guidelines do not mandate rejection of the donor, but most donor banks state that they screen donors and exclude donors who have any indication of transmitting a higher risk of a hereditary disease. Genetic testing of sperm donors varies among sperm banks; the specific tests performed should be ascertained when using sperm from one of these banks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/18\">",
"     18",
"    </a>",
"    ]. Concerns have been raised about the frequency of genetic traits in the pool of young sperm donors, since these genes may be asymptomatic and thus unknowingly transmitted. Therefore it is important that intended parents be made aware of the limitations of current genetic testing of prospective donors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Infection precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor sperm samples are quarantined for at least 180",
"    <span class=\"nowrap\">",
"     days/six",
"    </span>",
"    months after the date of donation to allow testing and retesting of the donors for communicable diseases. The panel of laboratory tests listed in the table are performed prior to donation or within seven days after recovery of the specimen, after quarantine, and at six month intervals. These tests must be performed in a Clinical Laboratory Improvement Amendments (CLIA) certified or CLIA exempt laboratory. The tests used must be FDA licensed, approved or cleared donor-screening tests.",
"   </p>",
"   <p>",
"    If the tests are negative on initial screening, donor samples are prepared for cryopreservation. If the donor tests negative again, after a minimum of 180 days, samples can be released for use. Although physical separation of specimens that are eligible or quarantined is not required, specimens must be clearly identified and labeled appropriately. Specimens that are ineligible must be physically separated from eligible and quarantined specimens. Donor eligibility records must be maintained for 10 years after the date of distribution, disposition, or expiration, whichever is later. If test results are initially positive, the results should be verified and then the individual should be contacted, counseled, and treated according to standard medical practice guidelines.",
"   </p>",
"   <p>",
"    In addition, it is recommended that gamete donors with confirmed or suspected West Nile virus infection be deferred until 14 days after resolution of the infection or 28 days from the onset of symptoms, whichever is later [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=see_link\">",
"     \"Epidemiology and pathogenesis of West Nile virus infection\"",
"    </a>",
"    .) Similarly, donors who have received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    and individuals who have been infected by a recent recipient of the vaccine are advised to defer donation until the vaccine scab has spontaneously separated or until 14 days after resolution of any vaccine-related complications. Finally, donors with recent significant fever, flu-like illnesses, viral meningitis, encephalitis, or meningoencephalitis should be deferred until healthy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Donors whose serological results are positive for cytomegalovirus (CMV) undergo testing to determine whether the infection is likely to be recent or old. Sperm samples from recently infected donors are discarded [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/23\">",
"     23",
"    </a>",
"    ]. Some providers will use sperm samples from men with evidence of remote CMV infection if the recipient is also positive for CMV, but practice patterns vary [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/24\">",
"     24",
"    </a>",
"    ]. If the recipient is CMV negative, she should be counseled that ideally she should receive sperm from a CMV negative donor. However, it is reasonable to allow a patient to choose a donor who is CMV positive (remote infection), but who meets all other criteria, as long as she provides informed consent indicating that she understands that it is possible to contract CMV from the washed donor sperm.",
"   </p>",
"   <p>",
"    A California cryobank reported 47 infections among 48,000 recipients of donor insemination between 1986 and 2004 (1 infection per 10,000 recipients) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/25\">",
"     25",
"    </a>",
"    ]. The rate dropped to 1 in 25,000 for the last 10 years of the study, when semen specimens were processed more intensively. It was not possible to ascertain the proportion of these infections attributable to infection in the semen sample versus recipient factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Semen specimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single donor produces several semen specimens. Donors produce each specimen in a private room on site. These specimens should meet minimal semen parameters (",
"    <a class=\"graphic graphic_table graphicRef68389 \" href=\"UTD.htm?6/37/6747\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of male infertility\", section on 'Standard semen analysis'",
"    </a>",
"    .) Studies indicate that donor sperm can result in pregnancy over a wide range of donor sperm concentration, motility, and morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proper sperm processing is crucial to successful insemination. Processing for intrauterine insemination separates the sperm from the seminal fluid so that only the most motile, morphologically normal sperm are inseminated. These two characteristics are the most important specimen-related factors affecting outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/28\">",
"     28",
"    </a>",
"    ]. This process is also critical in removing the prostaglandins, inflammatory cells, debris, and proteins from the whole semen specimen, and concentrating the specimen in a small volume. Details of procedure for sperm processing are outside the scope of this topic review.",
"   </p>",
"   <p>",
"    Unwashed sperm can be used for intracervical insemination or for self-insemination. Pregnancy rates are lower with unwashed sperm, thus washed sperm and intrauterine insemination are typically recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Screening recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A routine medical and reproductive history is taken and a general physical examination is performed. Laboratory screening is similar to a standard prenatal panel and includes blood type, Rh factor, antibody screen; testing for immunity to rubella and varicella; testing for active cytomegalovirus infection; and appropriate assessments for the presence of sexually transmitted diseases (HIV, syphilis, gonorrhea, chlamydia, hepatitis B and C) and HTLV type I and II when clinically indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/5\">",
"     5",
"    </a>",
"    ]. ACOG",
"    <span class=\"nowrap\">",
"     prenatal/preconception",
"    </span>",
"    guidelines also suggest screening women for cystic fibrosis and other genetic diseases for which they are at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .) Theoretically, patients could opt out of this recommendation since the donors are screened for genetic diseases.",
"   </p>",
"   <p>",
"    Since most pregnancies occur within six cycles, an infertility evaluation should be initiated in woman who have not conceived after six months of inseminations and have not had a previous evaluation. Given the costs of TDI, it makes sense to assess the recipient's fertility even before proceeding with the procedure, especially in women with risk factors for subfertility. As an example, women with risk factors for tubal occlusion should have hysterosalpingography. Screening for ovarian reserve with a day 3 FSH and estradiol testing provides additional potentially prognostic information in women over 40 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Choosing the donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can refer to the American Association of Tissue Banks website (",
"    <a class=\"external\" href=\"file://www.aatb.org/\">",
"     www.aatb.org",
"    </a>",
"    ) to find accredited sperm banks. Sperm banks offer varying levels of information about their donors. Some types of information provided include donor profiles (race; height; weight; hair, eye and skin color; educational level; religion; ethnic background), audio tapes, hobbies, baby photos, personality profiles, staff impression reports, essays written by the donor, a report of facial features, and prior history of success in producing a pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/29\">",
"     29",
"    </a>",
"    ]. This information may be free; however, some banks will charge for more detailed descriptions or photos. Some banks also offer a consultation service for donor matching.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All medical records, including screening evaluations and cycle outcomes, are maintained as permanent records. Informed consent is obtained from the donor to collect sperm and from the recipient for the insemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient lies in a dorsal lithotomy position on a standard gynecological examination table with her feet in stirrups. A speculum is placed in the vagina and the cervix is visualized. Neither local anesthetic nor antibiotic prophylaxis is needed.",
"   </p>",
"   <p>",
"    The sperm specimen is aspirated into a 1.0 cc syringe. The needle is removed and the plastic syringe is attached to a flexible 18-cm polyethylene catheter (a standard intrauterine insemination catheter) (",
"    <a class=\"graphic graphic_picture graphicRef56297 \" href=\"UTD.htm?5/29/5597\">",
"     picture 1",
"    </a>",
"    ). All air is removed from the syringe and catheter and the catheter is inserted through the endocervical canal and should extend 5.5 cm in a typical uterus. The sperm are then injected. Mild cramping may occur. After the injection, the catheter is slowly removed and the patient instructed to remain lying flat and still for 15 minutes.",
"   </p>",
"   <p>",
"    The woman should be able to resume her normal activities upon leaving the office. Subsequent sexual intercourse has not been shown to impede fertilization, but most clinicians suggest abstinence for 24 hours after insemination.",
"   </p>",
"   <p>",
"    The process of intrauterine inseminations should only be performed at a clinic by certified health professionals including physicians and nurses who are experienced administering gynecological care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING SUCCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to improve pregnancy rates have focused upon the number of inseminated sperm, timing of insemination(s), and methods for insemination. The major nonmodifiable variables which reduce the likelihood of a successful outcome from the procedure include advanced maternal age and use of frozen sperm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal age plays a major role in determining a woman's fertility, regardless of the means used to achieve pregnancy (except donor egg) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    .) The effect of advanced maternal age on success of TDI was illustrated in a review of cumulative pregnancy rates in women under and over 30 years of age and included data from almost 3000 cycles over a 10 year interval [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/31\">",
"     31",
"    </a>",
"    ]. Women under 30 years old had higher pregnancy rates at three, six and 12 months than women over 30 years old (21, 40, and 62 percent versus 17, 26, and 44 percent respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/31\">",
"     31",
"    </a>",
"    ]. The maximum maternal age for administering TDI is at the discretion of the health professional or facility providing the recipient with her care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fresh versus frozen sperm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation and thaw methods decrease sperm motility and viability, which, in turn, appear to result in lower pregnancy rates. Concerns over a difference in success rates with use of fresh versus frozen donor sperm are mostly academic as current guidelines prohibit insemination of fresh donor sperm.",
"   </p>",
"   <p>",
"    The lower fecundity with frozen compared to fresh sperm was illustrated in two large, randomized, crossover trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, 381 patients received alternating cycles of fresh or cryopreserved semen [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/32\">",
"       32",
"      </a>",
"      ]. Fresh and frozen sperm cycles resulted in fecundity of 18.9 and 5.0 percent, respectively.",
"     </li>",
"     <li>",
"      The second trial involved 288 patients with a similar crossover design, but a higher number of motile sperm were inseminated in women in the cryopreserved arm by using a more concentrated cryoprotectant [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/33\">",
"       33",
"      </a>",
"      ]. Despite this intervention, fresh sperm cycles still resulted in greater fecundity than in the group receiving cryopreserved semen (27.4 and 10.4 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recent evidence suggests that long-term cryo-storage of sperm does not impact sperm motility, which is viewed as a predictor of sperm function after thawing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Number of inseminated sperm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from studies in cattle show that the number of",
"    <strong>",
"     fresh",
"    </strong>",
"    sperm inseminated must be over a critical threshold to achieve maximum pregnancy rates. When declining pregnancy rates in women after insemination of cryopreserved donor sperm were noted, the possibility of a critical threshold in humans was investigated, with variable findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the Central Semen Bank of Denmark (n = 3418 frozen ejaculates) showed that increasing the total motile sperm count from &lt;10x10(6) to 11 to 19x10(6) to &gt;19x10(6) increased the likelihood of achieving pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/35\">",
"       35",
"      </a>",
"      ]. However, once the count was above 19x10(6), no additional benefit was observed.",
"     </li>",
"     <li>",
"      Another study found that frozen ejaculates with at least 20x10(6) sperm yielded pregnancy rates that compared favorably with fresh samples containing more sperm [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a third study found no increase in pregnancy rate when inseminating with 1x10(6) versus &gt;5x10(6) motile sperm [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these data are discordant and there is no consensus on the optimal sperm count for insemination with cryopreserved sperm, most centers make an effort to select donors with consistently high sperm concentrations in their ejaculates. A large number of potential donors are rejected due to inadequate sperm counts. Our minimal criteria are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef68389 \" href=\"UTD.htm?6/37/6747\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Timing of insemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure must be done on the expected day of ovulation. Cryopreserved sperm have a shorter lifespan than fresh sperm, thus accurate timing is thought to be imperative. Insemination can be timed using basal body temperature charting, urinary LH surge, serum LH surge,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasound findings (dominant follicle &ge;18 mm) for determining ovulation.",
"   </p>",
"   <p>",
"    Detecting of the LH surge using a kit is the most common method. The LH surge appears in the urine within 12 hours after it appears in the serum; as a result, it can accurately predict ovulation and therefore the optimal time for insemination. The rise in serum LH typically occurs approximately 36 hours before the oocyte is released from the follicle into the fallopian tube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\", section on 'Timing of ovulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\", section on 'Measurement of LH surge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data from randomized trials comparing success rates of one versus two inseminations per cycle in women receiving cryopreserved donor sperm. Most centers perform a single insemination on the day after the LH surge. However, two observational studies found an increase in fecundity when two consecutive inseminations were performed midcycle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. For this reason, we perform an insemination on the day of and the day after the LH surge (documented by urine or serum testing).",
"   </p>",
"   <p>",
"    Women receiving donor insemination without any infertility diagnoses can pursue TDI in natural (fresh) cycles. After 3 to 6 natural (fresh) cycles, ovulation induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate or gonadotropins can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intrauterine versus intracervical insemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, intracervical inseminations (ICI) were performed with fresh donor semen. A volume of 1.5 to 2.5 mL was injected into the endocervical canal; fresh specimens were not injected into the uterus due to the potential for serious reactions to proteins, prostaglandins, and bacteria. Alternative modes of insemination have been explored because of increasing concerns about transmission of sexually transmitted diseases, the mandate for use of frozen specimens, and the subsequent decrease in pregnancy rates.",
"   </p>",
"   <p>",
"    Currently, the highest pregnancy rates are achieved with intrauterine insemination (IUI) using washed sperm. This technique bypasses vaginal and cervical factors that might impair fertility and increases 100-fold the number of sperm reaching the uterine cavity. A systematic review of randomized trials comparing IUI with intracervical inseminations showed IUI led to significantly higher pregnancy rates (OR 3.37, 95% CI 1.90-5.96) and higher live birth rates (OR 1.98, 95% CI 1.02-3.86), without increasing multiple birth rates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy rates and pregnancy outcomes in fertile women undergoing TDI with fresh semen are comparable to those in normal controls matched for age. The success of TDI can be illustrated by the following representative examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of couples undergoing TDI with fresh semen reported a fecundity rate (number of",
"      <span class=\"nowrap\">",
"       pregnancies/number",
"      </span>",
"      of treatment cycles) of 20 percent and a six-cycle cumulative pregnancy rate of 74 percent, which approached the pregnancy rate in women who discontinued oral contraceptive pills to attempt pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study compared TDI success rates in single (n = 122) versus lesbian (n = 35) women over 675 cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/13\">",
"       13",
"      </a>",
"      ]. The clinical pregnancy rate was 36 percent in single women and their cumulative pregnancy rate after six cycles was 47 percent. Lesbian women had a pregnancy rate of 57 percent and cumulative pregnancy rate of 70 percent. The difference in success rate could be explained by the older average age of the single women and disappeared when pregnancy rates were adjusted for this confounder.",
"     </li>",
"     <li>",
"      The French CECOS Federation has collected the largest amount of data on TDI pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/42\">",
"       42",
"      </a>",
"      ]. Outcomes from 21,597 pregnancies from TDI were registered. The mean weight at delivery, sex ratio, premature delivery rate, incidence of intrauterine growth retardation, presence of congenital anomalies and birth defects, ectopic pregnancy rate, and miscarriage rate were similar to those of the general French population. The multiple pregnancy rate was higher in the TDI group, reflecting the effects of ovarian hyperstimulation with ovulation induction medications. The incidence of chromosomal abnormalities was not increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, studies have shown that families created via donor insemination did not differ from families with naturally conceived children with respect to the quality of parenting or the psychological development or adjustment of the child [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/43-48\">",
"     43-48",
"    </a>",
"    ]. Exceptions to this general conclusion are some reports of hyperactivity in a proportion of TDI children, a small group of DI fathers who had problems relating to their children, and a study which reported TDI parents were over-anxious about their children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Most early studies involved families in which the method of conception was not disclosed. Other studies where disclosure was practiced continue to show good psychological outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/2,51-53\">",
"     2,51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fees for donor sperm vary by sperm bank and are based upon how sperm were prepared (washed versus unwashed sperm) and donor characteristics (level of education). Typical prices for unwashed sperm are $180 to $350, and $250 to $400 for washed sperm. These prices do not include storage, shipment, routine evaluation and blood tests, or the physician fees for performing the inseminations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LEGAL AND ETHICAL CONCERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, medical practices were not expected to keep permanent records of cycle outcomes or donor information. In fact, practitioners would often advise patients to conceal their method of conception, so that the name of the social father could be placed on the birth certificate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laws have subsequently been developed in the United States and abroad to protect the rights of social fathers to be legally recognized as the father, and the rights of children born from TDI to have access to their medical records. The ASRM 2002 guidelines reflect these changes, and several sperm banks offer an identity-release option, which allows banks to contact donors in the future for updated medical information and to provide identifying information to adult offspring who request it.",
"   </p>",
"   <p>",
"    As gamete donation has become more acceptable, other new areas of debate have arisen. Previously, only the use of third party, anonymous donors was supported; however, in the 2012 ASRM guidelines, the Ethics Committee discusses and supports the use of family members (intragenerational and some intergenerational) as gamete donors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/54\">",
"     54",
"    </a>",
"    ]. The Committee distinguished appropriate intrafamilial reproductive arrangements from those that involved consanguinity, placed undue influence (emotional or financial) on decisions to participate, and those that raised questions about lineage and parenting relations. Additional issues that should be addressed by a qualified counselor include emotional risks, potential impact on family relationships, the donor-recipient relationship, the future role of the donor in the offspring's life, and what information will be disclosed to the offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The ethical and legal issues of related donor insemination have been reviewed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other ethical dilemmas, as yet unresolved, include the concept of whether or not it should be mandated that donors' identity be available to allow later contact (if needed medically or desired), and whether or not parents should be required to disclose to their children their method of conception [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/56\">",
"     56",
"    </a>",
"    ]. Although selecting an anonymous donor remains an option in the United States, some other countries have mandated that all programs use only open-identity donors. The number of programs offering open-identity donors in the US is growing, and the ratio of open-identity donors to anonymous donors tends to increase over time in programs that offer this service [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ASRM has advised parents to disclose the method of conception to their offspring. Reasons for disclosure include the child's fundamental right to know his biologic origin and avoidance of the stress that arises when secrets are kept or the information is disclosed by accident. There is no good evidence that disclosure is harmful to the child. The ASRM similarly supports disclosure of a donor's identity; however, forced disclosure is not regulated or required by any governing body in the United States.",
"   </p>",
"   <p>",
"    Disclosure to donor offspring occurs earlier in lesbian couples and single mothers when compared to heterosexual couples. Even in heterosexual couples who expressed intent to disclose donor information to their offspring, fewer than 5 percent had done so by the time their child was 3 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/58\">",
"     58",
"    </a>",
"    ]. A survey of donor offspring suggests that later disclosure is associated with more negative feelings regarding their donor conception [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most donor offspring want to be told about their means of conception, desire in depth information about their donor's medical and social history, and express interest in meeting their donor and extended biologic family [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/60\">",
"     60",
"    </a>",
"    ]. In one study, for example, more than 80 percent of adolescents conceived with open-identity sperm donors expressed a moderate interest in requesting the identity and pursuing contact with their donor, and almost 90 percent expressed an interest in contacting others with the same sperm donor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of mandated disclosure on donor recruitment remains a point of concern. In Sweden, where legislation was passed mandating that a donor's identity be retained and made available to requesting offspring upon maturity, donor recruitment declined only transiently after the new regulations were implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/61\">",
"     61",
"    </a>",
"    ]. A small survey of donors in London showed that half would still donate if mandated to participate in an open-identity program; however, these were older men with children, characteristics that tend to be associated with more altruistically motivated donations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Demand for donors willing to release their identity is unknown. Data from Canada showed that only 21 percent of 240 patients who purchased donor sperm from April 2003 through March 2005 requested sperm from donors who would agree to release their identity; however, 95 percent of women without male partners made this choice [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11433/abstract/63\">",
"     63",
"    </a>",
"    ]. As with other ethical and legal aspects of TDI, these issues have no easy solution. However, as guidelines addressing them are developed it will be interesting to see their effect on the practice of TDI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic donor insemination refers to the introduction of semen into the vagina, uterus, or oviduct by a means other than sexual intercourse. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for donor insemination include male partner infertility, avoidance of diseases that may be transmitted or inherited from the male partner, and absence of a male partner. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines for the recruitment and screening of donors for the protection of both the donor and recipient are available. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The procedure is performed on the expected day of ovulation using a catheter to place washed donor sperm into the uterus. Older maternal age and use of frozen sperm decrease the success rate. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Factors affecting success'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy rates and pregnancy outcomes in fertile women undergoing TDI with fresh semen are comparable to those in normal controls matched for age. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/1\">",
"      Mascola L, Guinan ME. Screening to reduce transmission of sexually transmitted diseases in semen used for artificial insemination. N Engl J Med 1986; 314:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/2\">",
"      McWhinnie A. Gamete donation and anonymity: should offspring from donated gametes continue to be denied knowledge of their origins and antecedents? Hum Reprod 2001; 16:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/3\">",
"      Anger JT, Gilbert BR, Goldstein M. Cryopreservation of sperm: indications, methods and results. J Urol 2003; 170:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/4\">",
"      Shapiro S, Saphire DG, Stone WH. Changes in American A.I.D. practice during the past decade. Int J Fertil 1990; 35:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/5\">",
"      Practice Committee of American Society for Reproductive Medicine, Practice Committee of Society for Assisted Reproductive Technology. Recommendations for gamete and embryo donation: a committee opinion. Fertil Steril 2013; 99:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/6\">",
"      Garrido N, Zuzuarregui JL, Meseguer M, et al. Sperm and oocyte donor selection and management: experience of a 10 year follow-up of more than 2100 candidates. Hum Reprod 2002; 17:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/7\">",
"      Araneta MR, Mascola L, Eller A, et al. HIV transmission through donor artificial insemination. JAMA 1995; 273:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/8\">",
"      Klein J, Pe&ntilde;a JE, Thornton MH, Sauer MV. Understanding the motivations, concerns, and desires of human immunodeficiency virus 1-serodiscordant couples wishing to have children through assisted reproduction. Obstet Gynecol 2003; 101:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/9\">",
"      Gorrill MJ, Burry KA, Patton PE. Pregnancy outcomes using donor sperm insemination after failed in vitro fertilization with intracytoplasmic sperm injection cycles in couples with complex infertility disorders. Fertil Steril 2003; 80:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/10\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Interests, obligations, and rights of the donor in gamete donation. Fertil Steril 2009; 91:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/11\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Access to fertility treatment by gays, lesbians, and unmarried persons. Fertil Steril 2009; 92:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/12\">",
"      Curie-Cohen M, Luttrell L, Shapiro S. Current practice of artificial insemination by donor in the United States. N Engl J Med 1979; 300:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/13\">",
"      Ferrara I, Balet R, Grudzinskas JG. Intrauterine donor insemination in single women and lesbian couples: a comparative study of pregnancy rates. Hum Reprod 2000; 15:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/14\">",
"      Stern JE, Cramer CP, Garrod A, Green RM. Access to services at assisted reproductive technology clinics: a survey of policies and practices. Am J Obstet Gynecol 2001; 184:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/15\">",
"      Nagy ZP, Chang CC, Shapiro DB, et al. Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking. Fertil Steril 2009; 92:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/16\">",
"      Jurema MW, Vieira AD, Bankowski B, et al. Effect of ejaculatory abstinence period on the pregnancy rate after intrauterine insemination. Fertil Steril 2005; 84:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/17\">",
"      Ravel C, Berthaut I, Bresson JL, et al. Prevalence of chromosomal abnormalities in phenotypically normal and fertile adult males: large-scale survey of over 10,000 sperm donor karyotypes. Hum Reprod 2006; 21:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/18\">",
"      Sims CA, Callum P, Ray M, et al. Genetic testing of sperm donors: survey of current practices. Fertil Steril 2010; 94:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/19\">",
"      Callum P, Iger J, Ray M, et al. Outcome and experience of implementing spinal muscular atrophy carrier screening on sperm donors. Fertil Steril 2010; 94:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/20\">",
"      Maron BJ, Lesser JR, Schiller NB, et al. Implications of hypertrophic cardiomyopathy transmitted by sperm donation. JAMA 2009; 302:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/21\">",
"      Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile Virus. Fertil Steril 2005; 83:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/22\">",
"      Practice Committee of the American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. Society for assisted reproductive technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). Fertil Steril 2004; 81:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/23\">",
"      Bresson JL, Clavequin MC, Mazeron MC, et al. Risk of cytomegalovirus transmission by cryopreserved semen: a study of 635 semen samples from 231 donors. Hum Reprod 2003; 18:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/24\">",
"      Practice Committee of American Society for Reproductive Medicine. Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion. Fertil Steril 2013; 99:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/25\">",
"      Broder S, Sims C, Rothman C. Frequency of postinsemination infections as reported by donor semen recipients. Fertil Steril 2007; 88:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/26\">",
"      Polansky FF, Lamb EJ. Do the results of semen analysis predict future fertility? A survival analysis study. Fertil Steril 1988; 49:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/27\">",
"      Johnston RC, Kovacs GT, Lording DH, Baker HW. Correlation of semen variables and pregnancy rates for donor insemination: a 15-year retrospective. Fertil Steril 1994; 61:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/28\">",
"      Ombelet W, Deblaere K, Bosmans E, et al. Semen quality and intrauterine insemination. Reprod Biomed Online 2003; 7:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/29\">",
"      Navarrete T, Johnson A, Mixon B, Wolf D. The relationship between fertility potential measurements on cryobanked semen and fecundity of sperm donors. Hum Reprod 2000; 15:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/30\">",
"      Scott RT, Opsahl MS, Leonardi MR, et al. Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age. Hum Reprod 1995; 10:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/31\">",
"      Shenfield F, Doyle P, Valentine A, et al. Effects of age, gravidity and male infertility status on cumulative conception rates following artificial insemination with cryopreserved donor semen: analysis of 2998 cycles of treatment in one centre over 10 years. Hum Reprod 1993; 8:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/32\">",
"      Brown CA, Boone WR, Shapiro SS. Improved cryopreserved semen fecundability in an alternating fresh-frozen artificial insemination program. Fertil Steril 1988; 50:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/33\">",
"      Richter MA, Haning RV Jr, Shapiro SS. Artificial donor insemination: fresh versus frozen semen; the patient as her own control. Fertil Steril 1984; 41:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/34\">",
"      Yogev L, Kleiman SE, Shabtai E, et al. Long-term cryostorage of sperm in a human sperm bank does not damage progressive motility concentration. Hum Reprod 2010; 25:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/35\">",
"      Nielsen NC, Risum J, Bogaard Hansen K, Nissen U. Obtained pregnancies by AID using frozen semen in relation to specific qualities of the semen. Gynecol Obstet Invest 1984; 18:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/36\">",
"      Keel BA, Webster BW. Semen analysis data from fresh and cryopreserved donor ejaculates: comparison of cryoprotectants and pregnancy rates. Fertil Steril 1989; 52:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/37\">",
"      Campana A, Sakkas D, Stalberg A, et al. Intrauterine insemination: evaluation of the results according to the woman's age, sperm quality, total sperm count per insemination and life table analysis. Hum Reprod 1996; 11:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/38\">",
"      Centola GM, Mattox JH, Raubertas RF. Pregnancy rates after double versus single insemination with frozen donor semen. Fertil Steril 1990; 54:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/39\">",
"      Matilsky M, Geslevich Y, Ben-Ami M, et al. Two-day IUI treatment cycles are more successful than one-day IUI cycles when using frozen-thawed donor sperm. J Androl 1998; 19:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/40\">",
"      Besselink DE, Farquhar C, Kremer JA, et al. Cervical insemination versus intra-uterine insemination of donor sperm for subfertility. Cochrane Database Syst Rev 2008; :CD000317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/41\">",
"      Peek JC, Godfrey B, Matthews CD. Estimation of fertility and fecundity in women receiving artificial insemination by donor semen and in normal fertile women. Br J Obstet Gynaecol 1984; 91:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/42\">",
"      Lansac J, Thepot F, Mayaux MJ, et al. Pregnancy outcome after artificial insemination or IVF with frozen semen donor: a collaborative study of the French CECOS Federation on 21,597 pregnancies. Eur J Obstet Gynecol Reprod Biol 1997; 74:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/43\">",
"      Brewaeys A. Review: parent-child relationships and child development in donor insemination families. Hum Reprod Update 2001; 7:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/44\">",
"      Golombok S, MacCallum F, Goodman E, Rutter M. Families with children conceived by donor insemination: a follow-up at age twelve. Child Dev 2002; 73:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/45\">",
"      Nachtigall RD, Tschann JM, Quiroga SS, et al. Stigma, disclosure, and family functioning among parents of children conceived through donor insemination. Fertil Steril 1997; 68:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/46\">",
"      Chan RW, Raboy B, Patterson CJ. Psychosocial adjustment among children conceived via donor insemination by lesbian and heterosexual mothers. Child Dev 1998; 69:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/47\">",
"      Golombok S, Brewaeys A, Giavazzi MT, et al. The European study of assisted reproduction families: the transition to adolescence. Hum Reprod 2002; 17:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/48\">",
"      Golombok S, Jadva V, Lycett E, et al. Families created by gamete donation: follow-up at age 2. Hum Reprod 2005; 20:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/49\">",
"      Kovacs GT, Mushin D, Kane H, Baker HW. A controlled study of the psycho-social development of children conceived following insemination with donor semen. Hum Reprod 1993; 8:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/50\">",
"      Manuel, C. Les risques psychologiques de la conception par IAD pour l'enfant. Neuropsychiatrie de l'enfance 1990; 38:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/51\">",
"      Lycett E, Daniels K, Curson R, Golombok S. Offspring created as a result of donor insemination: a study of family relationships, child adjustment, and disclosure. Fertil Steril 2004; 82:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/52\">",
"      Scheib JE, Riordan M, Rubin S. Adolescents with open-identity sperm donors: reports from 12-17 year olds. Hum Reprod 2005; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/53\">",
"      Daniels K, Gillett W, Grace V. Parental information sharing with donor insemination conceived offspring: a follow-up study. Hum Reprod 2009; 24:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/54\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Using family members as gamete donors or surrogates. Fertil Steril 2012; 98:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/55\">",
"      Marshall LA. Ethical and legal issues in the use of related donors for therapeutic insemination. Urol Clin North Am 2002; 29:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/56\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Informing offspring of their conception by gamete donation. Fertil Steril 2004; 81:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/57\">",
"      Scheib JE, Cushing RA. Open-identity donor insemination in the United States: is it on the rise? Fertil Steril 2007; 88:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/58\">",
"      Golombok S, Murray C, Jadva V, et al. Non-genetic and non-gestational parenthood: consequences for parent-child relationships and the psychological well-being of mothers, fathers and children at age 3. Hum Reprod 2006; 21:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/59\">",
"      Jadva V, Freeman T, Kramer W, Golombok S. The experiences of adolescents and adults conceived by sperm donation: comparisons by age of disclosure and family type. Hum Reprod 2009; 24:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/60\">",
"      Mahlstedt PP, LaBounty K, Kennedy WT. The views of adult offspring of sperm donation: essential feedback for the development of ethical guidelines within the practice of assisted reproductive technology in the United States. Fertil Steril 2010; 93:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/61\">",
"      Daniels K, Lalos O. The Swedish insemination act and the availability of donors. Hum Reprod 1995; 10:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/62\">",
"      Daniels K, Blyth E, Crawshaw M, Curson R. Short communication: previous semen donors and their views regarding the sharing of information with offspring. Hum Reprod 2005; 20:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11433/abstract/63\">",
"      Wang, Y, Leader, A. Non-Anonymous (ID-Release) Donor Sperm Is Not the Preferred Choice of Women Who Are Undergoing Assisted Human Reproduction. Fertil Steril 2005; 84:S204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7423 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11433=[""].join("\n");
var outline_f11_10_11433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Male partner infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heritable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serodiscordance for viral infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Failed ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Absence of a male partner",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Donor requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Infection precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Semen specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Screening recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choosing the donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FACTORS AFFECTING SUCCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fresh versus frozen sperm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Number of inseminated sperm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Timing of insemination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intrauterine versus intracervical insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LEGAL AND ETHICAL CONCERNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7423|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/29/5597\" title=\"picture 1\">",
"      Insemination catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7423|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/39/29307\" title=\"table 1\">",
"      Sperm donor exclusion criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/37/6747\" title=\"table 2\">",
"      Minimal semen parameters recommended for sperm donors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=related_link\">",
"      Effect of advanced paternal age on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=related_link\">",
"      Epidemiology and pathogenesis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=related_link\">",
"      Evaluation of the menstrual cycle and timing of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_10_11434="Overview of the management of postoperative pulmonary complications";
var content_f11_10_11434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of postoperative pulmonary complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11434/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11434/contributors\">",
"     Michael M Johnson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11434/contributors\">",
"     Michelle V Conde, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11434/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/10/11434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/10/11434/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/10/11434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications are a major cause of morbidity and mortality during the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/1\">",
"     1",
"    </a>",
"    ]. The reported incidence of postoperative pulmonary complications ranges from 5 to 80 percent, depending upon the patient population and the criteria used to define a complication [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence also varies across hospitals, with one study reporting lower rates of complications in hospitals with a high volume of patients than in hospitals with a lower volume following esophagectomy, pancreatectomy, and intact abdominal aortic aneurysm repair [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditional definitions of postoperative pulmonary complications include atelectasis, bronchospasm, pneumonia, and exacerbation of chronic lung disease. However, the list can be expanded to include acute upper airway obstruction, complications from obstructive sleep apnea, pleural effusions, chemical pneumonitis, pulmonary edema, hypoxemia due to abdominal compartment syndrome, and tracheal laceration or rupture. Recognition and management of these postoperative pulmonary complications are reviewed here. Their prevention is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ATELECTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atelectasis is one of the most common postoperative pulmonary complications, particularly following abdominal and thoracoabdominal procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/4\">",
"     4",
"    </a>",
"    ]. Measures to prevent atelectasis have become an integral part of routine postoperative care, as described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H18#H18\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Lung expansion'",
"    </a>",
"    .) This section focuses on the management of postoperative atelectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20358221\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative atelectasis can be asymptomatic or it may manifest as increased work of breathing and hypoxemia. The onset of hypoxemia due to postoperative atelectasis tends to occur after the patient has left the post-anesthesia care unit. It typically becomes most severe during the second postoperative night and continues through the fourth or fifth postoperative night [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoxemia that develops earlier (ie, in the post-anesthesia care unit) should prompt the consideration of postoperative complications other than atelectasis, such as hypoventilation due to residual anesthetic effects and upper airway obstruction due to airway tissue edema. The latter may be due to the accumulation of pharyngeal secretions, prolapse of the tongue posteriorly, or tongue edema due to either surgical manipulation or an allergic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative atelectasis is usually caused by decreased compliance of lung tissue, impaired regional ventilation, retained airway secretions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postoperative pain that interferes with spontaneous deep breathing and coughing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These complications usually do not develop immediately following surgery, which explains why the onset of hypoxemia due to postoperative atelectasis tends to occur later, after the patient has left the post-anesthesia care unit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35795?source=see_link\">",
"     \"Atelectasis: Types and pathogenesis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to managing postoperative atelectasis depends upon whether the patient has abundant secretions, which we define as frequent expectoration, the expectoration of large amounts of sputum,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prominent rhonchi on auscultation. For patients without abundant secretions, continuous positive airway pressure may be beneficial. For patients with abundant secretions, chest physiotherapy and suctioning are appropriate. Some patients with abundant secretions may also benefit from bronchoscopy; the absence of air bronchograms may help identify patients who are more likely to benefit from bronchoscopy, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3776622\">",
"    <span class=\"h3\">",
"     Few respiratory secretions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous positive airway pressure (CPAP) may be beneficial to patients who develop hypoxemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased respiratory effort due to postoperative atelectasis in the setting of few secretions. This was demonstrated by a multicenter trial in which 209 patients with hypoxemia (an arterial oxygen tension to inspiratory oxygen fraction ratio",
"    <span class=\"nowrap\">",
"     [PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"     ]",
"    </span>",
"    of &le;300 mmHg) due to postoperative atelectasis following elective major abdominal surgery were randomly assigned to receive supplemental oxygen plus CPAP or supplemental oxygen alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/9\">",
"     9",
"    </a>",
"    ]. CPAP decreased the incidence of endotracheal intubation (1 versus 10 percent), pneumonia (2 versus 10 percent), infection (3 versus 10 percent), and sepsis (2 versus 9 percent). The study aimed to include only patients with hypoxemia due to postoperative atelectasis, by excluding patients who were more likely to have an alternative cause of postoperative hypoxemia (eg, patients with cardiac or pulmonary comorbidities, hypercapnia and respiratory acidosis, acute respiratory distress syndrome, hypotension, or impaired consciousness). Important limitations to this evidence are that the trial was unblinded and terminated early due to benefit.",
"   </p>",
"   <p>",
"    Although these findings have not been universal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/10\">",
"     10",
"    </a>",
"    ], we believe the potential benefits of a trial of CPAP outweigh the risks in most patients who have hypoxemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased respiratory effort due to postoperative atelectasis without abundant respiratory secretions. We monitor patients closely during the trial of CPAP so that intubation can be performed if it becomes clinically indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Abundant respiratory secretions",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with clinically significant postoperative atelectasis and abundant respiratory secretions should be suctioned frequently and receive chest physiotherapy (ie, postural drainage and percussion). Oral suctioning is appropriate for patients who are able to expectorate their secretions, but many patients are unable to expectorate their secretions and require nasotracheal suctioning. Suctioning and chest physiotherapy are relatively low risk, inexpensive interventions with important potential benefits. The notion that there are potential benefits is based upon clinical experience and indirect evidence from patients with lung diseases characterized by abundant secretions (eg, cystic fibrosis, bronchiectasis), since there is a lack of data among postoperative patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H9#H9\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Chest physiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of flexible bronchoscopy is uncertain. We believe that flexible bronchoscopy should not be performed routinely prior to or instead of chest physiotherapy, but may have a role in cases that are unresponsive to suctioning and chest physiotherapy. This approach is supported by the following evidence.",
"   </p>",
"   <p>",
"    Several studies evaluated the use of flexible bronchoscopy to extract secretions from patients with atelectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. The results were variable, but overall, bronchoscopy had little benefit. These results may have been due to a true lack of effect (perhaps secretions reaccumulate, rendering the bronchoscopy ineffective) or due to the study design. With respect to the study design, many studies combined patients with and without air bronchograms (air bronchograms indicate airways that are free of secretions). Flexible bronchoscopy is least effective when air bronchograms exist and it is possible that the lack of effect among patients with air bronchograms could obscure a beneficial effect among patients without air bronchograms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/13,15-17\">",
"     13,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An illustrative trial randomly assigned 31 patients with acute lobar atelectasis following thoracic or abdominal surgery to immediate bronchoscopy followed by chest physiotherapy or chest physiotherapy alone without the initial bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/15\">",
"     15",
"    </a>",
"    ]. Chest physiotherapy was performed every four hours and consisted of five minutes of chest percussion, five minutes of postural drainage, deep breathing to total lung capacity for three minutes with an incentive spirometer (or multiple 1 to 2 liter inflations using an anesthesia bag if the patient was intubated), coughing (or tracheal suctioning if the patient was either intubated or had an ineffective cough), and inhalation of ten breaths of isoetharine (an inhaled bronchodilator):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When patients who underwent flexible bronchoscopy followed by chest physiotherapy were compared to those who received chest physiotherapy alone, the mean percentage of resolution of volume loss following bronchoscopy was nearly identical to that following the first chest physiotherapy session, suggesting that flexible bronchoscopy did not add any initial benefit to chest physiotherapy alone.",
"     </li>",
"     <li>",
"      When patients with air bronchograms were compared to patients without air bronchograms, those without air bronchograms had better resolution of volume loss at 24 hours regardless of which intervention they received. This suggests that air bronchograms predict slower spontaneous resolution of the atelectasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CPAP and the mucolytic, N-acetylcysteine, do not have a role in the routine management of patients with abundant respiratory secretions. Regarding CPAP, the excess secretions are a contraindication to CPAP because the patient-device interface tends to impede suctioning. Regarding N-acetylcysteine, it has not been studied as a therapy for postoperative atelectasis, but it seems unlikely that it would be beneficial given its lack of effect in preventing postoperative atelectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link&amp;anchor=H4#H4\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H665782\">",
"    <span class=\"h1\">",
"     BRONCHOSPASM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchospasm is common during the postoperative period. Clinical manifestations include dyspnea, wheezing, chest tightness, tachypnea, small tidal volumes, a prolonged expiratory time, and hypercapnia. Postoperative bronchospasm can be caused by aspiration, histamine release incited by medications (eg, opiates, tubocurarine, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    ), an allergic response to medications, or an exacerbation of a chronic pulmonary condition, such as asthma or chronic obstructive pulmonary disease. It can also be caused by reflex constriction of bronchial smooth muscles due to tracheal stimulation by secretions, suctioning, endotracheal intubation, or other surgical stimulation. Reflex bronchoconstriction is particularly common when the bronchodilatory effects of inhalational anesthetics wane [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of postoperative bronchospasm consists of treating the underlying cause, removing potential contributors (eg, medications), and pharmacotherapy. Short-acting inhaled beta-2-agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    ) are bronchodilators that are considered first-line pharmacotherapy. The short-acting inhaled anticholinergic agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide, is also a bronchodilator that may have an additive effect on the degree of bronchodilation. The decision about whether to use an inhaled beta-2-agonist alone or to add ipratropium bromide is made on a case-by-case basis, depending upon the severity of bronchospasm. Patients who do not improve after one or two doses of the inhaled bronchodilators may benefit from the addition of systemic glucocorticoids.",
"   </p>",
"   <p>",
"    Methylxanthines (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ) and systemic beta-2-agonists are generally not used for the management of postoperative bronchospasm because the inhaled agents provide comparable or greater bronchodilation with fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally speaking, the approach to managing postoperative bronchospasm is similar to management of an exacerbation of asthma or COPD, which are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666174\">",
"    <span class=\"h1\">",
"     PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pneumonia has clinical manifestations and a diagnostic approach that is nearly identical to other types of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). However, it has some unique risk factors and treatment considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/23\">",
"     23",
"    </a>",
"    ]. This section focuses on postoperative pneumonia; other types of HAP and VAP are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666798\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pneumonia tends to occur within five postoperative days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/23\">",
"     23",
"    </a>",
"    ]. It may present with fever, leukocytosis, increased secretions, and pulmonary infiltrates on chest radiographs. Hypoxemia may develop, or the patient may require more supplemental oxygen to maintain the same oxyhemoglobin saturation. Respiratory distress, dyspnea, tachypnea, small tidal volumes, and hypercapnia may also occur. The minute ventilation often increases prior to the development of any blood gas abnormalities, a consequence of the patient becoming more catabolic due to the developing infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666181\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal strategy to diagnose postoperative pneumonia is uncertain and controversial. However, it is important because diagnosis based upon clinical criteria alone may result in over-diagnosis and inappropriate antibiotic therapy (resulting in the selection of resistant organisms), whereas stringent diagnostic criteria may lead to under-diagnosis, inadequate antibiotic coverage, and a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally speaking, postoperative pneumonia should be suspected in any patient who has clinical signs of infection (eg, fever, purulent sputum, leukocytosis, and worsening oxygenation) and a new radiographic infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with suspected postoperative pneumonia may be evaluated using the same diagnostic approach that is used for patients with suspected VAP, which is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of postoperative pneumonia can be difficult because there are many other postoperative causes of fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary infiltrates, such as atelectasis, pulmonary embolism, and acute lung injury. This was illustrated in a prospective cohort study of 129 consecutive surgical ICU patients with abnormal chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/26\">",
"     26",
"    </a>",
"    ]. Forty-eight percent of the patients were recovering from operative procedures and causes of pulmonary infiltrates in this population included pneumonia (30 percent), pulmonary edema (29 percent), acute lung injury (15 percent), and atelectasis (13 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666188\">",
"    <span class=\"h2\">",
"     Pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pneumonia is frequently caused by resistant organisms. This was demonstrated by a series of 837 patients with suspected postoperative pneumonia, occurring within the first 14 days following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/23\">",
"     23",
"    </a>",
"    ]. Microbiologic sampling was performed in 718 of the patients (86 percent), including bronchoscopic sampling in 367 of the patients (44 percent):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases of pneumonia occur within five postoperative days (61 percent).",
"     </li>",
"     <li>",
"      Organisms were cultured from the respiratory samples of almost half of the patients (46 percent).",
"     </li>",
"     <li>",
"      More than one organism was cultured from some patients (29 percent).",
"     </li>",
"     <li>",
"      Most of the positive cultures were obtained from patients in whom pneumonia was diagnosed before the fifth postoperative day.",
"     </li>",
"     <li>",
"      Gram-negative bacteria and Staphylococcus aureus were the most commonly cultured microorganisms, while the most frequent bacterial combinations were Enterobacteriaceae plus either Staphylococcus aureus or streptococci. Haemophilus influenzae and Streptococcus pneumoniae accounted for 19 percent and 10 percent, respectively, of the microorganisms isolated from respiratory and blood cultures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are risk factors for postoperative pneumonia caused by particular microorganisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Haemophilus influenzae or Streptococcus pneumoniae &ndash; Traumatically injured patients appear to be at increased risk for postoperative pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Staphylococcus aureus &ndash; Neurosurgical patients (particularly those who are mechanically ventilated), victims of blunt trauma and coma, and patients who have sustained closed head injuries seem to be at increased risk for postoperative pneumonia due to Staphylococcus aureus [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Additional risk factors for Staphylococcus pneumonia include: chronic kidney disease, diabetes mellitus, a history of injection drug use, and recent influenza [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/29\">",
"       29",
"      </a>",
"      ]. Previous antibiotic use is a risk factor for methicillin resistant S. aureus (MRSA) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa &ndash; No particular type of surgery has been convincingly shown to increase the likelihood of postoperative Pseudomonas pneumonia. However, risk factors for Pseudomonas pneumonia include: intubation &gt;8 days, structural lung disease (eg, bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease [COPD]), corticosteroid therapy, malnutrition, and prolonged exposure to antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Prolonged exposure to antibiotics has been defined as receipt of antibiotics for more than 48 hours during the 10 days preceding the episode of pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link\">",
"       \"Pseudomonas aeruginosa pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acinetobacter species &ndash; Acinetobacter species are a well-recognized cause of postoperative pneumonia, although no particular type of surgery has been shown to predispose patients to postoperative Acinetobacter pneumonia. The most important risk factor for Acinetobacter pneumonia is mechanical ventilation. Multidrug resistance is an increasing problem and Acinetobacter pneumonia is associated with a high mortality rate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link&amp;anchor=H1211125#H1211125\">",
"       \"Treatment and prevention of Acinetobacter infection\", section on 'Pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anaerobic species &ndash; The role of anaerobes in the pathogenesis of postoperative pneumonia is uncertain. Abdominal surgery is generally considered a risk factor for pneumonia due to anaerobic organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/24\">",
"       24",
"      </a>",
"      ], but several studies suggest that anaerobes may not be important pathogens in this setting. As an example, studies that cultured bronchoscopy specimens or mini-bronchoalveolar lavage (mini-BAL) specimens for anaerobic bacteria identified no such organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/37-41\">",
"       37-41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666230\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of postoperative pneumonia involves the collection of respiratory specimens for microbiological analysis, followed by the initiation of empiric antimicrobial therapy. Once the microbiological data has been reported and the patient&rsquo;s response to empiric therapy assessed, the antimicrobial regimen should be tailored.",
"   </p>",
"   <p>",
"    The collection of respiratory specimens, selection of an empiric antimicrobial regimen, and subsequent adjustments to the antimicrobial regimen are similar to that for other types of HAP and VAP. These interventions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link&amp;anchor=H322290#H322290\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Respiratory sampling'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Empiric treatment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The following considerations are specific for postoperative pneumonia and should be incorporated into the selection of an appropriate empiric antibiotic regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common pathogens reported in postoperative pneumonia are Gram-negative bacilli (eg, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter species) and Staphylococcus aureus. Haemophilus influenzae or Streptococcus pneumoniae are also common [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postoperative pneumonia is often polymicrobial in origin. The most frequent bacterial combinations appear to be Enterobacteriaceae plus either Staphylococcus aureus or streptococci [",
"      <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Victims of trauma are particularly susceptible to pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, or Staphylococcus aureus. Neurosurgical patients, especially those requiring mechanical ventilation, are also at increased risk for pneumonia due to Staphylococcus aureus.",
"     </li>",
"     <li>",
"      Anaerobic coverage with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      may be considered following thoracoabdominal surgery, although its value is uncertain. Antimicrobial coverage of aerobic bacteria should be continued if anaerobic coverage is added.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H226546\">",
"    <span class=\"h1\">",
"     ACUTE UPPER AIRWAY OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute upper airway obstruction typically occurs during the immediate postoperative period. It usually manifests as stridor if the obstruction is incomplete or aphonia if the obstruction is complete. Patients also may develop respiratory distress with dyspnea, tachypnea, tachycardia, and diaphoresis. Causes of acute upper airway obstruction include laryngeal edema, iatrogenic vocal cord paralysis, laryngospasm, and obstruction from the tongue or other soft tissues.",
"   </p>",
"   <p>",
"    Acute upper airway obstruction is a medical emergency that requires immediate evaluation by a clinician who is capable of performing endotracheal intubation. Ideally, the clinician should have significant experience in airway management, including the ability to intubate the patient using a fiberoptic laryngoscope. Inhaled bronchodilating medications or helium-oxygen mixtures may be beneficial to patients who do not require immediate intubation, while the cause of the acute upper airway obstruction is evaluated and treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link\">",
"     \"Physiology and clinical use of heliox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXACERBATION OF OBSTRUCTIVE SLEEP APNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a common disorder characterized by apneas and hypopneas due to repetitive complete or partial collapse of the upper airway during sleep. The repetitive upper airway collapse may lead to frequent awakenings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    episodic oxyhemoglobin desaturation. The pathogenesis, clinical presentation, diagnosis, natural history, and management of OSA are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OSA can be exacerbated during the postoperative period, which manifests as more frequent, more severe, or more prolonged episodes of oxyhemoglobin desaturation during sleep. This is often accompanied by new or worse hypercapnia. The frequency of oxyhemoglobin desaturation was demonstrated by a series of 438 patients with known or suspected OSA who underwent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/42\">",
"     42",
"    </a>",
"    ]. Oxyhemoglobin desaturation to less than 90 percent during sleep occurred in 16 percent of patients, while oxyhemoglobin desaturation to less than 80 percent during sleep occurred in 7 percent of patients. These episodes usually occurred within the first 24 to 48 hours after the surgical procedure. The propensity of patients with OSA to develop postoperative hypoxemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercapnia increases the likelihood of an adverse clinical outcome, such as reintubation, myocardial ischemia, cardiac arrhythmias, hypoxic encephalopathy, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several factors that probably contribute to postoperative exacerbation of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/43\">",
"     43",
"    </a>",
"    ]. Anesthetic agents, sedatives, and opioids promote relaxation of pharyngeal muscles during sleep, which may increase the frequency, severity, and duration of upper airway collapse. Anesthetic agents may also blunt the hypoxic and hypercapnic respiratory centers, thereby compromising the protective arousal response. Finally, patients are often supine following surgery and this position may predispose some patients to worse OSA.",
"   </p>",
"   <p>",
"    The postoperative management of patients with known or suspected OSA is reviewed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34965?source=see_link\">",
"     \"Postoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PLEURAL EFFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small pleural effusions are common during the immediate postoperative period following abdominal surgery. This was demonstrated by a series of 200 abdominal surgery patients who had posteroanterior, left lateral, and bilateral decubitus radiographs performed 48 to 72 hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/44\">",
"     44",
"    </a>",
"    ]. Pleural effusions were found in 97 patients (49 percent). Among the pleural effusions, 52 percent were &lt;4 mm, 27 percent were 4 to 10 mm, and 22 percent were &gt;10 mm (on the decubitus radiographs). Most effusions were exudates. A pleural effusion was more common after upper abdominal surgery, among patients with postoperative atelectasis, and among patients with free abdominal fluid. All of the effusions resolved without specific therapy with the exception of one, in which the pleural fluid culture grew Staphylococcus aureus.",
"   </p>",
"   <p>",
"    Most postoperative pleural effusions resolve spontaneously within a few days and, therefore, do not require intervention. However, atypical characteristics of either the pleural effusion or the patient&rsquo;s clinical course warrant diagnostic evaluation of pleural effusions. Postoperative pleural effusions are evaluated in the same way that other pleural effusions are evaluated. The diagnostic evaluation of a pleural effusion is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subphrenic abscess is a complication of surgery that may induce pleural effusions; however, the effusions associated with a subphrenic abscess are distinct from the usual postoperative pleural effusion in that they usually become apparent about 10 days after surgery and are typically associated with signs and symptoms of systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural effusions that develop following cardiac surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=see_link\">",
"     \"Pleural effusions following cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHEMICAL PNEUMONITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical patients are at risk for chemical pneumonitis resulting from the aspiration of acidic gastric contents during the perioperative period. The clinical features of chemical pneumonitis include the abrupt onset of dyspnea and tachycardia. Patients may also exhibit fever, bronchospasm, hypoxemia, cyanosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pink frothy sputum. Infiltrates may appear in one or both lower lobes, usually within the first 24 hours. In a series of more than 172,000 consecutive adults who underwent procedures involving general anesthesia, aspiration of gastric contents occurred in 1 of every 3216 procedures with an overall mortality of 1 in 71,829 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/46\">",
"     46",
"    </a>",
"    ]. While the incidence of aspiration is infrequent in healthy adults, aspiration is more common in pediatric and obstetric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/47\">",
"     47",
"    </a>",
"    ]. Most aspirations occurred during tracheal extubation or laryngoscopy; a high American Society of Anesthesiologists (ASA) class and emergency surgery were each associated with greater risk of aspiration (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"     table 1",
"    </a>",
"    ). The increased risk for aspiration and chemical pneumonitis during the perioperative period is probably related to ineffective upper airway reflexes due to the induction of anesthesia and the use of muscle relaxants and central respiratory depressant medications.",
"   </p>",
"   <p>",
"    The clinical course of chemical pneumonitis varies. Full recovery is the usual outcome. In the series above, patients who did not develop a cough, wheeze, &gt;10 percent oxyhemoglobin desaturation, or radiological abnormalities within two hours of aspiration or completion of the procedure, had no respiratory sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/46\">",
"     46",
"    </a>",
"    ]. However, some patients develop a secondary bacterial infection (ie, aspiration pneumonia) or acute respiratory distress syndrome (ARDS). In a series of more than 300,000 adult surgical patients, the prevalence of aspiration pneumonia was 0.8 percent, which varied among hospitals and by surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/48\">",
"     48",
"    </a>",
"    ]. The following patient characteristics were independently associated with the development of aspiration pneumonia: male gender, nonwhite race, age &gt;60 years, dementia, chronic obstructive pulmonary disease, renal disease, malignancy, moderate-to-severe liver disease, and emergency department admission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Witnessed aspiration of gastric secretions in the pharynx should prompt the clinician to immediately turn the patient&rsquo;s head to the side (ie, lateral head positioning), assuming integrity of the cervical spine, and then to suction the patient&rsquo;s oropharynx. Endotracheal intubation should be considered if airway reflexes are absent or compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/21\">",
"     21",
"    </a>",
"    ]. If there is suspicion of an unwitnessed intraoperative or postoperative aspiration event, the patient should be monitored closely over the ensuing 24 to 48 hours for the development of aspiration pneumonitis. Treatment is supportive, which may include supplemental oxygen, noninvasive mechanical ventilation, or conventional mechanical ventilation. Prophylactic administration of corticosteroids or antibiotics is not indicated. However, if the clinical findings have not resolved after 48 hours, antibiotic therapy may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/49\">",
"     49",
"    </a>",
"    ]. Specific antibiotic therapy should be instituted in the setting of a secondary bacterial infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link&amp;anchor=H6#H6\">",
"     \"Aspiration pneumonia in adults\", section on 'Chemical pneumonitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link&amp;anchor=H11#H11\">",
"     \"Aspiration pneumonia in adults\", section on 'Bacterial infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PULMONARY EDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pulmonary edema can be cardiogenic, noncardiogenic, or a combination of both.",
"   </p>",
"   <p>",
"    Postoperative cardiogenic pulmonary edema occurs most often within the initial 36 postoperative hours when fluid retention exceeds 67",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day according to a series of 13 patients who died from pulmonary edema following elective noncardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/50\">",
"     50",
"    </a>",
"    ]. Cardiogenic pulmonary edema was identified by chest radiography and elevated pulmonary artery pressures, and then confirmed at autopsy. The diagnosis and management of cardiogenic pulmonary edema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important cause of postoperative noncardiogenic edema is negative pressure pulmonary edema, which can result from laryngospasm or other forms of upper airway obstruction following extubation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Patients usually present with signs of acute upper airway obstruction following extubation and, upon relief of the obstruction, immediately develop dyspnea with pink frothy sputum and bilateral infiltrates on their chest radiograph. Less often, the development of pulmonary edema can be delayed for several hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, it is important that patients who experience postanesthetic laryngospasm be monitored longer than usual [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The recommended postanesthetic monitoring period in this patient population ranges from 2 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Pulmonary hemorrhage and frank hemoptysis have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is estimated that negative pressure pulmonary edema follows 0.05 to 0.1 percent of all procedures involving intubation and general anesthesia, but is often attributed to other etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients with a predisposition to upper airway obstruction are at the greatest risk for negative pressure pulmonary edema; however, laryngospasm-induced pulmonary edema following extubation has also been reported in young, healthy, athletic adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Risk factors for upper airway obstruction include obesity and having a short neck, obstructive sleep apnea, or acromegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/62\">",
"     62",
"    </a>",
"    ]. It also includes previous ear, nose, and throat surgery. In one case series, patients who were extubated during Stage 2 anesthesia (as opposed to being fully awake [Stage 1 anesthesia]) were at increased risk of laryngospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of negative pressure pulmonary edema is multifactorial, but appears to be related to the generation of markedly negative intrathoracic pressure due to forced inspiration against a closed glottis, referred to as a Mueller (or reverse Valsalva) maneuver. As the intrathoracic pressure becomes more negative, blood flow to the right heart increases. This causes the pulmonary vascular bed to dilate, the interstitial pressure around the capillaries to become more negative, and intravascular fluid to be drawn into the interstitial space. This worsens gas exchange and triggers a cascade of hypoxemia, catecholamine release, and systemic and pulmonary hypertension. The result is an acute increase in afterload, which worsens transcapillary fluid efflux and increases interstitial and alveolar edema [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of negative pressure pulmonary edema is supportive. All patients receive supplemental oxygen and some may benefit from diuresis if they are hypervolemic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/58\">",
"     58",
"    </a>",
"    ]. Bronchodilators",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    noninvasive continuous positive airway pressure (CPAP) may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/58\">",
"     58",
"    </a>",
"    ], although some patients will require reintubation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/63\">",
"     63",
"    </a>",
"    ]. Most cases resolve spontaneously in a relatively short period of time with no long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6689607\">",
"    <span class=\"h1\">",
"     PULMONARY EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pulmonary embolism is a well-known postoperative pulmonary complication. The clinical manifestations, diagnosis, and treatment of pulmonary embolism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H981566\">",
"    <span class=\"h1\">",
"     ABDOMINAL COMPARTMENT SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive hypoxemia may be the initial manifestation of abdominal compartment syndrome (ACS). ACS refers to symptomatic organ dysfunction resulting from an increase in the intraabdominal pressure. It is most common in trauma patients who require massive fluid resuscitation following injury or emergent abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/64\">",
"     64",
"    </a>",
"    ]. The incidence of ACS in trauma patients is estimated to be between 2 and 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. ACS may also be due to tight surgical closures or burn scars that reduce abdominal compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/67\">",
"     67",
"    </a>",
"    ]. The diagnosis and management of ACS are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     TRACHEAL LACERATION OR RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laceration or rupture of the upper airway is an unusual but well-described complication of endotracheal intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. Clinical and radiographic signs of the injuries include respiratory compromise, subcutaneous emphysema, pneumomediastinum, and unilateral or bilateral pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laceration or rupture of the upper airway may result in immediate respiratory compromise, or it may not be recognized until after extubation if the injury causes only a slow air leak or is masked by the endotracheal tube. In one series of 14 patients with iatrogenic airway lacerations, only two patients (14 percent) were diagnosed intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/70\">",
"     70",
"    </a>",
"    ]. The median duration until diagnosis for the remaining patients was 24 hours.",
"   </p>",
"   <p>",
"    Surgical management is generally required and may involve sternotomy, thoracotomy, or cervicotomy. Conservative management may be considered in clinically stable patients with small (&lt;2 cm) tears, minimal air leaks, or prohibitively high operative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/10/11434/abstract/68,69,73\">",
"     68,69,73",
"    </a>",
"    ]. Other complications of intubation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=see_link\">",
"     \"Endotracheal tube management and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/1/32785?source=see_link\">",
"       \"Patient information: Atelectasis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H981698\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary complications are a major cause of morbidity and mortality during the postoperative period. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atelectasis is one of the most common postoperative pulmonary complications. It can be asymptomatic or manifest as increased work of breathing and hypoxemia. Postoperative atelectasis tends to develop after the patient has left the post-anesthesia care unit. The initial approach to managing postoperative atelectasis depends upon whether the patient has abundant secretions, which we define as frequent expectoration, the expectoration of large amounts of sputum,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prominent rhonchi on auscultation (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Atelectasis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients without abundant respiratory secretions who have hypoxemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased respiratory effort due to postoperative atelectasis, we suggest a trial of continuous positive airway pressure (CPAP) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with abundant respiratory secretions and clinically significant postoperative atelectasis, we suggest frequent suctioning and chest physiotherapy (ie, postural drainage and percussion) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition, we suggest that bronchoscopy NOT be routinely performed as a first-line intervention prior to suctioning and chest physiotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Bronchoscopy should be reserved for patients who are unresponsive to suctioning and chest physiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchospasm is common during the postoperative period. Treatment involves treating the underlying cause, removing potential contributors (eg, medications), and pharmacotherapy. For patients with post-operative bronchospasm, we recommend short-acting inhaled beta-2-agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"       metaproterenol",
"      </a>",
"      ) as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The addition of a short-acting inhaled anticholinergic,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      , may be beneficial if the bronchospasm is severe. (See",
"      <a class=\"local\" href=\"#H665782\">",
"       'Bronchospasm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative pneumonia tends to occur within five postoperative days. It has clinical manifestations and a diagnostic approach that is nearly identical to other types of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Postoperative pneumonia is frequently caused by resistant organisms, such as Gram-negative bacteria and Staphylococcus aureus, or multiple organisms. The management of postoperative pneumonia involves collection of respiratory specimens for microbiological analysis, followed by the initiation of empiric antimicrobial therapy. Once the microbiological data has been reported and the patient&rsquo;s response to empiric therapy assessed, the antimicrobial regimen should be tailored. (See",
"      <a class=\"local\" href=\"#H666174\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute upper airway obstruction typically occurs during the immediate postoperative period. It usually manifests as stridor if the obstruction is incomplete or aphonia if the obstruction is complete. Acute upper airway obstruction is a medical emergency that requires immediate evaluation by a clinician who is capable of performing endotracheal intubation. (See",
"      <a class=\"local\" href=\"#H226546\">",
"       'Acute upper airway obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea (OSA) can be exacerbated during the postoperative period, which manifests as more frequent, more severe, or more prolonged episodes of oxyhemoglobin desaturation during sleep. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Exacerbation of obstructive sleep apnea'",
"      </a>",
"      above.) The postoperative management of patients with known or suspected OSA is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34965?source=see_link\">",
"       \"Postoperative management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small pleural effusions are common during the immediate postoperative period following abdominal surgery. Most resolve spontaneously within a few days and, therefore, do not require intervention. However, atypical characteristics of either the pleural effusion or the patient&rsquo;s clinical course (eg, signs of infection [fevers, chest infiltrate, worsening productive cough]) warrant diagnostic evaluation of the effusion. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pleural effusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional postoperative pulmonary complications include chemical pneumonitis due to aspiration, pulmonary edema, pulmonary embolism, abdominal compartment syndrome, and tracheal laceration or rupture. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Chemical pneumonitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Pulmonary edema'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6689607\">",
"       'Pulmonary embolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H981566\">",
"       'Abdominal compartment syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Tracheal laceration or rupture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/1\">",
"      Lawrence VA, Hilsenbeck SG, Mulrow CD, et al. Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med 1995; 10:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/2\">",
"      Fisher BW, Majumdar SR, McAlister FA. Predicting pulmonary complications after nonthoracic surgery: a systematic review of blinded studies. Am J Med 2002; 112:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/3\">",
"      Dimick JB, Pronovost PJ, Cowan JA Jr, et al. Variation in postoperative complication rates after high-risk surgery in the United States. Surgery 2003; 134:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/4\">",
"      Xue FS, Li BW, Zhang GS, et al. The influence of surgical sites on early postoperative hypoxemia in adults undergoing elective surgery. Anesth Analg 1999; 88:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/5\">",
"      Rosenberg J, Ullstad T, Rasmussen J, et al. Time course of postoperative hypoxaemia. Eur J Surg 1994; 160:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/6\">",
"      Powell JF, Menon DK, Jones JG. The effects of hypoxaemia and recommendations for postoperative oxygen therapy. Anaesthesia 1996; 51:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/7\">",
"      Wahba RM. Airway closure and intraoperative hypoxaemia: twenty-five years later. Can J Anaesth 1996; 43:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/8\">",
"      Platell C, Hall JC. Atelectasis after abdominal surgery. J Am Coll Surg 1997; 185:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/9\">",
"      Squadrone V, Coha M, Cerutti E, et al. Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. JAMA 2005; 293:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/10\">",
"      Evans TW. International Consensus Conferences in Intensive Care Medicine: non-invasive positive pressure ventilation in acute respiratory failure. Organised jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Soci&eacute;t&eacute; de R&eacute;animation de Langue Fran&ccedil;aise, and approved by the ATS Board of Directors, December 2000. Intensive Care Med 2001; 27:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/11\">",
"      Barrett CR Jr. Flexible fiberoptic bronchoscopy in the critically ill patient. Methodology and indications. Chest 1978; 73:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/12\">",
"      Milledge JS. Therapeutic fibreoptic bronchoscopy in intensive care. Br Med J 1976; 2:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/13\">",
"      Wanner A, Landa JF, Nieman RE Jr, et al. Bedside bronchofiberscopy for atelectasis and lung abscess. JAMA 1973; 224:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/14\">",
"      Feldman NT, Huber GL. Fiberoptic bronchoscopy in the intensive care unit. Int Anesthesiol Clin 1976; 14:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/15\">",
"      Marini JJ, Pierson DJ, Hudson LD. Acute lobar atelectasis: a prospective comparison of fiberoptic bronchoscopy and respiratory therapy. Am Rev Respir Dis 1979; 119:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/16\">",
"      Lindholm CE, Ollman B, Snyder J, et al. Flexible fiberoptic bronchoscopy in critical care medicine. Diagnosis, therapy and complications. Crit Care Med 1974; 2:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/17\">",
"      Bowen TE, Fishback ME, Green DC. Treatment of refractory atelectasis. Ann Thorac Surg 1974; 18:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/18\">",
"      Jepsen S, Nielsen PH, Klaerke A, Johansen K. [The effect of systemic N-acetylcysteine on postoperative expectoration. A prospective, randomized double-blind study]. Ugeskr Laeger 1989; 151:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/19\">",
"      Jepsen S, Klaerke A, Nielsen PH, et al. Systemic administration of N-acetylcysteine has no effect on postoperative lung function following elective upper laparotomy in lung healthy patients. Acta Anaesthesiol Scand 1989; 33:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/20\">",
"      Jepsen S, Nielsen PH, Klaerke A, et al. Peroral N-acetylcysteine as prophylaxis against bronchopulmonary complications of pulmonary surgery. Scand J Thorac Cardiovasc Surg 1989; 23:185.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Anesthesia, 4th ed, Barash P, Cullen B, Stoelting R (Eds), Lippincott-Williams &amp; Wilkins, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/22\">",
"      Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma. Cochrane Database Syst Rev 2012; 12:CD002742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/23\">",
"      Montravers P, Veber B, Auboyer C, et al. Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study. Crit Care Med 2002; 30:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/24\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/25\">",
"      Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988; 93:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/26\">",
"      Singh N, Falestiny MN, Rogers P, et al. Pulmonary infiltrates in the surgical ICU: prospective assessment of predictors of etiology and mortality. Chest 1998; 114:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/27\">",
"      Campbell W, Hendrix E, Schwalbe R, et al. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Crit Care Med 1999; 27:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/28\">",
"      Espersen F, Gabrielsen J. Staphylococcus aureus pneumonia as a complication during treatment of neurosurgical patients with mechanical ventilation. Scand J Infect Dis 1981; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/29\">",
"      Rello J, Quintana E, Ausina V, et al. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/30\">",
"      Berrouane Y, Daudenthun I, Riegel B, et al. Early onset pneumonia in neurosurgical intensive care unit patients. J Hosp Infect 1998; 40:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/31\">",
"      Rello J, Ausina V, Ricart M, et al. Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med 1994; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/32\">",
"      Niederman MS. Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences. Semin Respir Infect 1990; 5:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/33\">",
"      Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/34\">",
"      Fagon JY, Chastre J, Domart Y, et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/35\">",
"      Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/36\">",
"      Garnacho-Montero J, Ortiz-Leyba C, Fern&aacute;ndez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/37\">",
"      Chastre J, Viau F, Brun P, et al. Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients. Am Rev Respir Dis 1984; 130:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/38\">",
"      Fagon JY, Chastre J, Hance AJ, et al. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993; 103:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/39\">",
"      Chastre J, Fagon JY, Soler P, et al. Diagnosis of nosocomial bacterial pneumonia in intubated patients undergoing ventilation: comparison of the usefulness of bronchoalveolar lavage and the protected specimen brush. Am J Med 1988; 85:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/40\">",
"      Jim&eacute;nez P, Torres A, Rodr&iacute;guez-Roisin R, et al. Incidence and etiology of pneumonia acquired during mechanical ventilation. Crit Care Med 1989; 17:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/41\">",
"      Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999; 115:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/42\">",
"      Bolden N, Smith CE, Auckley D, et al. Perioperative complications during use of an obstructive sleep apnea protocol following surgery and anesthesia. Anesth Analg 2007; 105:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/43\">",
"      Bolden N, Smith CE, Auckley D. Avoiding adverse outcomes in patients with obstructive sleep apnea (OSA): development and implementation of a perioperative OSA protocol. J Clin Anesth 2009; 21:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/44\">",
"      Light RW, George RB. Incidence and significance of pleural effusion after abdominal surgery. Chest 1976; 69:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/45\">",
"      Goodman LR. Postoperative chest radiograph: I. Alterations after abdominal surgery. AJR Am J Roentgenol 1980; 134:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/46\">",
"      Warner MA, Warner ME, Weber JG. Clinical significance of pulmonary aspiration during the perioperative period. Anesthesiology 1993; 78:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/47\">",
"      Beck-Schimmer B, Bonvini JM. Bronchoaspiration: incidence, consequences and management. Eur J Anaesthesiol 2011; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/48\">",
"      Kozlow JH, Berenholtz SM, Garrett E, et al. Epidemiology and impact of aspiration pneumonia in patients undergoing surgery in Maryland, 1999-2000. Crit Care Med 2003; 31:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/49\">",
"      Rebuck JA, Rasmussen JR, Olsen KM. Clinical aspiration-related practice patterns in the intensive care unit: a physician survey. Crit Care Med 2001; 29:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/50\">",
"      Arieff AI. Fatal postoperative pulmonary edema: pathogenesis and literature review. Chest 1999; 115:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/51\">",
"      Timby J, Reed C, Zeilender S, Glauser FL. \"Mechanical\" causes of pulmonary edema. Chest 1990; 98:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/52\">",
"      McConkey PP. Postobstructive pulmonary oedema--a case series and review. Anaesth Intensive Care 2000; 28:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/53\">",
"      Willms D, Shure D. Pulmonary edema due to upper airway obstruction in adults. Chest 1988; 94:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/54\">",
"      Wilson GW, Bircher NG. Acute pulmonary edema developing after laryngospasm: report of a case. J Oral Maxillofac Surg 1995; 53:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/55\">",
"      Hamlin W, Schnobel L, Smith B. The patient with noncardiogenic pulmonary edema. J Post Anesth Nurs 1991; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/56\">",
"      Oswalt CE, Gates GA, Holmstrom MG. Pulmonary edema as a complication of acute airway obstruction. JAMA 1977; 238:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/57\">",
"      Schwartz DR, Maroo A, Malhotra A, Kesselman H. Negative pressure pulmonary hemorrhage. Chest 1999; 115:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/58\">",
"      Mulkey Z, Yarbrough S, Guerra D, et al. Postextubation pulmonary edema: a case series and review. Respir Med 2008; 102:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/59\">",
"      Deepika K, Kenaan CA, Barrocas AM, et al. Negative pressure pulmonary edema after acute upper airway obstruction. J Clin Anesth 1997; 9:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/60\">",
"      Holmes JR, Hensinger RN, Wojtys EW. Postoperative pulmonary edema in young, athletic adults. Am J Sports Med 1991; 19:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/61\">",
"      Cascade PN, Alexander GD, Mackie DS. Negative-pressure pulmonary edema after endotracheal intubation. Radiology 1993; 186:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/62\">",
"      Lathan SR, Silverman ME, Thomas BL, Waters WC 4th. Postoperative pulmonary edema. South Med J 1999; 92:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/63\">",
"      Halow KD, Ford EG. Pulmonary edema following post-operative laryngospasm: a case report and review of the literature. Am Surg 1993; 59:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/64\">",
"      Ertel W, Oberholzer A, Platz A, et al. Incidence and clinical pattern of the abdominal compartment syndrome after \"damage-control\" laparotomy in 311 patients with severe abdominal and/or pelvic trauma. Crit Care Med 2000; 28:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/65\">",
"      Hong JJ, Cohn SM, Perez JM, et al. Prospective study of the incidence and outcome of intra-abdominal hypertension and the abdominal compartment syndrome. Br J Surg 2002; 89:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/66\">",
"      Balogh Z, McKinley BA, Cocanour CS, et al. Secondary abdominal compartment syndrome is an elusive early complication of traumatic shock resuscitation. Am J Surg 2002; 184:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/67\">",
"      Hobson KG, Young KM, Ciraulo A, et al. Release of abdominal compartment syndrome improves survival in patients with burn injury. J Trauma 2002; 53:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/68\">",
"      G&oacute;mez-Caro Andr&eacute;s A, Moradiellos D&iacute;ez FJ, Aus&iacute;n Herrero P, et al. Successful conservative management in iatrogenic tracheobronchial injury. Ann Thorac Surg 2005; 79:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/69\">",
"      Borasio P, Ardissone F, Chiampo G. Post-intubation tracheal rupture. A report on ten cases. Eur J Cardiothorac Surg 1997; 12:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/70\">",
"      Massard G, Roug&eacute; C, Dabbagh A, et al. Tracheobronchial lacerations after intubation and tracheostomy. Ann Thorac Surg 1996; 61:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/71\">",
"      Sternfeld D, Wright S. Tracheal rupture and the creation of a false passage after emergency intubation. Ann Emerg Med 2003; 42:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/72\">",
"      Hirose K, Visser BC. Images in clinical medicine. Massive subcutaneous emphysema after tracheal perforation. N Engl J Med 2004; 351:e2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/10/11434/abstract/73\">",
"      Carbognani P, Bobbio A, Cattelani L, et al. Management of postintubation membranous tracheal rupture. Ann Thorac Surg 2004; 77:406.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4401 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11434=[""].join("\n");
var outline_f11_10_11434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H981698\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ATELECTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20358221\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3776622\">",
"      - Few respiratory secretions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Abundant respiratory secretions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H665782\">",
"      BRONCHOSPASM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H666174\">",
"      PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666798\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666181\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666188\">",
"      Pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666230\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H226546\">",
"      ACUTE UPPER AIRWAY OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXACERBATION OF OBSTRUCTIVE SLEEP APNEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PLEURAL EFFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHEMICAL PNEUMONITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PULMONARY EDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6689607\">",
"      PULMONARY EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H981566\">",
"      ABDOMINAL COMPARTMENT SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      TRACHEAL LACERATION OR RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H981698\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8733\" title=\"table 1\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35795?source=related_link\">",
"      Atelectasis: Types and pathogenesis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/1/32785?source=related_link\">",
"      Patient information: Atelectasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16728?source=related_link\">",
"      Pleural effusions following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34965?source=related_link\">",
"      Postoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_10_11435="WHO thin melanoma trial";
var content_f11_10_11435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO thin melanoma trial",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Thickness, mm",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Narrow margin (1cm)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wide margin (3 cm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Rate of local recurrence",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rate of local recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0-1.0",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        3 (1.6 percent)",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        1 (0.6 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.1-2.0",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        5 (4.2 percent)",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        2 (1.5 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Cascinelli Sem Surg Onc 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11435=[""].join("\n");
var outline_f11_10_11435=null;
var title_f11_10_11436="Migratory skin lesions";
var content_f11_10_11436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infections associated with migratory skin lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous larva migrans",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"       <td>",
"        Creeping eruption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dracunculiasis",
"       </td>",
"       <td>",
"        Focal in sub-Saharan Africa",
"       </td>",
"       <td>",
"        Movement of worm just before eruption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fascioliasis",
"       </td>",
"       <td>",
"        Worldwide in areas where sheep and cattle are raised",
"       </td>",
"       <td>",
"        Migratory areas of inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gnathostomiasis",
"       </td>",
"       <td>",
"        Most common in Asia but also found in other areas",
"       </td>",
"       <td>",
"        Migratory inflammatory subcutaneous swellings; urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hookworm",
"       </td>",
"       <td>",
"        Worldwide; most common in tropical, subtropical areas&nbsp;with poor sanitation",
"       </td>",
"       <td>",
"        Itchy tracts at points of penetration of larvae through skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loiasis",
"       </td>",
"       <td>",
"        Central and western Africa",
"       </td>",
"       <td>",
"        Migratory inflammatory swellings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paragonimiasis",
"       </td>",
"       <td>",
"        Most common in east and SE Asia, Africa",
"       </td>",
"       <td>",
"        Migratory swelling or subcutaneous nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sparganosis",
"       </td>",
"       <td>",
"        Parasite found on all continents; most human cases from SE Asia",
"       </td>",
"       <td>",
"        Edematous, painful migratory swellings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strongyloidiasis",
"       </td>",
"       <td>",
"        Most common in tropical, subtropical areas",
"       </td>",
"       <td>",
"        Itchy, papular and migratory serpiginous lesions (larva currens)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myiasis",
"       </td>",
"       <td>",
"        Dominant Diptera species vary with region",
"       </td>",
"       <td>",
"        Visible movement of maggot(s) within lesion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11436=[""].join("\n");
var outline_f11_10_11436=null;
var title_f11_10_11437="Macroscopic magnetic moment";
var content_f11_10_11437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Creation of macroscopic magnetic moment in MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 210px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Excess of magnetic moments aligned parallel to the main magnetic field (B",
"    <sub>",
"     0",
"    </sub>",
"    ) creates a macroscopic magnetic moment (M",
"    <sub>",
"     0",
"    </sub>",
"    ). The random phases of the individual magnetic vectors cause cancellation of the transverse component of magnetization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11437=[""].join("\n");
var outline_f11_10_11437=null;
var title_f11_10_11438="Incidence of HCC";
var content_f11_10_11438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of hepatocellular carcinoma in various countries and ethnic groups (per 100,000 per year)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Country",
"       </td>",
"       <td class=\"subtitle1\">",
"        Males",
"       </td>",
"       <td class=\"subtitle1\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mozambique",
"       </td>",
"       <td>",
"        112.9",
"       </td>",
"       <td>",
"        30.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zimbabwe",
"       </td>",
"       <td>",
"        64.6",
"       </td>",
"       <td>",
"        25.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gambia",
"       </td>",
"       <td>",
"        33.1",
"       </td>",
"       <td>",
"        12.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Senegal",
"       </td>",
"       <td>",
"        25.6",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        South Africa (Cape)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Black",
"       </td>",
"       <td class=\"sublist_other\">",
"        26.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Colored",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Caucasian",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Algeria",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nigeria",
"       </td>",
"       <td>",
"        15.4",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Argentina",
"       </td>",
"       <td>",
"        9.9",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brazil",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peru",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jamaica",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chinese",
"       </td>",
"       <td class=\"sublist_other\">",
"        19.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Black",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Japanese",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Caucasian",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        Canada",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eskimos",
"       </td>",
"       <td class=\"sublist_other\">",
"        6.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alberta",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Switzerland",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Italy",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spain",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        France",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Germany",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Denmark",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yugoslavia",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Czechoslovakia",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        United Kingdom",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ireland",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        China",
"       </td>",
"       <td>",
"        34.4",
"       </td>",
"       <td>",
"        11.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        Singapore",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chinese",
"       </td>",
"       <td class=\"sublist_other\">",
"        31.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malay",
"       </td>",
"       <td class=\"sublist_other\">",
"        15.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Indian",
"       </td>",
"       <td class=\"sublist_other\">",
"        14.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Korea",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        Japan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Miyagi",
"       </td>",
"       <td class=\"sublist_other\">",
"        11.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nagasaki",
"       </td>",
"       <td class=\"sublist_other\">",
"        25.8",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        India",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Philippines",
"       </td>",
"       <td>",
"        19.9",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hong Kong",
"       </td>",
"       <td>",
"        32.3",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pakistan",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        New Zealand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maori",
"       </td>",
"       <td class=\"sublist_other\">",
"        11.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-Maori",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"        Pacific Polynesian",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Islands",
"       </td>",
"       <td class=\"sublist_other\">",
"        26.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Australia",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawaii",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11438=[""].join("\n");
var outline_f11_10_11438=null;
var title_f11_10_11439="Standard cricothyrotomy step eight";
var content_f11_10_11439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard cricothyrotomy step eight",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <font class=\"red\">",
"     <font color=\"black\">",
"      Replace the inner cannula and inflate the cuff.",
"     </font>",
"    </font>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_10_11439=[""].join("\n");
var outline_f11_10_11439=null;
